10-Q

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-20-286931.txt : 20201105 0001193125-20-286931.hdr.sgml : 20201105 20201105165128 ACCESSION NUMBER: 0001193125-20-286931 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 201291285 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 10-Q 1 d945763d10q.htm 10-Q 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File Number

000-14656

REPLIGEN CORPORATION

(Exact Name of Registrant as Specified in its Charter)


Delaware		04-2729386
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)


41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA		02453
(Address of Principal Executive Offices)		(Zip Code)

(781) 250-0111

Registrant’s Telephone Number, Including Area Code

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	RGEN	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation

S-T

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a

non-accelerated

filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule

12b-2

of the Exchange Act.:

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule

12b-2

of the Exchange Act.): Yes ☐ No ☒

The number of shares outstanding of the registrant’s common stock on November 2, 2020 was 52,619,271.

Table of Contents


		PAGE

PART I - FINANCIAL INFORMATION

Item 1.	Financial Statements (interim periods unaudited)

	Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019		3

	Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2020 and 2019		4

	Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended September 30, 2020 and 2019		5

	Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019		7

	Notes to Unaudited Consolidated Financial Statements		8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		28

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		40

Item 4.	Controls and Procedures		41

PART II - OTHER INFORMATION

Item 1.	Legal Proceedings		42

Item 1A.	Risk Factors		42

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		42

Item 3.	Defaults Upon Senior Securities		42

Item 4.	Mine Safety Disclosures		42

Item 5.	Other Information		42

Item 6.	Exhibits		43

Signatures			44

Table of Contents

PART I – FINANCIAL INFORMATION

ITEM 1.

Financial Statements

REPLIGEN CORPORATION

CONSOLIDATED BALANCE SHEETS

(Unaudited, amounts in thousands, except share data)


	September 30, 2020			December 31, 2019
Assets
Current assets:
Cash and cash equivalents	$	553,302		$	528,392
Restricted cash		—			9,015
Accounts receivable, net of allowances of $621 and $525 at September 30, 2020 and December 31, 2019, respectively		55,830			43,068
Royalties and other receivables		95			148
Unbilled receivables		—			456
Inventories, net		78,531			54,832
Prepaid expenses and other current assets		8,970			5,917

Total current assets		696,728			641,828
Property, plant and equipment, net		55,355			48,455
Intangible assets, net		215,385			212,552
Goodwill		482,043			468,413
Deferred tax assets		2,192			2,920
Operating lease right of use assets		24,201			25,707
Other assets		412			238

Total assets	$	1,476,316		$	1,400,113

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	14,483		$	11,425
Operating lease liability		4,460			3,557
Accrued liabilities		32,041			33,331

Total current liabilities		50,984			48,313
Convertible senior notes, net		240,942			232,767
Deferred tax liabilities		29,435			29,944
Operating lease liability, long-term		26,378			26,995
Other liabilities, long-term		3,707			2,326

Total liabilities		351,446			340,345

Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding		—			—
Common stock, $0.01 par value; 80,000,000 shares authorized; 52,606,700 shares at September 30, 2020 and 52,078,258 shares at December 31, 2019 issued and outstanding		526			521
Additional paid-in capital		1,087,996			1,068,431
Accumulated other comprehensive loss		(9,723	)		(15,027	)
Retained earnings		46,071			5,843

Total stockholders’ equity		1,124,870			1,059,768

Total liabilities and stockholders’ equity	$	1,476,316		$	1,400,113

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

REPLIGEN CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(Unaudited, amounts in thousands, except per share data)


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue:
Products	$	94,029		$	69,419		$	257,521		$	200,701
Royalty and other revenue		31			26			91			70

Total revenue		94,060			69,445			257,612			200,771

Costs and operating expenses:
Cost of product revenue		39,626			31,425			108,471			88,978
Research and development		4,422			5,427			13,460			14,278
Selling, general and administrative		29,051			24,629			83,277			67,326

Total costs and operating expenses		73,099			61,481			205,208			170,582

Income from operations		20,961			7,964			52,404			30,189

Other income (expenses):
Investment income		82			1,898			1,699			3,616
Loss on extinguishment of debt		—			(5,650	)		—			(5,650	)
Interest expense		(3,052	)		(2,857	)		(9,032	)		(6,326	)
Other (expenses) income		(248	)		316			(632	)		(23	)

Other expenses, net		(3,218	)		(6,293	)		(7,965	)		(8,383	)

Income before income taxes		17,743			1,671			44,439			21,806
Income tax provision		3,191			12			4,211			3,999

Net income	$	14,552		$	1,659		$	40,228		$	17,807

Earnings per share:
Basic	$	0.28		$	0.03		$	0.77		$	0.38

Diluted	$	0.27		$	0.03		$	0.75		$	0.37

Weighted average common shares outstanding:
Basic		52,545			50,852			52,341			47,087

Diluted		53,469			51,809			53,300			47,930

Net income	$	14,552		$	1,659		$	40,228		$	17,807
Other comprehensive income (loss):
Foreign currency translation adjustment		4,390			(6,741	)		5,304			(9,901	)

Comprehensive income (loss)	$	18,942		$	(5,082	)	$	45,532		$	7,906

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

REPLIGEN CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited, amounts in thousands, except share data)


	Nine Months Ended September 30, 2020
	Common Stock				Additional Paid- In Capital		Accumulated Other Comprehensive Loss			Retained Earnings		Total Stockholders’ Equity
	Number of Shares		Par Value		Additional Paid- In Capital		Accumulated Other Comprehensive Loss			Retained Earnings		Total Stockholders’ Equity
Balance at December 31, 2019		52,078,258	$	521	$	1,068,431	$	(15,027	)	$	5,843	$	1,059,768
Net income		—		—		—		—			40,228		40,228
Exercise of stock options and vesting of stock units		528,442		5		7,073		—			—		7,078
Stock-based compensation expense		—		—		12,492		—			—		12,492
Translation adjustment		—		—		—		5,304			—		5,304

Balance as of September 30, 2020		52,606,700	$	526	$	1,087,996	$	(9,723	)	$	46,071	$	1,124,870


	Three Months Ended September 30, 2020
	Common Stock				Additional Paid- In Capital		Accumulated Other Comprehensive Loss			Retained Earnings		Total Stockholders’ Equity
	Number of Shares		Par Value		Additional Paid- In Capital		Accumulated Other Comprehensive Loss			Retained Earnings		Total Stockholders’ Equity
Balance at June 30, 2020		52,494,884	$	525	$	1,082,096	$	(14,113	)	$	31,519	$	1,100,027
Net income		—		—		—		—			14,552		14,552
Exercise of stock options and vesting of stock units		111,816		1		1,675		—			—		1,676
Stock-based compensation expense		—		—		4,225		—			—		4,225
Translation adjustment		—		—		—		4,390			—		4,390

Balance as of September 30, 2020		52,606,700	$	526	$	1,087,996	$	(9,723	)	$	46,071	$	1,124,870


	Nine Months Ended September 30, 2019
	Common Stock					Additional Paid- In Capital			Accumulated Other Comprehensive Loss			Retained Earnings/ (Accumulated Deficit)			Total Stockholders’ Equity
	Number of Shares			Par Value		Additional Paid- In Capital			Accumulated Other Comprehensive Loss			Retained Earnings/ (Accumulated Deficit)			Total Stockholders’ Equity
Balance at December 31, 2018		43,917,378		$	439	$	642,590		$	(11,893	)	$	(15,568	)	$	615,568
Net income		—			—		—			—			17,807			17,807
Issuance of common stock for debt conversion		2,316,229			23		198,734			—			—			198,757
Reduction for equity component from debt conversion, net of tax		—			—		(200,079	)		—			—			(200,079	)
Exercise of stock options and vesting of stock units		311,299			3		1,055			—			—			1,058
Issuance of common stock pursuant to the acquisition of C Technologies, Inc.		779,221			8		53,930			—			—			53,938
Tax withholding on vesting of restricted stock units		(3,077	)		—		(290	)		—			—			(290	)
Equity component of 0.375% senior convertible notes, net of tax		—			—		38,088			—			—			38,088
Proceeds from issuance of common stock, net of issuance cost of $18,607		4,731,531			48		320,665			—			—			320,713
Stock-based compensation expense		—			—		9,459			—			—			9,459
Translation adjustment		—			—		—			(9,901	)		—			(9,901	)

Balance as of September 30, 2019		52,052,581		$	521	$	1,064,152		$	(21,794	)	$	2,239		$	1,045,118

Table of Contents


	Three Months Ended September 30, 2019
	Common Stock					Additional Paid- In Capital			Accumulated Other Comprehensive Loss			Retained Earnings		Total Stockholders’ Equity
	Number of Shares			Par Value		Additional Paid- In Capital			Accumulated Other Comprehensive Loss			Retained Earnings		Total Stockholders’ Equity
Balance at June 30, 2019		48,086,422		$	481	$	892,960		$	(15,053	)	$	580	$	878,968
Net income		—			—		—			—			1,659		1,659
Issuance of common stock for debt conversion		2,316,200			23		198,732			—			—		198,755
Reduction of equity component from debt conversion, net of tax		—			—		(200,079	)		—			—		(200,079	)
Exercise of stock options and vesting of stock units		66,036			1		493			—			—		494
Tax withholding on vesting of restricted stock units		(3,077	)		—		(290	)		—			—		(290	)
Equity component of 0.375% senior convertible notes, net of tax		—			—		38,088			—			—		38,088
Proceeds from issuance of common stock, net of issuance cost of $6,981		1,587,000			16		131,073			—			—		131,089
Stock-based compensation expense		—			—		3,175			—			—		3,175
Translation adjustment		—			—		—			(6,741	)		—		(6,741	)

Balance as of September 30, 2019		52,052,581		$	521	$	1,064,152		$	(21,794	)	$	2,239	$	1,045,118

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

REPLIGEN CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, amounts in thousands)


	Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities:
Net income	$	40,228		$	17,807
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		19,581			14,791
Non-cash interest expense		8,175			4,863
Stock-based compensation expense		12,492			9,459
Deferred income taxes, net		72			(9,680	)
Loss on extinguishment of debt		—			5,650
Other		228			114
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable		(11,515	)		(6,734	)
Royalties and other receivables		157			26
Unbilled receivables		456			2,047
Inventories		(22,767	)		(4,891	)
Prepaid expenses and other assets		(2,908	)		(1,075	)
Operating lease right of use assets		2,574			787
Other assets		(260	)		(66	)
Accounts payable		3,317			(780	)
Accrued expenses		(2,712	)		7,263
Operating lease liability		(831	)		(607	)
Long-term liabilities		1,467			10,568

Total cash provided by operating activities		47,754			49,542

Cash flows from investing activities:
Acquisitions, net of cash acquired		(28,445	)		(182,154	)
Additions to capitalized software costs		(3,585	)		(4,630	)
Purchases of property, plant and equipment		(11,067	)		(11,413	)

Total cash used in investing activities		(43,097	)		(198,197	)

Cash flows from financing activities:
Proceeds from exercise of stock options		7,088			1,058
Payment of tax withholding obligation on vesting of restricted stock		(10	)		(290	)
Proceeds from issuance of convertible debt, net		—			278,555
Proceeds from issuance of common stock, net		—			320,713
Repayment of senior convertible notes		—			(114,989	)

Total cash provided by financing activities		7,078			485,047

Effect of exchange rate changes on cash, cash equivalents and restricted cash		4,160			(7,785	)

Net increase in cash, cash equivalents and restricted cash		15,895			328,607

Cash, cash equivalents and restricted cash, beginning of period		537,407			193,822

Cash, cash equivalents and restricted cash, end of period	$	553,302		$	522,429

Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	$	1,456		$	—

Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes	$	—		$	198,757

Fair value of common stock issued for acquisition of C Technologies, Inc.	$	—		$	53,938

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

REPLIGEN CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1.	Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form

10-Q

and Article 10 of Regulation

S-X

and do not include all of the information and footnote disclosures required by GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form

10-K

(“Form

10-K”)

for the fiscal year ended December 31, 2019.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum LifeSciences, LLC and its subsidiaries (“Spectrum”), C Technologies, Inc. (“C Technologies”), Engineered Molding Technology (“EMT”) and Repligen Singapore Pte. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation.

The Company made no material changes in the application of

its

significant accounting policies that were disclosed in its Form

10-K.

In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.

Risks and Uncertainties

The ultimate impact that the current pandemic of the novel coronavirus (“COVID-19”), may have on the Company and its customers, employees, suppliers, vendors, business partners and distribution channels is currently unknown. The Company is closely monitoring the impact of this evolving situation on all aspects of its business. While COVID-19 did not materially affect the Company’s financial results and business operations in the Company’s three and nine months ended September 30, 2020, the Company is unable to predict the impact that COVID-19 may have on its financial position and operations moving forward due to numerous uncertainties. These estimates may change as new events occur and additional information is obtained, and actual results could differ materially from these estimates under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-19 and will make adjustments to its operations as necessary.

Recent Accounting Standards Updates

We consider the applicability and impact of all Accounting Standards Updates on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued Accounting Standards Updates that we feel may be applicable to the Company are as follows:

Recently Issued Accounting Standard Updates – Adopted During the Period

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”)

2018-13,

“Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.”

ASU

2018-13

includes amendments that aim to improve the effectiveness of fair value measurement disclosures. The amendments in this guidance modify the disclosure requirements on fair value measurements based on the concepts in FASB Concepts Statement,

“Conceptual Framework for Financial Reporting - Chapter 8: Notes to Financial Statements

”

including the consideration of costs and benefits. The Company adopted ASU

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

Table of Contents

In August 2018, the FASB issued ASU

2018-15,

“Intangibles – Goodwill and Other –

Internal-Use

Software (Subtopic

350-40):

Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.”

ASU

2018-15

aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain

internal-use

software (and hosting arrangements that include an

internal-use

software license). The guidance also requires the entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. The Company adopted ASU

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

In June 2016, the FASB issued ASU

2016-13,

“

Financial Instruments-Credit Losses (Topic 326).”

ASU

2016-13

significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU

2016-13

replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments, including short-term trade receivables and contract assets, and expands disclosure requirements for credit quality of financial assets. The Company adopted ASU

2016-13

on January 1, 2020. The Company assessed all potential impacts that the adoption of this guidance has on its consolidated financial statements. Based on the composition of the Company’s investment portfolio, accounts receivable, current market conditions and historical credit loss activity, the adoption of ASU

2016-13

by the Company did not have a material impact on its consolidated financial position, results of operations or cash flows as of and for the three and nine months ended September 30, 2020. The Company continues to monitor processes and controls for indications of an adjustment for future economic conditions at quarterly and annual reporting periods. See Note 5,

“Credit Losses,”

below for more information on the Company’s adoption of ASC 326.

In November 2018, the FASB issued ASU

2018-18,

“Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.”

ASU

2018-18

clarifies the interaction between Topic 808,

“Collaborative Arrangements,”

and Topic 606,

“Revenue from Contracts with Customers,”

by making targeted improvements to GAAP for collaborative arrangements and providing guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. This includes improving comparability in the presentation of revenue for certain transactions between collaborative arrangement participants by allowing presentation of the units of account in collaborative arrangements that are within the scope of Topic 606 together with revenue accounted for under Topic 606. The Company adopted ASU

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

In December 2019, the FASB issued ASU

2019-12,

“

Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes.”

ASU

2019-12

simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, including, but not limited to, the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, the exceptions related to the recognition of a deferred tax liability related to an equity method investment and the exception to methodology for calculating income taxes in an interim period when a

year-to-date

loss exceeds the anticipated loss for the year. The Company adopted ASU

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

Recently Issued Accounting Standard Updates – Not Yet Adopted

In August 2020, the FASB issued ASU

2020-06,

“

Debt - Debt with Conversion and Other Options (Subtopic

470-20)

and Derivatives and Hedging - Contracts in Entity

’

s Own Equity (Subtopic

815-40).

”

ASU

2020-06

simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU

2020-06

also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU

2020-06

is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the timing and impact of the adoption of ASU

2020-06

on the Company’s consolidated financial statements.

Table of Contents

2.	Fair Value Measurements

The Company uses various valuation approaches in determining the fair value of its assets and liabilities. The Company employs a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:


		Level 1 –		Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
		Level 2 –		Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
		Level 3 –		Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for financial statement disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is categorized is based on the lowest level input that is significant to the overall fair value measurement.

As of September 30, 2020 and December 31, 2019, cash and cash equivalents on the Company’s consolidated balance sheets included $395.6 million and $415.6 million, respectively, in a money market account. These funds are valued on a recurring basis using Level 1 inputs.

In July 2019, the Company issued $287.5 million aggregate principal amount of the Company’s 0.375% Convertible Senior Notes due July 15, 2024 (the “2019 Notes”). Interest is payable semi-annually in arrears on January 15 and July 15 of each year. The 2019 Notes will mature on July 15, 2024

unless earlier converted or repurchased in accordance with their terms. As of September 30, 2020, the carrying value of the 2019 Notes was $240.9 million, net of unamortized discount, and the fair value of the 2019 Notes was $416.0 million. The fair value of the 2019 Notes is a Level 1 valuation and was determined based on the most recent trade activity of the 2019 Notes as of September 30, 2020. The 2019 Notes are discussed in more detail in Note 8,

“Convertible Senior Notes”

to these consolidated financial statements.

The Company’s

non-financial

assets include goodwill and other intangible assets, which we classify as Level 3 items. These assets are measured at fair value on a

non-recurring

basis as part of our impairment testing. See Note 6,

“Goodwill and Intangible Assets,”

below for additional information related to goodwill and intangible assets, and our impairment testing.

During the three and nine months ended September 30, 2020, there were no remeasurements to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis.

3.	Acquisitions

Engineered Molding Technology LLC

On July 13, 2020, the Company completed the acquisition of 100% of the membership interests of Engineered Molding Technology LLC (“EMT”), a New York limited liability company

pursuant to a Membership Interest Purchase Agreement, dated June 26, 2020, by and among the Company, EMT, and Michael Pandori and Todd Etesse, the legal and beneficial owners of EMT (such acquisition, the “EMT Acquisition”).

EMT, which is headquartered in Clifton Park, New York, is an innovator and manufacturer of

single-use

silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molding as well as their over-molded connectors and silicone tubing products are key components in

single-use

filtration and chromatography systems. EMT’s products will complement and expand Repligen’s

single-use

product offerings.

Consideration Transferred

The EMT

Acquisition

was accounted for as a purchase of a business under ASC 805,

“Business Combinations”.

Total consideration paid was $28.5 million

which included $2.2 million

deposited into an escrow account against which the Company may make claim

for indemnification

Under the acquisition method of accounting, the net assets of EMT were recorded as of the acquisition date, at their respective fair values, and consolidated with those of Repligen. The fair value of the net tangible assets acquired is estimated to be approximately $1.5 million, the fair value of the intangible assets acquired is estimated to be $14.4 million, and the residual goodwill is estimated to be approximately $12.6 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. The preparation of the valuation required the use of significant assumptions and

estimates

. Critical estimates included, but were not

Table of Contents

limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that Repligen believes to be reasonable. However, actual results may differ from these estimates.

Acquisition

related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred $1.0 million and $1.1 million of acquisition related costs during the three and nine months ended September 30, 2020. The transaction costs are included in selling, general and

administrative

expenses in the consolidated statements of comprehensive income (loss).

Fair Value of Net Assets Acquired

The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period (which will not exceed 12 months from July 13, 2020). Any such revisions or changes may be material. The components and allocation of the purchase price consists of the following amounts (amounts in thousands):


Cash and cash equivalents	$	69
Accounts receivable		1,057
Inventory		449
Prepaid expenses and other current assets		7
Fixed assets, net		472
Operating lease right of use assets		1,050
Customer relationships		11,080
Developed technology		2,910
Trademark and tradename		320
Non-compete agreements		50
Goodwill		12,573
Accounts payable		(283	)
Accrued liabilities		(190	)
Operating lease liability		(211	)
Operating lease liability, long-term		(839	)

Fair value of net assets acquired	$	28,514

Acquired Goodwill

The goodwill of $12.6 million represents future economic benefits expected to arise from anticipated synergies from the integration of EMT. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the EMT Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes.

Intangible Assets

The following table sets forth the components of the identified intangible assets associated with the EMT Acquisition and their estimated useful lives:


	Useful life		Fair Value
			(Amounts in thousands)
Customer relationships		14 years	$	11,080
Developed technology		11 years		2,910
Trademark and tradename		14 years		320
Non-competition agreements		3 years		50

			$	14,360

Table of Contents

Revenue, Net Income and Pro Forma Presentation

The Company has included the operating results of EMT in its consolidated statements of comprehensive income (loss) since the July 13, 2020 acquisition date. The Company does not consider this acquisition to be material to its consolidated statements of comprehensive income (loss) and therefore has not included pro forma results.

C Technologies, Inc.

On May 31, 2019, Repligen acquired C Technologies, pursuant to the terms of a Stock Purchase Agreement (the “Agreement”), by and among Repligen, C Technologies and Craig Harrison, an individual and sole stockholder of C Technologies (such acquisition, the “C Technologies Acquisition”).

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred $4.0 million in transaction costs for the nine months ended September 30, 2019. The transaction costs are included in selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). In connection with the transaction, an additional $9.0 million was paid to employees during the second quarter of 2020, based on their continued employment with the Company one year after the date of the close of the C Technologies Acquisition.

The

Company has recognized $3.7 million of compensation expense associated

with

this amount due to employees

during the nine months ended September 30, 2020

and has recognized $9.0 million of compensation expense associated with this amount due since the C Technologies Acquisition.

Fair Value of Net Assets Acquired

The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. The Company obtained this information during due diligence and through other sources. In the months after closing, the Company obtained additional information about these assets and liabilities as it learned more about C Technologies. The Company refined the estimates of fair value to more accurately allocate the purchase price. Only items identified as of the acquisition date were considered for subsequent adjustment. We made appropriate adjustments to the purchase price allocation during the measurement period, which was one year from the acquisition date. The components and allocation of the purchase price consists of the following amounts (amounts in thousands):


Cash and cash equivalents	$	3,795
Restricted cash		26,933
Accounts receivable		3,044
Inventory		3,783
Prepaid expenses and other current assets		93
Fixed assets		40
Operating lease right of use asset		3,836
Customer relationships		59,680
Developed technology		28,920
Trademark and tradename		1,570
Non-competition agreements		660
Goodwill		142,314
Deferred taxes		895
Accounts payable		(436	)
Accrued liabilities		(2,767	)
Accrued bonus		(26,928	)
Deferred revenue		(1,709	)
Operating lease liability		(51	)
Operating lease liability, long-term		(3,785	)

Fair value of net assets acquired	$	239,887

Acquired Goodwill

The goodwill of $142.3 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Pursuant to the Company’s business combination accounting policy included in Note 2,

“

Summary of Significant Accounting Policies – Business Combinations, Goodwill and Intangible Assets,

”

of the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2019, the Company

Table of Contents

recorded goodwill adjustments for the effects on goodwill of changes to net assets acquired during the period that such change is identified, provided that any such change is within the measurement period (up to one year from the date of the acquisition). In March 2020, the Company recorded an adjustment to goodwill of $0.3 million related to additional state income tax liabilities to be paid to the seller, which were incurred from the Company’s finalized 338(h)(10) tax election.

Revenue, Net Income and Pro Forma Presentation

The Company recorded revenue from C Technologies of $9.0 million and $23.3 million for the three and nine months ended September 30, 2020, respectively, and $16.4 million from May 31, 2019, the date of acquisition, to December 31, 2019. The Company recorded a net income from C Technologies’ results of operations of $2.1 million and a net loss of $0.8 million for the three and nine months ended September 30, 2020, respectively, and a net loss of $7.4 million from May 31, 2019 to December 31, 2019. The Company has included the operating results of C Technologies in its consolidated statements of comprehensive income (loss) since the May 31, 2019 acquisition date. The following pro forma financial information presents the combined results of operations of Repligen and C Technologies as if the acquisition had occurred on January 1, 2019 after giving effect to certain pro forma adjustments. The pro forma adjustments reflected herein include only those adjustments that are directly attributable to the C Technologies Acquisition, factually supportable and have a recurring impact. These pro forma adjustments include amortization expense on the acquired identifiable intangible assets, adjustments to stock-based compensation expense for equity compensation issued to C Technologies employees and the income tax effect of the adjustments made. In addition, acquisition-related transaction costs and an accounting adjustment to record inventory at fair value were excluded from pro forma net income in 2019.

Prior to the C Technologies Acquisition, C Technologies did not generate monthly or quarterly financial statements that were prepared in accordance with GAAP.

The following pro forma financial information does not reflect any adjustments for anticipated expense savings resulting from the acquisition and is not necessarily indicative of the operating results that would have actually occurred had the transaction been consummated on January 1, 2019 or of future results (amounts in thousands, except per share data):


	Nine Months Ended September 30,
	2019
Pro forma total revenue	$	209,960
Pro forma net income	$	21,012
Pro forma earnings per share:
Basic	$	0.45

Diluted	$	0.44

4.	Revenue Recognition

The Company generates revenue from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. Under ASC 606,

“Revenue from Contracts with Customers,”

revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers.

Disaggregation of Revenue

Revenues for the three and nine months ended September 30, 2020 and 2019 were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Product revenue	$	94,029	$	69,419	$	257,521	$	200,701
Royalty and other income		31		26		91		70

Total revenue	$	94,060	$	69,445	$	257,612	$	200,771

When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s

Table of Contents

revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenues are generated from two customers; therefore, economic factors specific to these two customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows.

Disaggregated revenue from contracts with customers by geographic region can be found in Note 15,

“Segment Reporting,”

below.

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Cytiva (formerly GE Healthcare)		N/A		N/A		N/A	$	23,759
MilliporeSigma		N/A	$	9,458	$	29,387	$	28,354

Chromatography Products

The Company’s chromatography products include a number of products used in the downstream purification and quality control of biological drugs. The majority of chromatography revenue relates to the OPUS

pre-packed

chromatography column line. OPUS columns are designed to be disposable following a production campaign. Each OPUS column is delivered

pre-packaged

with the customer’s choice of chromatography resin, which is either provided by the Company for the customer or customer supplied. In either scenario, the OPUS column and resin are not interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Chromatography product revenue is generally recognized at a point in time upon transfer of control to the customer.

Filtration Products

The Company’s filtration products generate revenue through the sale of KrosFlo

hollow fiber TFF systems, TangenX

flat sheet cassettes, Spectrum

hollow fiber filters, membranes and modules, XCell ATF

systems and related consumables

Supporting our systems, we also sell

ProConnex

single-use

flow path assemblies

and custom silicone-based, single-use flow path assemblies and components from EMT

The Company’s KrosFlo systems are used in the filtration, isolation, purification and concentration of biologics and diagnostic products. TFF is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process development and process scale applications in biopharmaceutical manufacturing. Sales of large-scale systems generally include components and consumables as well as training and installation services at the request of the customer. Because the initial sale of components and consumables are necessary for the operation of the system, such items are combined with the systems as a single performance obligation. Training and installation services do not significantly modify or customize these systems and therefore represent a distinct performance obligation.

The Company’s TangenX flat sheet cassettes (SIUS

, SIUS Gamma

and PRO) are not highly interdependent on one another and are therefore considered distinct products that represent separate performance obligations. Product revenue from the sale of TangenX flat sheet cassettes are generally recognized at a point in time upon transfer of control of the customer.

The Company’s other filtration product offerings are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Revenue on these products is generally recognized at a point in time upon transfer of control to the customer. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC

606-10-55-18.

The Company also markets the XCell ATF system, a technologically advanced filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest. XCell ATF systems typically include a filtration system and consumables (i.e., tubing sets, metal stands) as well as training and installation services at the request of the customer. The filtration system and consumables are considered distinct products and therefore represent separate performance obligations. First time purchasers of the systems typically purchase a controller that is shipped with the tubing set(s) and metal stand(s). The controller is not considered distinct as it is a proprietary product that is highly interdependent with the filtration system; therefore, the controller is combined with the filtration system and accounted for as a single performance obligation. The training and installation services do not significantly modify or customize the XCell ATF system and therefore represent a distinct performance obligation. XCell

ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally

Table of Contents

recognized at a point in time upon transfer of control to the customer. XCell ATF system service revenue related to training and installation services is generally recognized over time, as the customer simultaneously receives and consumes the benefits as the Company performs. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC

606-10-55-18.

On July 13, 2020, the Company consummated the EMT Acquisition and added EMT’s silicone-based,

single-use

components and manifolds to its filtration franchise. These products are key components in

single-use

filtration and chromatography systems and will help expand its line of

single-use

ProConnex flow paths, streamline its supply chain for ATF and provide more flexibility as the Company scales and expands its

single-use

and systems portfolios.

Process Analytics Products

The Process Analytics franchise generates revenue primarily through the sale of the SoloVPE and FlowVPE Slope Spectroscopy systems, consumables and service. These products complement and support the Company’s existing Filtration, Chromatography and Proteins franchises as they allow end users to make

in-line

protein concentration measurements in filtration, chromatography and fill-finish applications, designed to allow for real-time process monitoring.

Protein Products

The Company’s Protein franchise generates revenue through the sale of Protein A affinity ligands and growth factors. Protein A ligands are an essential component of Protein A chromatography resins (media) used in the purification of virtually all

mAb-based

drugs on the market or in development. The Company manufactures multiple forms of Protein A ligands under long-term supply agreements with major life sciences companies, who in turn sell their Protein A chromatography media to end users (biopharmaceutical manufacturers). The Company also manufactures growth factors for sale under long-term supply agreements with certain life sciences companies as well as

for

direct sales to its customers. Each protein product is considered distinct and therefore represents a separate performance obligation. Protein product revenue is generally recognized at a point in time upon transfer of control to the customer.

Other Products

The Company’s other products include operating room products sold to hospitals. Other product revenue is generally recognized at a point in time upon transfer of control to the customer.

Transaction Price Allocated to Future Performance Obligations

Remaining performance obligations represents the transaction price of contracts for which work has not been performed or has been partially performed. The Company’s future performance obligations relate primarily to the installation and training of certain of its systems sold to customers. These performance obligations are completed within one year of receipt of a purchase order from its customers. Accordingly, the Company has elected to not disclose the value of these unsatisfied performance obligations as provided under ASC

606-10-50-14.

Contract Balances from Contracts with Customers

The following table provides information about receivables and deferred revenues from contracts with customers as of September 30, 2020 (amounts in thousands):


	2020
Balances from contracts with customers only:
Accounts receivable	$	55,830
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	$	10,141
Revenue recognized during the nine-month period ended September 30, 2020 relating to:
The beginning deferred revenue balance	$	3,133
Changes in pricing related to products or services satisfied in previous periods	$	—

The timing of revenue recognition, billings and cash collections results in the accounts receivables and deferred revenue balances on the Company’s consolidated balance sheets.

Table of Contents

A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional, and recorded as a contract asset, if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due.

When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met.

Costs to Obtain or Fulfill a Customer Contract

The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature.

Applying the practical expedient in paragraph

340-40-25-4,

the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. When shipping and handling costs are incurred after a customer obtains control of the products, the Company accounts for these as costs to fulfill the promise and not as a separate performance obligation.

5.	Credit Losses

Effective January 1, 2020, the Company adopted ASU

2016-13,

“Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,”

prospectively. ASU

2016-13

replaces the incurred loss impairment model with an expected credit loss impairment model for financial instruments, including trade receivables. The guidance requires entities to consider forward-looking information to estimate expected credit losses, resulting in earlier recognition of losses for receivables that are current or not yet due. Upon adoption, changes in the allowance were not material for the transition period starting January 1, 2020 through the nine months ended September 30, 2020.

The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and a review of the current status of customers’ trade accounts receivables. Customers are pooled based on sharing specific risk factors, including geographic location. Due to the short-term nature of such receivables, the estimated accounts receivable that may not be collected is based on aging of the accounts receivable balances.

Customers are assessed for credit worthiness upfront through a credit review, which includes assessment based on the Company’s analysis of their financial statements when a credit rating is not available. The Company evaluates contract terms and conditions, country and political risk, and may require prepayment to mitigate risk of loss. Specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The Company monitors changes to the receivables balance on a timely basis, and balances are written off as they are determined to be uncollectable after all collection efforts have been exhausted. Estimates of potential credit losses are used to determine the allowance. It is based on assessment of anticipated payment and all other historical, current and future information that is reasonably available.

The accounts receivable balance on the Company’s consolidated balance sheet as of September 30, 2020 was $55.8 million, net of $0.6 million of allowances. The following table provides a roll-forward of the allowance for credit losses in 2020 that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected (amounts in thousands):

Table of Contents


	2020
Balance at January 1, 2020	$	(525	)
Current period change for expected credit losses		(133	)

Balance at March 31, 2020		(658	)
Current period change for write-offs		37
Current period change for expected credit losses		83

Balance at June 30, 2020		(538	)
Current period change for expected credit losses		(83	)

Balance at September 30, 2020	$	(621	)

6.	Goodwill and Intangible Assets

Goodwill

Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment at least annually in accordance with ASC 350,

“Intangibles – Goodwill and Other”

. The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2020 (amounts in thousands):


Balance as of December 31, 2019	$	468,413
Acquisition of Engineered Molding Technology		12,573
Goodwill adjustment related to C Technologies, Inc.		293
Cumulative translation adjustment		764

Balance as of September 30, 2020	$	482,043

During each of the fourth quarters of 2019, 2018 and 2017, the Company completed its annual impairment assessments and concluded that goodwill was not impaired in any of those years. The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three and nine months ended September 30, 2020.

Intangible Assets

Intangible assets with a definitive life are amortized over their useful lives using the straight-line method, and the amortization expense is recorded within cost of product revenue and selling, general and administrative expenses in the Company’s statements of comprehensive income (loss). Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for the Company’s products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at September 30, 2020.

Indefinite-lived assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented.

Table of Contents

Intangible assets, net consisted of the following at September 30, 2020:


	September 30, 2020
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Useful Life (in years)
	(Amounts in thousands)
Finite-lived intangible assets:
Technology - developed	$	85,196	$	(13,054	)	$	72,142		18
Patents		240		(240	)		—		8
Customer relationships		172,325		(33,861	)		138,464		15
Trademarks		4,072		(480	)		3,592		19
Other intangibles		1,750		(1,263	)		487		3

Total finite-lived intangible assets		263,583		(48,898	)		214,685		16
Indefinite-lived intangible asset:
Trademarks		700		—			700		—

Total intangible assets	$	264,283	$	(48,898	)	$	215,385

Intangible assets consisted of the following at December 31, 2019:


	December 31, 2019
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Useful Life (in years)
	(Amounts in thousands)
Finite-lived intangible assets:
Technology - developed	$	82,169	$	(9,669	)	$	72,500		19
Patents		240		(240	)		—		8
Customer relationships		160,825		(25,642	)		135,183		15
Trademarks		3,752		(333	)		3,419		20
Other intangibles		1,697		(947	)		750		3

Total finite-lived intangible assets		248,683		(36,831	)		211,852		16
Indefinite-lived intangible asset:
Trademarks		700		—			700		—

Total intangible assets	$	249,383	$	(36,831	)	$	212,552

Amortization expense for finite-lived intangible assets was $4.0 million and $3.9 million for the three months ended September 30, 2020 and 2019, respectively. Amortization expense was $11.8 million and $9.6 million for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, the Company expects to record the following amortization expense in future periods (amounts in thousands):


For the Nine Months Ended September 30,	Estimated Amortization Expense
2020 (remaining three months)	$	3,964
2021		15,855
2022		15,853
2023		15,749
2024		15,298
2025 and thereafter		147,966

Total	$	214,685

Table of Contents

7.	Consolidated Balance Sheet Detail

Inventories, net

Inventories, net consists of the following:


	As of
	September 30, 2020		December 31, 2019
	(Amounts in thousands)
Raw materials	$	42,201	$	29,328
Work-in-process		6,192		8,360
Finished products		30,138		17,144

Total inventories, net	$	78,531	$	54,832

Property, Plant and Equipment

Property, plant and equipment consist of the following:


	As of
	September 30, 2020			December 31, 2019
	(Amounts in thousands)
Land	$	1,023		$	1,023
Buildings		989			764
Leasehold improvements		29,776			23,905
Equipment		39,094			36,257
Furniture, fixtures and office equipment		8,055			6,312
Computer hardware and software		14,468			8,810
Construction in progress		6,416			6,707
Other		348			56

Total property, plant and equipment		100,169			83,834
Less - Accumulated depreciation		(44,814	)		(35,379	)

Total property, plant and equipment, net	$	55,355		$	48,455

Depreciation expense totaled $2.8 million and $1.8 million for the three months ended September 30, 2020 and 2019, respectively. Depreciation expenses totaled $7.8 million and $5.2 million for the nine months ended September 30, 2020 and 2019, respectively.

Accrued Liabilities

Accrued liabilities consist of the following:


	As of
	September 30, 2020		December 31, 2019
	(Amounts in thousands)
Employee compensation	$	14,652	$	19,850
Taxes		2,759		3,874
Royalty and license fees		1,000		123
Warranties		737		1,500
Professional fees		1,745		1,081
Deferred revenue		10,141		5,005
Other		1,007		1,898

Total accrued liabilities	$	32,041	$	33,331

8.	Convertible Senior Notes

0.375% Convertible Senior Notes due 2024

On July 19, 2019, the Company issued $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (“2019 Notes”), which includes the underwriters’ exercise in full of an option to purchase an additional $37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other related offering expenses payable by the Company, were approximately $278.5 million.

Table of Contents

The 2019 Notes are senior, unsecured obligations of the Company, and bear interest at a rate of 0.375% per year. Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020. The 2019 Notes will mature on July 15, 2024, unless earlier repurchased or converted in accordance with their terms. The initial conversion rate for the 2019 Notes is 8.6749 shares of the Company’s common stock per $1,000 principal amount of 2019 Notes (which is equivalent to an initial conversion price of approximately $115.28 per share). Prior to the close of business on the business day immediately preceding April 15, 2024, the 2019 Notes will be convertible at the option of the holders of 2019 Notes only upon the satisfaction of specified conditions and during certain periods. Thereafter until the close of business on the second scheduled trading day immediately preceding the maturity date, the 2019 Notes will be convertible at the options of the holders of 2019 Notes at any time regardless of these conditions. Conversion of the 2019 Notes will be settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. The 2019 Notes are not redeemable by the Company prior to maturity.

Holders of 2019 Notes may require the Company to repurchase their 2019 Notes upon the occurrence of a fundamental change prior to maturity at a repurchase price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but excluding, the date of repurchase. In connection with certain corporate events, the Company will, under certain circumstances, increase the conversion rate for holders of 2019 Notes who elect to convert their 2019 Notes in connection with such corporate events.

As of September 30, 2020, the conditions allowing holders of the 2019 Notes to convert have not been met and therefore the 2019 Notes are not yet convertible and are recorded as a long-term liability in the Company’s consolidated balance sheet at September 30, 2020. No 2019 Notes were converted by the holders of such notes in the third quarter of 2020. In the event the closing price conditions are met in the fourth quarter of 2020 or a future fiscal quarter, the 2019 Notes will be convertible at a holder’s option during the immediately following fiscal quarter.

The Company accounts for the 2019 Notes as separate liability and equity components. We determined the carrying amount of the liability component as the present value of its cash flows using a discount rate of 4.5% based on comparative convertible transactions for similar companies. The proceeds allocated to the debt conversion feature were $52.1 million. This amount was calculated by deducting the carrying value of the liability component from the principal amount of the 2019 Notes as a whole. The difference represents a debt discount that is amortized to interest expense on the Company’s consolidated statement of comprehensive income (loss) over the term of the 2019 Notes using the effective interest rate method. The Company will assess the equity classification of the cash conversion feature quarterly, and it is not

re-measured

as long as it continues to meet the conditions for equity classification.

The Company allocates transaction costs related to the issuance of the 2019 Notes to the liability and equity components using the same proportions as the initial carrying value of the 2019 Notes. Transaction costs related to the liability component were $7.4 million and are being amortized to interest expense using the effective interest method over the term of the 2019 Notes. Transaction costs attributable to the equity component were $1.6 million and are netted with the equity component of the 2019 Notes in stockholders’ equity of the Company’s consolidated balance sheet at September 30, 2020.

The net carrying value of the liability component of the 2019 Notes is as follows:


	As of
	September 30, 2020			December 31, 2019
	(Amounts in thousands)
0.375% convertible senior notes due 2024:
Principal amount	$	287,500		$	287,500
Less: unamortized debt discount		(40,764	)		(47,921	)
Less: unamortized debt issuance costs		(5,794	)		(6,812	)

Total debt		240,942			232,767
Less: current portion		—			—

Net carrying amount	$	240,942		$	232,767

Interest expense recognized on the 2019 Notes for the three months ended September 30, 2020 was $0.3 million, $2.4 million and $0.3 million for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. Interest expense recognized on the 2019 Notes for the nine months ended September 30, 2020 was $0.8 million, $7.2 million and $1.0 million for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. The effective interest rate on the 2019 Notes is 5.1%, which included the interest on the

Table of Contents

2019 Notes, amortization of the debt discount and debt issuance costs. As of September 30, 2020, the carrying value of the 2019 Notes was $240.9 million and the fair value of the principal was $416.0 million. The fair value of the 2019 Notes was determined based on the most recent trade activity of the 2019 Notes as of September 30, 2020.

Conversion of the 2.125% Convertible Senior Notes due 2021

The Company utilized a portion of the proceeds from the issuance of the 2019 Notes to settle its outstanding 2.125% Convertible Senior Notes due 2021 (the “2016 Notes”) during the third quarter of 2019. On July 16, 2019, the Company entered into separate privately negotiated agreements with certain holders of the 2016 Notes to exchange an aggregate of $92.0 million principal aggregate amount of the 2016 Notes for shares of the Company’s common stock, together with cash, in private placement transactions (the “Note Exchanges”). On July 19, 2019 and July 22, 2019, the Company used approximately $92.3 million (including $0.3 million of accrued interest) and 1,850,155 shares of its common stock valued at $161.0 million to settle the Note Exchanges for total consideration of $253.3 million, of which $163.6 million was allocated to reacquiring the equity component of the 2016 Notes. The Company allocated the consideration transferred to the liability and equity components using the same proportions as the initial carrying value of the 2016 Notes. The transaction resulted in a loss on extinguishment of debt of $4.6 million in the Company’s consolidated statements of comprehensive income (loss) for the three and nine months ended September 30, 2019.

On July 19, 2019, the Company issued a Notice of Redemption in respect of the 2016 Notes, which provided that, on September 23, 2019, the Company would redeem all 2016 Notes that had not been converted, repurchased or exchanged prior to such date at a redemption price in cash equal to 100% of the principal amount thereof plus accrued and unpaid interest. On September 23, 2019, the Company used $23.0 million and 466,045 shares of its common stock valued at $37.8 million to settle the remaining 2016 Notes for a total of $60.8 million, of which $38.3 million was allocated to reacquiring the equity component of the 2016 Notes. This transaction resulted in a loss on extinguishment of debt of $1.1 million recorded on the Company’s consolidated statements of comprehensive income (loss). The total loss for the three and nine months ended September 30, 2019 of $5.7 million represents the difference between the fair value of the liability component of the 2016 Notes and its related carrying value immediately before the exchange.

The fair value of the liability component was calculated using a discounted cash flow technique with an effective interest rate of 3.9%, representing the estimated nonconvertible debt borrowing rate with a maturity as of the measurement date consistent with the 2016 Notes maturity date of June 1, 2021. In addition, in accordance with this guidance, a portion of the fair value of the consideration transferred is allocated to the reacquisition of the equity component, which is the difference between the fair value of the consideration transferred and the fair value of the liability component immediately before the exchange. As a result, on a gross basis, $200.1 million was allocated to the reacquisition of the equity component of the original instrument, which is recorded net of deferred taxes within additional

paid-in

capital on the Company’s consolidated balance sheet.

The cash conversion feature of the 2016 Notes required bifurcation from the 2016 Notes and was initially accounted for as an equity instrument classified to stockholders’ equity, as the conversion feature was determined to be clearly and closely related to the Company’s stock. Based on market data available for publicly traded, senior, unsecured corporate bonds issued by companies in the same industry and asset base and with similar maturity, the Company estimated the implied interest rate, assuming no conversion option. Assumptions used in the estimate represent what market participants would use in pricing the liability component, including market interest rates, credit standing, and yield curves, all of which are defined as Level 2 observable inputs. The estimated implied interest rate was applied to the 2016 Notes, which resulted in a fair value of the liability component of $96.3 million upon issuance, calculated as the present value of implied future payments based on the $115.0 million aggregate principal amount. The equity component of the 2016 Notes was recognized as a debt discount, recorded in additional

paid-in

capital, and represents the difference between the aggregate principal of the 2016 Notes and the fair value of the 2016 Notes without conversion option on their issuance date. The debt discount was amortized to interest expense using the effective interest method over five years, or the life of the 2016 Notes.

Interest expense recognized on the 2016 Notes for the three months ended September 30, 2019 was $0.1 million, $0.5 million and $0.1 million for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. Interest expense recognized on the 2016 Notes for the nine months ended September 30, 2019 was $1.3 million, $2.4 million and $0.4 million for the contractual coupon interest, the accretion of the debt discount and the amortization of the debt issuance costs, respectively. The effective interest rate on the 2016 Notes was 6.6%, which included the interest on the 2016 Notes, amortization of the debt discount and debt issuance costs.

Table of Contents

9.	Stockholders’ Equity

Public Offerings of Common Stock

On July 19, 2019, the Company completed a public offering in which 1,587,000 shares of its common stock, including the underwriters’ exercise in full of an option to purchase an additional 207,000 shares, were sold to the public at a price of $87.00 per share (the “Stock Offering”). The net proceeds of the Stock Offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, were approximately $131.1 million.

On May 3, 2019, the Company completed a public offering in which 3,144,531 shares of its common stock, which includes the underwriters’ exercise in full of an option to purchase up to an additional 410,156 shares, were sold to the public at a price of $64.00 per share. The total proceeds received by the Company from this offering, net of underwriting discounts and commissions and other estimated offering expenses payable by the Company, totaled approximately $189.6 million.

Stock Option and Incentive Plans

At the Company’s 2018 annual meeting of shareholders held on May 16, 2018, the Company’s shareholders approved the 2018 Stock Option and Incentive Plan (the “2018 Plan”). Under the 2018 Plan the number of shares of the Company’s common stock that are reserved and available for issuance is 2,778,000 plus the number of shares of common stock available for issuance under the Company’s Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan”). The shares of common stock underlying any awards under the 2018 Plan and 2012 Plan (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At September 30, 2020, 2,325,314 shares were available for future grant under the 2018 Plan.

Stock-Based Compensation

For the three months ended September 30, 2020 and 2019, th

Company recorded stock-based compensation expense of $4.2 million and $3.2 million, respectively, for share-based awards granted under the Plans. For the nine months ended September 30, 2020 and 2019, the Company recorded stock-based compensation expense of $12.5 million and $9.5 million, respectively. The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income (loss):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
			(Amounts in thousands)
Cost of product revenue	$	563	$	375	$	1,421	$	992
Research and development		326		351		1,092		992
Selling, general and administrative		3,336		2,449		9,979		7,475

Total stock-based compensation	$	4,225	$	3,175	$	12,492	$	9,459

The 2018 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Employee grants under the Plans generally vest over a three to five-year period, with

20%-33%

vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to

non-employee

directors under the Plans generally vest over one year. In the first quarter of 2018, to create a longer-term retention incentive, the Company’s Compensation Committee granted long-term incentive compensation awards to its Chief Executive Officer consisting of both stock options and restricted stock units (“RSUs”) that are subject to time-based vesting over nine years. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At September 30, 2020, options to purchase 723,914 shares and 675,567 stock units were outstanding under the Plans.

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value RSUs. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company issues performance stock units to certain employees that are tied to company and/or individual performance metrics and recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures.

Table of Contents

Information regarding option activity for the nine months ended September 30, 2020 under the Plans is summarized below:


	Shares			Weighted average exercise price		Weighted- Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Options outstanding at December 31, 2019		957,559		$	30.81
Granted		69,698		$	104.61
Exercised		(303,343	)	$	23.37
Forfeited/expired/cancelled		—		$	—

Options outstanding at September 30, 2020		723,914		$	41.03		7.02	$	77,102

Options exercisable at September 30, 2020		339,191		$	31.00		6.05	$	39,528

Vested and expected to vest at September 30, 2020 (1)		693,689					6.98	$	74,178

(1)

non-executive

level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total

pre-tax

intrinsic value (the difference between the closing price of the common stock on September 30, 2020, the last business day of the third quarter of 2020, of $147.54 per share and the exercise price of each

in-the-money

option) that would have been received by the option holders had all option holders exercised their options on September 30, 2020. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2020 and 2019 was $30.7 million and $5.2 million, respectively.

The weighted average grant date fair value of options granted during the nine months ended September 30, 2020 and 2019 was $48.13 and $30.07, respectively. The total fair value of stock options that vested during the nine months ended September 30, 2020 and 2019 was $2.6 million and $2.9 million, respectively.

The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2020 under the Plans is summarized below:


	Shares			Weighted- Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Unvested at December 31, 2019		734,984
Awarded		187,942
Vested		(225,204	)
Forfeited/expired/cancelled		(22,155	)

Unvested at September 30, 2020		675,567			3.39	$	99,673

Vested and expected to vest at September 30, 2020 (1)		650,436			3.20	$	95,965

(1)

Represents the number of vested stock units as of September 30, 2020 plus the number of unvested stock units expected to vest as of September 30, 2020 based on the unvested outstanding stock units at September 30, 2020 adjusted for estimated forfeiture rates of 8% for awards granted to

non-executive

level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total

pre-tax

intrinsic value (equal to the closing price of the common stock on September 30, 2020, the last business day of the third quarter of 2020, of $147.54 per share, as stock units do not have an exercise price) that would have been received by the stock unit holders had all holders exercised on September 30, 2020. The aggregate intrinsic value of stock units vested during the nine months ended September 30, 2020 and 2019 was $25.0 million and $15.5 million, respectively.

Table of Contents

The weighted average grant date fair value of stock units vested during the nine months ended September 30, 2020 and 2019 was $66.00 and $33.46, respectively. The total fair value of stock units that vested during the nine months ended September 30, 2020 and 2019 was $9.8 million and $7.6 million, respectively.

As of September 30, 2020, there was $47.0 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.61 years. The Company expects 1,833,239 unvested options and stock units to vest over the next five years.

10.	Commitments and Contingencies

Licensing and Research Agreements

The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements which require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three and nine months ended September 30, 2020 and 2019.

In June 2018, the Company secured an agreement with Navigo

Proteins

for the exclusive

co-development

of multiple affinity ligands for which Repligen holds commercialization rights. The Company is manufacturing and has agreed to supply the first of these ligands,

NGL-Impact

, exclusively to Purolite Life Sciences (“Purolite”), who will pair the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for

NGL-Impact

and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration.

In September 2020, Repligen and Navigo Proteins successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of COVID-19 vaccines. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which will be marketed by Repligen.

The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $0.2 million and $0.4 million during the three and nine months ended September 30, 2020

, respectively

11.	Accumulated Other Comprehensive Loss

The following shows the changes in the components of accumulated other comprehensive loss for the nine months ended September 30, 2020 which consisted of only foreign currency translation adjustments for the periods shown (amounts in thousands):


	Foreign
	Currency
	Translation
	Adjustment
Balance as of December 31, 2019	$	(15,027	)
Other comprehensive income		5,304

Balance as of September 30, 2020	$	(9,723	)

12.	Income Taxes

The Company’s effective tax rate for the three and nine months ended

September

30, 2020 was 18.0% and 9.5%, compared to 0.7% and 18.3% for the corresponding periods in the prior year. The effective tax rates for the three and nine months ended

September

30, 2020 and 2019 were lower than the U.S. statutory rate of 21% primarily due to windfall benefits on stock option exercises and the vesting of stock units.

The Company is subject to a territorial tax system under the Tax Cuts and Jobs Act (“TCJA”) enacted in December 2017, in which the Company is required to provide for tax on Global Intangible

Low-Taxed

Income (“GILTI”) earned by certain foreign subsidiaries. The Company has adopted an accounting policy to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense.

On March 27, 2020, President Trump signed the $2.2 trillion bipartisan Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The CARES Act, the third congressional bill to address

COVID-19,

provides for loans and other benefits to businesses, expanded unemployment insurance, direct payments to those with middle-income and below wages, new appropriations funding for healthcare and other priorities, and tax changes, including deferrals of employer payroll tax

Table of Contents

liabilities, coupled with an employee retention tax credit and rollbacks of TCJA limitations on net operating losses (“NOLs”) and the Section 163(j) business interest limitation and a TCJA technical correction on qualified improvement property. The Company evaluated the provisions of the CARES Act and no provision had a material effect on the Company’s financial position or results of operations at September 30, 2020 and the three and nine months then ended.

The Company’s tax returns are subject to examination by federal, state and international tax authorities for the following periods:


Jurisdiction	Fiscal Years Subject to Examination
United States - federal and state		2016-2019
Sweden		2013-2019
Germany		2019
Netherlands		2013-2019

13.	Earnings Per Share

The Company reports earnings per share in accordance with ASC 260,

“Earnings Per Share,”

which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards, performance stock units and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised

“in-the-money”

stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. In periods when the Company has a net loss, stock awards are excluded from the calculation of earnings per share as their inclusion would have an antidilutive effect.

Basic and diluted weighted average shares outstanding were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands, except per share data)
Net income	$	14,552	$	1,659	$	40,228	$	17,807

Weighted average shares used in computing net income per share - diluted		52,545		50,852		52,341		47,087
Effect of dilutive shares:
Stock options and restricted stock awards		916		957		951		843
Dilutive effect of unvested performance stock units		8		—		8		—

Dilutive potential common shares		924		957		959		843

Weighted average shares used in computing net income per share - diluted		53,469		51,809		53,300		47,930

Earnings per share:
Basic	$	0.28	$	0.03	$	0.77	$	0.38

Diluted	$	0.27	$	0.03	$	0.75	$	0.37

At September 30, 2020, there were outstanding options to purchase 723,914 shares of the Company’s common stock at a weighted average exercise price of $41.03 per share and 675,567 shares of common stock issuable upon the vesting of stock units, which include RSUs and performance stock units. For the three and nine months ended September 30, 2020, 60,202 and 117,160 shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive.

At September 30, 2019, there were outstanding options to purchase 959,916 shares of the Company’s common stock at a weighted average exercise price of $30.44 per share and 740,213 shares issuable upon the vesting of stock units. For the three and nine months ended September 30, 2019, 47,705 and 85,503 shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive.

Table of Contents

As provided by the terms of the indenture underlying the

2016

Notes, the Company had a choice to settl

the conversion obligation for the

2016

Notes in cash, shares or any combination of the two. During the third quarter of

2019

, the Company settled the remaining

2016

Notes for a total aggregate principal of $

115.0

million and

2,316,200

shares of its common stock. As of March

2019

, the par value of the

2016

Notes is not included in the calculation of diluted earnings per share, but the dilutive effect of the conversion premium is considered in the calculation of diluted earnings per share using the treasury stock method. The dilutive impact of the

2016

Notes was based on the difference between the Company’s current period average stock price and the conversion price of the

2016

Notes, provided there was a premium.

In July 2019, the Company issued $287.5 million aggregate principal amount of the 2019 Notes. As provided by the terms of the indenture underlying the 2019 Notes, conversion of the 2019 Notes will be settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. As of

September

30, 2020, the 2019 Notes were not convertible. The Company currently intends to settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company applies the provisions of ASC 260,

“Earnings Per Share”,

Subsection

10-45-44,

to determine the diluted weighted average shares outstanding as it relates to the conversion spread on the 2019 Notes. Accordingly, the par value of the 2019 Notes is not included in the calculation of diluted income per share, but the dilutive effect of the conversion premium is considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the 2019 Notes is based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there is a premium. Pursuant to this accounting standard, there is no dilution from the accreted principal of the 2019 Notes for the three and nine months ended September 30, 2020.

14.	Related Party Transactions

Certain facilities leased by Spectrum are owned by Roy Eddleman, the former owner of Spectrum. As of September 30, 2020, Mr. Eddleman owned greater than 5% of the Company’s outstanding shares and the Company considers him to be a related party. The lease amounts paid to this shareholder prior to the public offering were negotiated in connection with the Spectrum Acquisition. The Company incurred rent expense totaling $0.1 million and $0.5 million for the three and nine months ended September 30, 2020 related to these leases.

15.	Segment Reporting

The Company views its operations, makes decisions regarding how to allocate resources and manages its business as one reportable segment and one reporting unit. As a result, the financial information disclosed herein represents all of the material financial information related to the Company.

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue by customers’ geographic locations:
North America		50	%		54	%		48	%		51	%
Europe		36	%		33	%		38	%		37	%
APAC /Other		14	%		13	%		14	%		12	%

Total revenue		100	%		100	%		100	%		100	%

Concentrations of Credit Risk and Significant Customers

Financial instruments that subject the Company to significant concentrations of credit risk primarily consist of cash and cash equivalents, marketable securities and accounts receivable. Per the Company’s investment policy, cash equivalents and marketable securities are invested in financial instruments with high credit ratings and credit exposure to any one issue, issuer (with the exception of U.S. treasury obligations) and type of instrument is limited. At September 30, 2020 and December 31, 2019, the Company had no investments associated with foreign exchange contracts, options contracts or other foreign hedging arrangements.

Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential

write-off

of accounts receivable is maintained, the Company has not written off any significant accounts to date. To control credit risk, the Company performs regular credit evaluations of its customers’ financial condition.

Table of Contents

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020			2019
Cytiva (formerly GE Healthcare)		N/A		N/A			N/A			12	%
MilliporeSigma		N/A		14	%		11	%		14	%

There were no accounts receivable balances as of September 30, 2020 representing 10% or more of the Company’s total trade accounts receivable and royalties and other receivable balances. As of December 31, 2019, the accounts receivable balance with Cytiva (formerly GE Healthcare) represented 18% of the Company’s total trade accounts receivable and royalties and other receivables balances.

16.	Subsequent Events

Acquisition of

Non-Metallic

Solutions, Inc.

On October 15, 2020, the Company entered into a Stock Purchase Agreement with

Non-Metallic

Solutions, Inc. (“NMS”), a Massachusetts corporation, and William Malloneé and Derek Masser, the legal and beneficial owners of NMS, to purchase NMS, which transaction subsequently closed on October 20, 2020 (the “NMS Acquisition”).

NMS, which is headquartered in Auburn, Massachusetts, is a manufacturer of fabricated plastics, custom containers, and related assemblies and components used in the manufacturing of biologic drugs. NMS’s products will complement and expand Repligen’s

single-use

product offerings.

The Company will account for the NMS Acquisition as a purchase of a business under the acquisition method of accounting and has engaged a third-party valuation firm to assist with the valuation of the business acquired. The estimated purchase price allocation for the NMS Acquisition will be included in the Annual Report on Form

10-K

for the period ended December 31, 2020. As disclosed in the Quarterly Report on Form 10-Q for the period ended June 30, 2020, the Company voluntarily adopted the amendments to financial disclosure requirements around the significance tests in the “significant subsidiaries” definition in Rule 1-02(w), Securities Act Rule 405, and Exchange Act Rule 12b-2. As a result, the Company determined that NMS is not a significant subsidiary and therefore no separate financial statements are required.

Proposed Acquisition of ARTeSYN Biosolutions

On October 27, 2020, the Company executed an Equity and Asset Purchase Agreement (“Purchase Agreement”) with ARTeSYN Biosolutions Holdings Ireland Limited, a company organized under the laws of Ireland (“ARTeSYN”), Third Creek Holdings, LLC, a Nevada limited liability company, Alphinity, LLC, a Nevada limited liability company (“Alphinity”, and together with Third Creek Holdings, LLC the “Sellers”), and Michael Gagne, solely in his capacity as the representative of the Sellers, pursuant to which the Company will acquire (i) all of the outstanding equity securities of ARTeSYN and (ii) certain assets from Alphinity related to the business of ARTeSYN (collectively, the “ARTeSYN Acquisition”) for approximately $200 million, comprised of approximately $130 million in cash to Third Creek and Alphinity and approximately $70 million in Repligen common stock to Third Creek. Subject to certain closing conditions, including the expiration and termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, the transaction is expected to close in the fourth quarter of 2020.

ARTeSYN, headquartered in Waterford, Ireland, is a biosystems innovator that has had success with its single-use chromatography and filtration systems, which are considered the gold standard in downstream bioprocessing due to their performance, automation and low hold-up volumes. The proposed ARTeSYN Acquisition, combined with the recent acquisitions of EMT and NMS, further establishes Repligen as a premier player in single-use systems and associated integrated flow path assemblies. ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing and media/buffer prep workflows. In addition, the Company has integrated unique flow path assemblies utilizing EMT’s silicone extrusion and molding technology, to deliver highly differentiated, low hold-up volume systems that minimize product loss during processing.

The Company will account for the ARTeSYN Acquisition as a purchase of a business under ASC 805. Under the acquisition method of accounting, the net assets of ARTeSYN will be recorded as of the acquisition date, at their respective fair values, and consolidated with those of the Company. The Company has engaged a third-party valuation firm to assist with the valuation of the business acquired, which is expected to be completed in the fourth quarter of 2020. The preparation of the valuation requires the use of significant assumptions and estimates. Critical estimates will include, but are not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. Actual results may differ from these estimates.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Overview

Repligen and its subsidiaries, collectively doing business as Repligen Corporation (“Repligen”, “we”, “our”, or “the Company”) is a global life sciences company that develops and commercializes highly innovated bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.

As the overall market for biologics continues to grow and expand, our customers – primarily large biopharmaceutical companies and contract development and manufacturing organizations – face critical production cost, capacity, quality and time pressures. Built to address these concerns, our products are helping to set new standards for the way biologics are manufactured. We are committed to inspiring advances in bioprocessing as a trusted partner in the production of critical biologic drugs – including monoclonal antibodies (“mAb”), recombinant proteins, vaccines and gene therapies – that are improving human health worldwide.

We currently operate as one bioprocessing business, with a comprehensive suite of products to serve both upstream and downstream processes in biological drug manufacturing. Building on over 35 years of industry expertise, we have developed a broad and diversified product portfolio that reflects our passion for innovation and the customer-first culture that drives our entire organization. We continue to capitalize on opportunities to maximize the value of our product platform through both organic growth initiatives (internal innovation and commercial leverage) and targeted acquisitions.

Our Products

Our bioprocessing business is comprised of four main franchises, three of which we sell directly to

end-users

(Chromatography, Filtration and Process Analytics) and one that we sell primarily through supply agreements (Proteins).

Direct-to-Customer

Products

Since 2012, we have significantly expanded our

direct-to-customer

presence through our Chromatography, Filtration and Process Analytics franchises, each of which includes novel and differentiated technologies. We have diversified and grown our

direct-to-customer

product offering through internal innovation and through strategic, accretive acquisitions of assets or businesses that leverage existing product lines and/or expand our customer and geographic scope.

To support our sales growth goals for these products, we make ongoing investments in our commercial organization, our research and development (“R&D”) team and our manufacturing capacity. Our commercial and R&D teams work together to develop and launch new products and applications that address specific biomanufacturing challenges, and to build new markets for acquired technologies. We have seven key manufacturing sites across the United States, Sweden and Germany, with additional capacity being added by the end of 2021 in the Netherlands. We regularly evaluate and invest in capacity as needed to ensure timely deliveries and to stay ahead of increased customer demand for our products.

A substantial piece of our revenue comes from consumable and/or single-campaign

(“single-use”)

products as compared to associated equipment. The customization, scalability and

plug-and-play

convenience of consumable and/or

single-use

products, and in many cases the closed nature of our technologies, make them ideal for use in biologics manufacturing processes where contamination risk is a critical concern of our customers.

Chromatography

Our Chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. The main driver of growth in this portfolio is our OPUS

pre-packed

column product line.

Additional chromatography products include our affinity capture resins, such as CaptivA

Protein A resins, that are used in a small number of commercial drug processes and our ELISA test kits, used by quality control departments to detect and measure the presence of leached Protein A and/or growth factor in the final product.

OPUS

Pre-Packed

Columns

Our Chromatography franchise features a wide range of OPUS columns, which we deliver to our customers sealed and

pre-packed

with their choice of resin. These are

single-use

multiple-use

disposable columns that replace the use of customer-packed glass columns used in downstream purification processes. By designing OPUS columns to be a technologically advanced and flexible option for the purification of biologics from process development through clinical and commercial-scale manufacturing, Repligen has become a leader in the

pre-packed

column (“PPC”) market. Our biomanufacturing customers value the significant cost savings that OPUS columns deliver by reducing set up time, labor, equipment and facility costs – in addition to delivering product consistency and “plug and play” convenience.

Table of Contents

We launched our first production-scale OPUS columns in 2012 and have since added larger diameter options that scale up to use with 2,000 liter bioreactors. Our OPUS 80R column is the largest available PPC on the market for use in late-stage clinical or commercial purification processes. We have also introduced next-generation features such as a resin recovery port on our larger columns, which allows our customers to remove and reuse the recovered resin in other applications. We believe the OPUS

5-80R

product line is the most flexible and platformable PPC product offered in the marketplace today, and is serving the purification needs of customers manufacturing monoclonal antibodies (“mAb”) and other biologics such as vaccines and cell and gene therapies (“C&GT”).

In addition to our larger scale OPUS columns, our portfolio includes our smaller-scale OPUS columns, including specifically RoboColumn

, MiniChrom

™

and ValiChrom

™

columns for process development and validation. These columns are used in high-throughput process development screening, viral clearance validation studies and scale down validation of chromatography processes.

We maintain customer-facing centers in both the United States and Europe for OPUS columns, and offer our customers an unmatched ability to pack any of over 100 resins in our OPUS

5-80R

range and any of over 300 resin choices in our small-scale OPUS columns.

Other Chromatography

Our Chromatography portfolio also includes ELISA kits, which are analytical test kits to quantitate the proteins and growth factors, and chromatography resins, including our CaptivA brand.

Filtration

XCell ATF

Cell Retention Systems

Our Filtration products offer a number of advantages to manufacturers of biologic drugs and are used in development, clinical and commercial-scale production. Our XCell Alternating Tangential Flow (“ATF”) systems are used primarily in upstream perfusion (continuous) cell culture processing.

XCell ATF is a cell retention technology. The system is comprised of an advanced hollow fiber (“HF”) filtration device, a low shear pump and a controller. The XCell ATF system is connected to a bioreactor and enables the cell culture to be run continuously, with cells being retained in the bioreactor, fresh nutrients (cell culture media) being fed into the reactor continuously and clarified biological product and cell waste being removed continuously. The cells are maintained in a consistent nutrient-rich environment and can reach cell densities

two-

and three-times higher than those achieved by standard

fed-batch

culture. By continuously removing waste products from the fermenter, the XCell ATF systems routinely increases cell densities to

two-

or three-times the levels achieved by standard

fed-batch

culture. As a result, product yield is increased, which improves facility utilization and can reduce the size of a bioreactor required to manufacture a given volume of biologic drug product. XCell ATF systems are available in a wide range of sizes that can easily scale from laboratory use through full production with bioreactors as large as 5,000 liters.

Through internal innovation, we developed and launched

single-use

formats of the original stainless steel XCell ATF devices to address increasing industry demand for

single-use

sterile systems with

“plug-and-play”

technology. The XCell ATF device is now available to customers in both its original configuration (steel housing and

single-use

filters) in all sizes (2, 4, 6 and 10), and/or as a

single-use

device (disposable housing/filter combination) in most sizes (2, 6, and 10). The availability of XCell ATF technology in a

single-use

format eliminates the time intensive workflow associated with autoclaving, leading to an 80% reduction in implementation speed. The

single-use

format also enables our customers to accelerate evaluations of the product with a lower initial overall cost of ownership.

In September 2018, we entered into a collaboration agreement with industry leader Sartorius Stedim Biotech (“SSB”) to integrate our XCell ATF controller technology into SSB’s BIOSTAT

STR large-scale,

single-use

bioreactors, to create novel perfusion-enabled bioreactors.

TangenX

Flat Sheet Cassettes

In December 2016, we acquired TangenX

™

Technology Corporation (“TangenX”), balancing our upstream XCell ATF systems with a portfolio of flat-sheet tangential flow filtration (“TFF”) cassettes used in downstream biologic drug concentration and formulation processes. The TangenX product portfolio includes our

single-use

SIUS

™

brand, providing customers with a high-performance, cost saving alternative to reusable TFF cassettes.

Table of Contents

TFF is a rapid and efficient method for the concentration and formulation of biomolecules that is widely used in many applications in biopharmaceutical development and manufacturing. SIUS cassettes are the only purpose built

single-use

TFF cassettes on the market. The cassette features a high performing membrane and unique cartridge construction that enables a lower price point. Each disposable cassette is delivered

pre-sanitized

and ready to be equilibrated and used for tangential flow, ultrafiltration and diafiltration applications. Use of SIUS TFF cassettes eliminates

non-value-added

steps of cleaning, testing between uses, storage and flushing required in reusable TFF products, providing cost and time savings. The cassettes are interchangeable with filter hardware from multiple manufacturers, simplifying customer trial and adoption of SIUS products.

Spectrum

Hollow Fibers

We acquired Spectrum Life Sciences LLC (“Spectrum”) and its subsidiaries in August 2017 to strengthen our filtration business with the addition of a leading portfolio of HF filtration solutions, including fully integrated KrosFlo

TFF Systems with Konduit sensing and ProConnex

Flow Path

single-use

assemblies. KrosFlo family of TFF systems for product concentration is fully scalable from 2 milliliters to 5,000 liters – from

lab-scale

to commercial manufacturing. Designed for purification and formulation applications, KrosFlo Systems enable robust downstream ultrafiltration and microfiltration.

We also gained the Spectra/Por

portfolio of laboratory and process dialysis products and in 2019, we launched the SpectraFlo

™

Dynamic Dialysis Systems. Also, in 2019 we introduced the KrosFlo

TFDF

™

(Tangential Flow Depth Filtration) Systems, which we believe have the potential to disrupt and displace traditional harvest clarification operations. The KrosFlo TFDF system includes control hardware, novel high throughput tubular depth filters and ProConnex

single-use

TFDF flow paths. When used for cell culture clarification,

single-use

KrosFlo TFDF technology delivers unprecedented high flux (>1,000 LMH), high capacity, low turbidity, and minimal dilution, making the technology a high-performance alternative to traditional centrifugation and depth filtration approaches to harvest clarification. TFDF technology also provides benefits such as low

hold-up

volume, high recovery, small footprint, simple set up and disposal, scalability and reduced process time.

The Spectrum product line of HF filters and systems are used in

bench-top

through commercial-scale processes, primarily for the filtration, purification and concentration of biologics and diagnostic products. Our KrosFlo filtration systems and equipment offer both standard and customized solutions to bioprocessing customers, with particular strength in consumable and

single-use

offerings.

With the acquisition of Spectrum, we substantially increased our direct sales presence in Europe and Asia, and we diversified our end markets to include all biologic classes, including mAb, vaccines, recombinant proteins and gene therapies.

Other Filtration

In 2018, we introduced our Konduit monitor to automate concentration and buffer exchange. We have broadened the application for Konduit monitor to include use with both HF TFF from Spectrum and our TangenX flat sheet TFF systems. We also self-manufacture HF filters that are used in our XCell ATF, KrosFlo TFF and KrosFlo TFDF systems.

On July 13, 2020, we consummated the acquisition of Engineered Molding Technology LLC (“EMT”), a New York liability company, and added EMT’s silicone-based,

single-use

components and manifolds to our filtration franchise. These products are key components in

single-use

filtration and chromatography systems and will help expand the Company’s line of

single-use

ProConnex flow paths, streamline our supply chain for ATF and provide more flexibility we scale and expand our

single-use

and systems portfolios.

Process Analytics

In May 2019, we consummated our acquisition of C Technologies, Inc. (“C Technologies”) and added a fourth franchise, Process Analytics, to our bioprocessing business. Our Process Analytics products complement and support our Filtration, Chromatography and Proteins franchises as they allow

end-users

to make

at-line

in-line

absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications.

SoloVPE

Device

Our SoloVPE Slope Spectroscopy

system is the industry standard for offline and

at-line

absorbance measurements for protein concentration determination in process development, manufacturing and quality control settings.

FlowVPE

Device

Our FlowVPE Slope Spectroscopy system enhances the power of Slope Spectroscopy and provides

in-line

protein concentration measurement for filtration, chromatography and fill-finish applications. A key benefit of this

in-line

solution is the ability to monitor a manufacturing process in real time. We are developing a next-generation FlowVPE to incorporate

GMP-compliant

software for production-scale biologics manufacturing.

Table of Contents

Use of VPE Slope Spectroscopy delivers multiple process benefits for our biopharmaceutical manufacturing customers, compared to traditional

UV-Vis

approaches. Key benefits include: the elimination of manual dilutions and sample transfers from process development/manufacturing to labs, rapid time to results (minutes versus hours), improved precision,

built-in

data quality for improved reporting and validation, and ease of use.

OEM Products (Proteins)

Our Proteins products are represented by our Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of mAb, and cell culture growth factor products, which are a key component of cell culture media used in upstream bioprocessing to increase cell density and improve product yield.

Proteins - Ligands

Through our Proteins business, we are a leading provider of Protein A affinity ligands and cell culture growth factors to life sciences companies. Protein A ligands are an essential “binding” component of Protein A affinity chromatography resins used in the purification of virtually all monoclonal antibody-based drugs on the market or in development. We manufacture multiple forms of Protein A ligands under long-term supply agreements with major life sciences companies including GE Healthcare (“GE”), MilliporeSigma and Purolite Life Sciences (“Purolite”), who in turn sell their Protein A chromatography resins to end users (mAb manufacturers). We have two manufacturing sites supporting overall global demand for our Protein A ligands: one in Lund, Sweden and another in Waltham, Massachusetts.

Protein A chromatography resins are considered the industry standard for purification of antibody-based therapeutics due to the ability of the Protein A ligand to very selectively bind to or “capture” antibodies from crude protein mixtures. Protein A resins are packed into the first chromatography column of typically three columns used in a mAb purification process. As a result of Protein A’s high affinity for antibodies, the mAb product is highly purified and concentrated within this first capture step before moving to polishing steps.

In June 2018, we entered into an agreement with Navigo Proteins GmbH (“Navigo”) for the exclusive

co-development

of multiple affinity ligands for which Repligen holds commercialization rights. We are manufacturing and have agreed to supply the first of these ligands,

NGL-Impact

A, exclusively to Purolite, who will pair our high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. We also signed a long-term supply agreement with Purolite for

NGL-Impact

A and potential additional affinity ligands that may advance from our Navigo collaboration. The Navigo and Purolite agreements are supportive of our strategy to secure and reinforce our Proteins franchise.

Proteins - Growth Factors

Most biopharmaceuticals are produced through an upstream mammalian cell culture process. In order to stimulate increased cell growth and maximize overall yield from a bioreactor, manufacturers often add growth factors, such as insulin, to their cell culture media. Our cell culture growth factor additives include LONG

IGF 1 (“LR3”), our insulin-like growth factor that has been shown to be up to 100 times more biologically potent than insulin (the industry standard), thereby increasing recombinant protein production in cell culture fermentation applications. LR3 is primarily sold through a distribution partnership with MilliporeSigma.

2020 Acquisitions

Proposed Acquisition of ARTeSYN Biosolutions

On October 27, 2020, the Company entered into an Equity and Asset Purchase Agreement (“Purchase Agreement”) with ARTeSYN Biosolutions Holdings Ireland Limited, a company organized under the laws of Ireland (“ARTeSYN”), Third Creek Holdings, LLC, a Nevada limited liability company, Alphinity, LLC, a Nevada limited liability company (“Alphinity”, and together with Third Creek Holdings, LLC the “Sellers”), and Michael Gagne, solely in his capacity as the representative of the Sellers, pursuant to which the Company will acquire (i) all of the outstanding equity securities of ARTeSYN and (ii) certain assets from Alphinity related to the business of ARTeSYN (collectively, the “ARTeSYN Acquisition”) for approximately $200 million, comprised of approximately $130 million in cash to Third Creek and Alphinity and approximately $70 million in Repligen common stock to Third Creek. Subject to certain closing conditions, including the expiration and termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended, the transaction is expected to close in the fourth quarter of 2020.

ARTeSYN, headquartered in Waterford, Ireland, is a biosystems innovator that has had success with its single-use chromatography and filtration systems, which are considered the gold standard in downstream bioprocessing due to their performance, automation and low hold-up volumes. The proposed ARTeSYN Acquisition, combined with the recent acquisitions of EMT and Non-Metallic Solutions, Inc., further establishes Repligen as a premier player in single-use systems and associated integrated flow path assemblies. ARTeSYN has established downstream processing leadership with a suite of state of the art single-use systems for chromatography, filtration, continuous manufacturing and media/buffer prep workflows. In addition, the Company has integrated unique flow path assemblies utilizing EMT’s silicone extrusion and molding technology, to deliver highly differentiated, low hold-up volume systems that minimize product loss during processing.

Non-Metallic

Solutions, Inc.

On October 15, 2020, the Company entered into a Stock Purchase Agreement with

Non-Metallic

single-use

product offerings.

Table of Contents

Engineered Molding Technology

On June 26, 2020, we entered into a Membership Interest Purchase Agreement with EMT and Michael Pandori and Todd Etesse, the legal and beneficial owners of EMT to purchase EMT, which transaction subsequently closed on July 13, 2020 (the “EMT Acquisition”).

EMT, which is headquartered in Clifton Park, New York, is an innovator and manufacturer of

single-use

silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and customer molding and over-molded connectors and silicone tubing products are key components in

single-use

filtration and chromatography systems. Its products complement and expand our

single-use

product offerings.

The EMT Acquisition was accounted for as a purchase of a business under Accounting Standards Codification No. (“ASC”) 805,

“Business Combinations.”

The cash paid for the EMT Acquisition was $28.5 million, which will be consideration transferred under ASC 805. This includes $2.2 million deposited into escrow for indemnification obligations of the sellers.

Critical Accounting Policies and Estimates

A “critical accounting policy” is one which is both important to the portrayal of our financial condition and results and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a description of our critical accounting policies that affect our more significant judgments and estimates used in the preparation of our consolidated financial statements, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations and our significant accounting policies in Note 2 to the consolidated financial statements included in our Annual Report on Form

10-K

for the year ended December 31, 2019 filed with the SEC.

Results of Operations

The following discussion of the financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the related footnotes thereto.

Revenues

Total revenue for the three and nine months ended September 30, 2020 and 2019 were as follows:


	Three Months Ended September 30,				Increase/(Decrease)					Nine Months Ended September 30,				Increase/(Decrease)
	2020		2019		$ Change		% Change			2020		2019		$ Change		% Change
	(Amounts in thousands, except for percentage data)
Revenue:
Products	$	94,029	$	69,419	$	24,610		35.5	%	$	257,521	$	200,701	$	56,820		28.3	%
Royalty and other		31		26		5		19.2	%		91		70		21		30.0	%

Total revenue	$	94,060	$	69,445	$	24,615		35.4	%	$	257,612	$	200,771	$	56,841		28.3	%

Product revenues

Since 2016, we have been increasingly focused on selling our products directly to customers in the pharmaceutical industry and to our contract manufacturers. Direct sales represented approximately 82% and 80% of our product revenue for the three months ended September 30, 2020 and 2019, respectively, and represented approximately 77% and 75% of our product revenue for the nine months ended September 30, 2020 and 2019, respectively. We expect that direct sales will continue to account for an increasing percentage of our product revenues, as the largest customer of our OEM products has begun to diversify its supply chain in 2020. Sales of our bioprocessing products can be impacted by the timing of large-scale production orders and the regulatory approvals for such antibodies, which may result in significant quarterly fluctuations.

Revenue from our chromatography products includes the sale of our OPUS chromatography columns, chromatography resins and ELISA test kits. Revenue from our filtration products includes the sale of our XCell ATF systems and consumables, KrosFlo filtration products, SIUS filtration products and the silicone-molded products offered by EMT, which we acquired on July 13, 2020. Revenue from protein products includes the sale of our Protein A ligands and cell culture growth factors. Revenue from our Process Analytics products includes the sale of our SoloVPE and FlowVPE systems and consumables. Other revenue primarily consists of revenue from the sale of our operating room products to hospitals, as well as freight revenue.

During the three and nine months ended September 30, 2020, product revenue increased by $24.6 million, or 35.5%, and $56.8 million, or 28.3%, as compared to the same periods of 2019. The increase is due to the continued adoption of our products by

Table of Contents

our key bioprocessing customers, particularly our chromatography and filtration products. Beginning in the second quarter of 2020, we have experienced an increase in overall sales as a result of accelerated demand for our protein and filtration products. The demand was broad-based covering mAb, gene therapy and

COVID-19

customers working on vaccines and therapeutics. We expect there will be a continued increase in direct sales through the remainder of 2020, especially from

COVID-19

customers as they

scale-up

and move candidates through the clinical trial process. In addition, demand for our protein and ligands products increased during the three and nine months ended September 30, 2020, as compared to the same periods of 2019. Sales of our bioprocessing products are impacted by the timing of orders, development efforts at our customers or

end-users

and regulatory approvals for biologics that incorporate our products, which may result in significant quarterly fluctuations. Such quarterly fluctuations are expected, but they may not be predictive of future revenue or otherwise indicate a trend. There was also a $14.6 million increase in revenue for the nine months ended September 30, 2020, as compared to the same periods of 2019 due to revenues generated by C Technologies. Since the acquisition date was in May 2019, only four months of revenue were included in the nine months ended September 30, 2019.

Royalty revenues

Royalty revenues in the three and nine months ended September 30, 2020 and 2019 relate to royalties received from a third-party systems manufacturer associated with our OPUS PD chromatography columns. Royalty revenues are variable and are dependent on sales generated by our partner.

Costs of product revenue and operating expenses

Total costs and operating expenses for the three and nine months ended September 30, 2020 and 2019 were comprised of the following:


	Three Months Ended September 30,				Increase/(Decrease)						Nine Months Ended September 30,				Increase/(Decrease)
	2020		2019		$ Change			% Change			2020		2019		$ Change			% Change
	(Amounts in thousands, except for percentage data)
Cost of product revenue	$	39,626	$	31,425	$	8,201			26.1	%	$	108,471	$	88,978	$	19,493			21.9	%
Research and development		4,422		5,427		(1,005	)		(18.5	%)		13,460		14,278		(818	)		(5.7	%)
Selling, general and administrative		29,051		24,629		4,422			18.0	%		83,277		67,326		15,951			23.7	%

Total costs and operating expenses	$	73,099	$	61,481	$	11,618			18.9	%	$	205,208	$	170,582	$	34,626			20.3	%

Cost of product revenue

Cost of product revenue increased 26.1% and 21.9% in the three and nine months ended September 30, 2020, compared to the same periods of 2019, due primarily to the increase in product revenue mentioned above and costs associated with higher product volume. An increase in manufacturing headcount resulted in higher employee-related costs for the three and nine months ended September 30, 2020, compared to the same periods of 2019. Additional facility costs, including personal protection equipment purchased for essential manufacturing personnel on site to protect against

COVID-19,

were also incurred during the three and nine months ended September 30, 2020 for which there were no comparable amounts in 2019.

Gross margins were 57.9% in both the three and nine months ended September 30, 2020. The gross margin for the three months ended September 30, 2020 includes $0.1 million of amortization of inventory

step-up

associated with the EMT Acquisition. The gross margins for the three and nine months ended September 30, 2019, which include $0.3 million and $1.5 million of amortization on inventory

step-up

associated with the C Technologies Acquisition in May 2019, were 54.7% and 55.7%, respectively. Excluding the

step-up

amortization, gross margins for the three and nine months ended September 30, 2019 were 55.2% and 56.4%. The increase in gross margins, excluding the inventory

step-up

amortization, in the three and nine months ended September 30, 2020, as compared to the same period of 2019, is due primarily to the increase in revenue mentioned above, and favorable product volumes and mix, partially offset by an increase in manufacturing headcount subsequent to September 30, 2019. Gross margins may fluctuate in future quarters based on expected production volume and product mix.

Research and development expenses

Research and development (“R&D”) expenses are related to bioprocessing products, which include personnel, supplies and other research expenses. Due to the size of the Company and the fact that these various programs share personnel and fixed costs, we do not track all of our expenses or allocate any fixed costs by program, and therefore, have not provided historical costs incurred by project.

Table of Contents

R&D expenses decreased 18.5% and 5.7% during the three and nine months ended September 30, 2020, compared to the same period of 2019. The decrease during the periods is primarily due to a decrease in R&D spending on projects, as most R&D personnel worked remotely for most of 2020 due to

COVID-19.

This is partially offset by a $1.2 million increase in R&D expenses year over year, related to C Technologies operations. The nine months ended September 30, 2020 only had four months of expenses since the acquisition was consummated on May 31, 2019.

We expect our R&D expenses for the remainder of 2020 to gradually increase to support new product development.

Selling, general and administrative expenses

Selling, general and administrative (“SG&A”) expenses include the costs associated with selling our commercial products and costs required to support our marketing efforts, including legal, accounting, patent, shareholder services, amortization of intangible assets and other administrative functions.

During the three and nine months ended September 30, 2020, SG&A costs increased by $4.4 million, or 18.0%, and $16.0 million, or 23.7%, as compared to the same periods of 2019. The increase is partially due to the continued expansion of our customer-facing activities to drive sales of our bioprocessing products, and the continued buildout of our administrative infrastructure, primarily through increased headcount, to support expected future growth. Stock-based compensation expense and other employee-related costs increased during the three and nine months ended September 30, 2020, as compared to the same period in 2019, resulting from an increase in headcount and higher share prices period over period. In addition, $5.9 million of the increase in SG&A costs for the nine months ended September 30, 2020, was related to the C Technologies operations, which was acquired in May 2019. C Technologies’ SG&A costs for the nine months ended September 30, 2020 include nine months of costs, compared to only four months in the same period of 2019.

Other expenses, net

The table below provides detail regarding our other expenses, net:


	Three Months Ended September 30,						Increase/(Decrease)						Nine Months Ended September 30,						Increase/(Decrease)
	2020			2019			$ Change			% Change			2020			2019			$ Change			% Change
	(Amounts in thousands, except for percentage data)
Investment income	$	82		$	1,898		$	(1,816	)		(95.7	%)	$	1,699		$	3,616		$	(1,917	)		(53.0	%)
Loss on extinguishment of debt		—			(5,650	)		5,650			(100.0	%)		—			(5,650	)		5,650			(100.0	%)
Interest expense		(3,052	)		(2,857	)		(195	)		6.8	%		(9,032	)		(6,326	)		(2,706	)		42.8	%
Other expenses		(248	)		316			(564	)		(178.5	%)		(632	)		(23	)		(609	)		2647.8	%

Total other expense, net	$	(3,218	)	$	(6,293	)	$	3,075			(48.9	%)	$	(7,965	)	$	(8,383	)	$	418			(5.0	%)

Investment income

Investment income includes income earned on invested cash balances. The decrease of $1.8 million and $1.9 million for the three and nine months ended September 30, 2020, as compared to the same periods of 2019, was attributable to a decrease in interest rates on our average invested cash balances. In March 2020, in response to the outbreak of

COVID-19

and to stay ahead of disruptions and economic slowdown, the Federal Reserve reduced federal funds rate to a range of 0.0% to 0.25%, which will continue to affect our investment income in future periods. Higher average invested cash balances during the three and nine months ended September 30, 2020, as compared to the same periods of 2019 due to the completion of a public offering and the issuance of our 2019 Notes during the third quarter of 2019, partially offset the decrease in interest rates mentioned above. We expect investment income to vary based on changes in the amount of funds invested and fluctuation of interest rates.

Loss on extinguishment of debt

The $5.6 million loss on extinguishment of debt in the three and nine months ended September 30, 2019, resulted from the settlement of our outstanding 2.125% Convertible Senior Notes due 2021 (the “2016 Notes”). The loss represents the difference between (i) the fair value of the liability component and (ii) the sum of the carrying value of the debt component and any unamortized debt issuance costs at the time of settlement.

Table of Contents

Interest expense

Interest expense in the three and nine months ended September 30, 2020 is from our 0.375% Convertible Senior Notes due 2024 (the “2019 Notes”), which were issued in July 2019. Interest expense in the three and nine months ended September 30, 2019 is from our 2016 Notes, which were settled during the third quarter of 2019. Interest expense increased $0.2 million and $2.7 million for the three and nine months ended September 30, 2020, as compared to the same periods in 2019.

The amortization of debt issuance costs on the 2019 Notes was $2.8 million and $8.2 million for the three and nine months ended September 30, 2020. Amortization of debt issuance costs on the 2019 Notes was $2.1 million for both the three and nine months ended September 30, 2019. The amortization of the debt issuance costs on the 2016 Notes was $0.6 million and $2.8 million for the three and nine months ended September 30, 2019, respectively.

Contractual coupon interest incurred on the 2019 Notes for the three and nine months ended September 30, 2020 was $0.3 million and $0.8 million, respectively. Interest calculated based on the carrying value related to the 2019 Notes for both the three and nine months ended September 30, 2019 was $0.2 million. Contractual coupon interest incurred on the 2016 Notes was $0.1 million and $1.3 million in the three and nine months ended September 30, 2019. Since the 2016 Notes were settled during July 2019, interest no longer accrued on the 2016 Notes subsequent to their settlement.

Other expenses

The change in other expenses during the three and nine months ended September 30, 2020, compared to the same period of 2019, is primarily attributable to foreign currency losses related to amounts due from

non-Swedish

krona-based customers and vendors.

Income tax provision

Income tax provision for the three and nine months ended September 30, 2020 and 2019 was as follows:


	Three Months Ended September 30,						Increase/(Decrease)					Nine Months Ended September 30,						Increase/(Decrease)
	2020			2019			$ Change		% Change			2020			2019			$ Change		% Change
	(Amounts in thousands, except for percentage data)
Income tax provision	$	3,191		$	12		$	3,179		26491.7	%	$	4,211		$	3,999		$	212		5.3	%
Effective tax rate		18.0	%		0.7	%							9.5	%		18.3	%

For the three and nine months ended September 30, 2020, we recorded an income tax expense of $3.2 million and $4.2 million, respectively. The effective tax rate was 18.0% and 9.5% for the three and nine months ended September 30, 2020 and is based upon the estimated income for the year ending December 31, 2020 and the composition of income in different jurisdictions and impacts of various discrete tax adjustments. The effective tax rate for the three and nine months ended September 30, 2020 was lower than the U.S. statutory rate of 21% primarily due to windfall benefits on stock option exercises and the vesting of stock units. We recorded a tax provision of less than $0.1 million and $4.0 million, respectively for the three and nine months ended September 30, 2019. The effective tax rate was 0.7% and 18.3% for the three and nine months ended September 30, 2019 and the composition of income in different jurisdictions and the impacts of various discrete tax adjustments. The effective tax rate for the three and nine months ended September 30, 2019 was lower than the U.S. statutory rate of 21% primarily due to windfall benefits on stock option exercise and the vesting of stock units.

Non-GAAP

Financial Measures

We provide

non-GAAP

adjusted income from operations; adjusted net income; and adjusted EBITDA as supplemental measures to GAAP measures regarding our operating performance. These financial measures exclude the items detailed below and, therefore, have not been calculated in accordance with GAAP. A detailed explanation and a reconciliation of each

non-GAAP

financial measure to its most comparable GAAP financial measure is provided below.

We include this financial information because we believe these measures provide a more accurate comparison of our financial results between periods and more accurately reflect how management reviews its financial results. We excluded the impact of certain acquisition-related items because we believe that the resulting charges do not accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Table of Contents

Non-GAAP

adjusted income from operations

Non-GAAP

adjusted income from operations is measured by taking income from operations as reported in accordance with GAAP and excluding acquisition and integration costs, intangible amortization and inventory

step-up

charges booked through our consolidated statements of comprehensive income (loss). The following is a reconciliation of income from operations in accordance with GAAP to

non-GAAP

adjusted income from operations for the three and nine months ended September 30, 2020 and 2019:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
GAAP income from operations	$	20,961	$	7,964	$	52,404	$	30,189
Non-GAAP adjustments to income from operations:
Acquisition and integration costs		1,849		2,953		6,536		9,573
Intangible amortization		3,925		3,900		11,677		9,562
Inventory step-up charges		144		314		144		1,483

Non-GAAP adjusted income from operations	$	26,879	$	15,131	$	70,761	$	50,807

Non-GAAP

adjusted net income

Non-GAAP

adjusted net income is measured by taking net income as reported in accordance with GAAP and excluding acquisition and integration costs, intangible amortization, inventory

step-up

charges, loss on extinguishment of debt,

non-cash

interest expense and the tax effects of these items. The following are reconciliations of net income in accordance with GAAP to

non-GAAP

adjusted net income for the three and nine months ended September 30, 2020 and 2019:


	Three Months Ended September 30,
	2020						2019
	Amount			Fully Diluted Earnings per Share			Amount			Fully Diluted Earnings per Share
	(Amounts in thousands, except per share data)
GAAP net income	$	14,552		$	0.27		$	1,659		$	0.03
Non-GAAP adjustments to net income:
Acquisition and integration costs		1,849			0.03			2,953			0.06
Intangible amortization		3,925			0.07			3,900			0.08
Loss on extinguishment of debt		—			—			5,650			0.11
Inventory step-up charges		144			0.00			314			0.01
Non-cash interest expense		2,759			0.05			2,631			0.05
Tax effect of intangible amortization and acquisition costs		(2,072	)		(0.04	)		(3,781	)		(0.07	)

Non-GAAP adjusted net income	$	21,157		$	0.40		$	13,326		$	0.26

Table of Contents


	Nine Months Ended September 30,
	2020						2019
	Amount			Fully Diluted Earnings per Share			Amount			Fully Diluted Earnings per Share
	(Amounts in thousands, except per share data)
GAAP net income	$	40,228		$	0.75		$	17,807		$	0.37
Non-GAAP adjustments to net income:
Acquisition and integration costs		6,536			0.12			10,074			0.21
Intangible amortization		11,677			0.22			9,562			0.20
Inventory step-up charges		144			0.00			1,483			0.03
Loss on extinguishment of debt		—			—			5,650			0.12
Non-cash interest expense		8,174			0.15			4,863			0.10
Tax effect of intangible amortization and acquisition costs		(6,334	)		(0.12	)		(7,742	)		(0.16	)

Non-GAAP adjusted net income	$	60,425		$	1.13		$	41,697		$	0.87

* Per share totals may not add due to rounding.

Adjusted EBITDA

Adjusted EBITDA is measured by taking net income as reported in accordance with GAAP, excluding investment income, interest expense, taxes, depreciation and amortization, acquisition and integration costs, inventory

step-up

charges and loss on extinguishment of debt booked through our consolidated statements of comprehensive income (loss). The following is a reconciliation of net income in accordance with GAAP to adjusted EBITDA for the three and nine months ended September 30, 2020 and 2019:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
	(Amounts in thousands)
GAAP net income	$	14,552		$	1,659		$	40,228		$	17,807
Non-GAAP EBITDA adjustments to net income:
Investment income		(82	)		(1,898	)		(1,699	)		(3,616	)
Interest expense		3,052			2,857			9,032			6,326
Tax provision		3,191			12			4,211			3,999
Depreciation		2,757			1,810			7,820			5,147
Amortization		3,953			3,928			11,760			9,644

EBITDA		27,423			8,368			71,352			39,307
Other non-GAAP adjustments:
Acquisition and integration costs		1,849			2,953			6,536			10,074
Loss on extinguishment of debt		—			5,650			—			5,650
Inventory step-up charges		144			314			144			1,483

Adjusted EBITDA	$	29,416		$	17,285		$	78,032		$	56,514

Liquidity and Capital Resources

We have financed our operations primarily through revenues derived from product sales, the issuance of the 2016 Notes in May 2016 and our 2019 Notes (defined below) in July 2019 and the issuance of common stock in our July 2019, May 2019 and July 2017 public offerings. Our revenue for the foreseeable future will primarily be limited to our bioprocessing product revenue.

At September 30, 2020, we had cash and cash equivalents (excluding restricted cash) of $553.3 million compared to cash and cash equivalents (excluding restricted cash) of $528.4 million at December 31, 2019.

On July 19, 2019, the Company issued $287.5 million aggregate principal amount of 0.375% Convertible Senior Notes due 2024 (“2019 Notes”), which included the underwriters’ exercise in full of an option to purchase an additional $37.5 million aggregate principal amount of 2019 Notes (the “Notes Offering” and, together with the Stock Offering in July 2019 as mentioned in Note 9,

“Stockholders’ Equity”

included in this report, the “Offerings”). The net proceeds of the Notes Offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, were $278.5 million. See Note 8,

Table of Contents

“Convertible Senior Notes,”

included in this report

for more information on this transaction. The Company utilized a portion of the proceeds from the Offerings to settle its outstanding 2016 Notes during the third quarter of 2019. On July 16, 2019, the Company entered into separate privately negotiated agreements with certain holders of the 2016 Notes to exchange an aggregate of $92.0 million principal aggregate amount of the 2016 Notes for shares of the Company’s common stock, together with cash, in private placement transactions (the “Note Exchanges”). On July 19, 2019 and July 22, 2019, the Company used approximately $92.3 million (including $0.3 million of accrued interest) and 1,850,155 shares of its common stock valued at $161.0 million to settle the Note Exchanges for total consideration of $253.3 million, of which $163.6 million was allocated to the equity component of the 2016 Notes. The Company allocated the consideration transferred to the liability and equity components using the same proportions as the initial carrying value of the 2016 Notes.

During the third quarter of 2020, the closing price of the Company’s common stock did not exceed 130% of the conversion price of the 2019 Notes for more than 20 trading days of the last 30 consecutive trading days of the quarter. Therefore, the 2019 Notes are not convertible at the option of the holders of the 2019 Notes during the fourth quarter of 2020 per the First Supplemental Indenture underlying the 2019 Notes. The 2019 Notes have a face value of $287.5 million and a carrying value of $240.9 million and are classified as long-term liabilities on the Company’s consolidated balance sheet as of September 30, 2020.

We intend to use the remaining net proceeds from the Offerings for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies, such as the acquisitions mentioned in Note 16,

“Subsequent Events,”

included in this report. It is the Company’s policy and intent to settle the face value of the 2019 Notes in cash and any excess conversion premium in shares of our common stock.

Cash flows


	Nine Months Ended September 30,						Increase/(Decrease)
	2020			2019			$ Change
	(Amounts in thousands)
Operating activities	$	47,754		$	49,542		$	(1,788	)
Investing activities		(43,097	)		(198,197	)		155,100
Financing activities		7,078			485,047			(477,969	)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		4,160			(7,785	)		11,945

Net increase in cash, cash equivalents and restricted cash	$	15,895		$	328,607		$	(312,712	)

Operating activities

For the nine months ended September 30, 2020, our operating activities provided cash of $47.8 million reflecting net income of $40.2 million and

non-cash

charges totaling $40.5 million primarily related to depreciation, amortization, deferred income taxes,

non-cash

interest expense and stock-based compensation charges. An increase in accounts receivable consumed $11.5 million of cash and was primarily driven by the 35.4%

year-to-date

increase in revenues. An increase in inventory manufactured of $22.8 million supports expected increases in future revenue. An increase in accounts payable and accrued liabilities of $1.1 million was primarily due to increased inventory purchases to support customer orders, offset by payment of acquisition-related bonuses for C Technologies during the second quarter of 2020. The remaining cash provided by operating activities resulted from favorable changes in various other working capital accounts.

For the nine months ended September 30, 2019, our operating activities provided cash of $49.5 million reflecting net income of $17.8 million

and non-cash charges

totaling $25.2 million primarily related to depreciation,

amortization, non-cash interest

expense, deferred taxes, loss on extinguishment of debt and stock-based compensation charges. An increase in accounts receivable consumed $6.7 million of cash and was primarily driven by the 41.3%

year-to-date

increase in revenues. An increase in inventory consumed $4.9 million to support future revenue, due to the addition of C Technologies on May 31, 2019. These movements were offset by an increase in accounts payable and accrued liabilities of $6.5 million due to the addition of C Technologies as well as a decrease in unbilled receivables of $2.0 million. The remaining cash provided by operating activities resulted from favorable changes in various other working capital accounts.

Investing activities

Our investing activities consumed $43.1 million of cash during the nine months ended September 30, 2020 related to the EMT Acquisition on July 13, 2020, as well as ongoing capital expenditures. Our investing activities consumed $198.2 million in the nine months ended September 30, 2019 related to the purchase of C Technologies, and capital expenditures. We consumed $28.5 million in cash (net of cash received) for the EMT Acquisition on July 13, 2020 and $182.2 million in cash (net of cash received) for the C Technologies Acquisition on May 31, 2019.

Table of Contents

Capital expenditures in 2020 and 2019 included $3.6 million and $4.6 million, respectively, for capitalized costs related to our

internal-use

software.

Financing activities

Cash provided by financing activities of $7.1 million for the nine months ended September 30, 2020 included proceeds from stock option exercises and the vesting of stock units during the period. Cash provided by financing activities of $485.0 million for the nine months ended September 30, 2019 included $320.7 million from the issuance of our common stock resulting from our public offerings completed in May and June 2019. In addition, in July 2019 we issued $287.5 million aggregate principal amount of the 2019 Notes for net proceeds of $278.6 million. Proceeds from stock option exercises during the nine months ended September 30, 2019 were $1.1 million. Offsetting these movements was $115.0 million of cash utilized by us in July 2019 to settle the 2016 Notes.

Working capital increased by approximately $52.2 million to $645.7 million at September 30, 2020 from $593.5 million at December 31, 2019 due to the various changes noted above.

Our future capital requirements will depend on many factors, including the following:

•

the expansion of our bioprocessing business;

•

the ability to sustain sales and profits of our bioprocessing products;

•

our ability to acquire additional bioprocessing products;

•

our identification and execution of strategic acquisitions or business combinations;

•

the scope of and progress made in our R&D activities;

•

the extent of any share repurchase activity; and

•

the success of any proposed financing efforts.

Absent acquisitions of additional products, product candidates or intellectual property, we believe our current cash balances are adequate to meet our cash needs for at least the next 24 months from the date of this filing. We expect operating expenses for the rest of the year to increase as we continue to expand our bioprocessing business. We expect to incur continued spending related to the development and expansion of our bioprocessing product lines and expansion of our commercial capabilities for the foreseeable future. Our future capital requirements may include, but are not limited to, purchases of property, plant and equipment, the acquisition of additional bioprocessing products and technologies to complement our existing manufacturing capabilities, and continued investment in our intellectual property portfolio.

We plan to continue to invest in our bioprocessing business and in key R&D activities associated with the development of new bioprocessing products. We actively evaluate various strategic transactions on an ongoing basis, including licensing or acquiring complementary products, technologies or businesses that would complement our existing portfolio. We continue to seek to acquire such potential assets that may offer us the best opportunity to create value for our shareholders. In order to acquire such assets, we may need to seek additional financing to fund these investments. If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements, including because of any such acquisition-related financing needs or lower demand for our products, we may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt funding. The sale of equity and convertible debt securities may result in dilution to our stockholders, and those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights. We may require additional capital beyond our currently anticipated amounts. Additional capital may not be available on reasonable terms, if at all.

Off-Balance

Sheet Arrangements

We do not have any special purpose entities or

off-balance

sheet financing arrangements as of September 30, 2020.

Table of Contents

Net Operating Loss Carryforwards

At December 31, 2019, we had net operating loss carryforwards of $0.2 million remaining. We had business tax credits carryforwards of $2.1 million available to reduce future federal income taxes, if any. The business tax credits carryforwards will continue to expire at various dates through December 2039. Net operating loss carryforwards and available tax credits are subject to review and possible adjustment by the Internal Revenue Service, state and foreign jurisdictions and may be limited in the event of certain changes in the ownership interest of significant stockholders.

Effects of Inflation

Our assets are primarily monetary, consisting of cash, cash equivalents and marketable securities. Because of their liquidity, these assets are not directly affected by inflation. Since we intend to retain and continue to use our equipment, furniture and fixtures and leasehold improvements, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form

10-Q

contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The forward-looking statements in this Quarterly Report on Form

10-Q

do not constitute guarantees of future performance. Investors are cautioned that statements in this Quarterly Report on Form

10-Q

which are not strictly historical statements, including, without limitation, express or implied statements or guidance regarding current or future financial performance and position, potential impairment of future earnings, management’s strategy, plans and objectives for future operations or acquisitions, product development and sales, product candidate research, development and regulatory approval, SG&A expenditures, intellectual property, development and manufacturing plans, availability of materials and product and adequacy of capital resources, our financing plans, and the projected impact of, and response to, the

COVID-19

coronavirus pandemic and the related downturn of the U.S. and global economies constitute forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which the Company operates, and management’s beliefs and assumptions. The Company undertakes no obligation to publicly update or revise the statements in light of future developments. In addition, other written and oral statements that constitute forward-looking statements may be made by the Company or on the Company’s behalf. Words such as “expect,” “seek,” “anticipate,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” or variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with the following: the ultimate impact of the coronavirus pandemic on our business or financial results; the success of current and future collaborative or supply relationships, including our agreements with Cytiva (formerly GE Healthcare), MilliporeSigma and Purolite; our ability to successfully grow our bioprocessing business, including as a result of acquisitions, commercialization or partnership opportunities, and our ability to develop and commercialize products; our ability to obtain required regulatory approvals; our compliance with all U.S. Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our patent and other intellectual property rights; the risk of litigation with collaborative partners; our limited manufacturing capabilities and our dependence on third-party manufacturers and value-added resellers; the effect of the pandemic of the novel coronavirus disease, including mitigation efforts and economic effects, on our business operations and the operations of our customers and suppliers; our ability to hire and retain skilled personnel; the market acceptance of our products, reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed life sciences companies; our history of losses and expectation of incurring losses; our ability to generate future revenues; our ability to successfully integrate our recently acquired businesses; our ability to raise additional capital to fund potential acquisitions; our volatile stock price; and the effects of our anti-takeover provisions. Further information on potential risk factors that could affect our financial results are included in the filings made by us from time to time with the Securities and Exchange Commission including under the sections entitled “Risk Factors” in our Annual Report on Form

10-K

for the year ended December 31, 2019 and our Quarterly Report on Form

10-Q

for the quarter ended March 31, 2020.

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Interest Rate Risk

We have historically held investments in commercial paper, U.S. Government and agency securities as well as corporate bonds and other debt securities. As a result, we have been exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer or otherwise. We do not have any such investments as of September 30, 2020. As a result, a hypothetical 100 basis point increase in interest rates would have no effect on our cash position as of September 30, 2020.

Table of Contents

We generally place our marketable security investments in high quality credit instruments, as specified in our investment policy guidelines. We believe that the conservative nature of our investments mitigates our interest rate exposure, and our investment policy limits the amount of our credit exposure to any one issue, issuer (with the exception of U.S. agency obligations) and type of instrument. We do not expect any material losses from our marketable security investments and therefore believe that our potential interest rate exposure is limited.

Foreign Exchange Risk

The reporting currency of the Company is U.S. dollars, and the functional currency of each of our foreign subsidiaries is its respective local currency. Our foreign currency exposures include the Swedish krona, Euro, British pound, Chinese yuan, Japanese yen, Singapore dollar, South Korean won and Indian rupee; of these, the primary foreign currency exposures are the Swedish krona, Euro and British pound. Exchange gains or losses resulting from the translation between the transactional currency and the functional currency are included in net income. Fluctuations in exchange rates may adversely affect our results of operations, financial position and cash flows. We currently do not seek to hedge this exposure to fluctuations in exchange rates.

ITEM 4.

CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

The Company’s management, with the participation of the principal executive officer and the principal financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules

13a-15(e)

15d-15(e)

under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, the principal executive officer and principal financial officer have concluded that, as of the end of such period, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control

We acquired Engineered Molding Technology LLC (“EMT”) on July 13, 2020. The financial results of EMT are included in our unaudited consolidated financial statements as of September 30, 2020 and for the quarter then ended. As this acquisition occurred in the third quarter of 2020, the scope of our assessment of our internal control over financial reporting does not include EMT. This exclusion is in accordance with the Securities and Exchange Commission’s general guidance that an assessment of a recently acquired business may be omitted from our scope in the year of acquisition.

In connection with our initiative to integrate and enhance our global information technology systems and business processes, we continued the phased implementation of a new enterprise resource planning (“ERP”) system. The ERP system is being implemented in phases through 2021. The second phase was completed during the third quarter of 2020. As a result of this implementation, we modified certain existing internal controls over financial reporting as well as implemented new controls and procedures related to the new ERP system as of September 30, 2020.

Other than the foregoing, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule

13a-15

or Rule

15d-15

that occurred in the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

ITEM 1A.

RISK FACTORS

The matters discussed in this Quarterly Report on

Form 10-Q include

forward-looking statements that involve risks or uncertainties. These statements are neither promises nor guarantees, but are based on various assumptions by management regarding future circumstances, over many of which Repligen has little or no control. A number of important risks and uncertainties, including those identified under the caption

“Risk Factors”

in Part I, Item 1A of our Annual Report on Form

10-K

for the period ended December 31, 2019 and in subsequent filings, could cause our actual results to differ materially from those in the forward-looking statements. There are no material changes to the risk factors described in our Annual Report on Form

10-K

for the period ended December 31, 2019 and our Quarterly Report on Form

10-Q

for the quarter ended March 31, 2020.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

Table of Contents

ITEM 6.

EXHIBITS

(a) Exhibits


Exhibit Number		Document Description

3.1		Restated Certificate of Incorporation, dated September 30, 1992 and amended September 17, 1999 (filed as Exhibit 3.1 to Repligen Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 1999 and incorporated herein by reference).

3.2		Certificate of Amendment to the Certificate of Incorporation of Repligen Corporation, effective as of May 16, 2014 (filed as Exhibit 3.1 to Repligen Corporation’s Current Report on Form 8-K filed on May 19, 2014 and incorporated herein by reference).

3.3		Second Amended and Restated Bylaws (filed as Exhibit 3.1 to Repligen Corporation’s Current Report on Form 8-K filed on May 23, 2017 and incorporated herein by reference).

31.1 +		Rule 13a-14(a)/15d-14(a) Certification.

31.2 +		Rule 13a-14(a)/15d-14(a) Certification.

32.1*		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS+		XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH+		Inline XBRL Taxonomy Extension Schema Document.

101.CAL+		Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF+		Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB+		Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE+		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104+		Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*).

#	Management contract or compensatory plan or arrangement.

+	Filed herewith.

*	Furnished herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	REPLIGEN CORPORATION

Date: November 5, 2020	By:	/S/ TONY J. HUNT
		Tony J. Hunt
		President and Chief Executive Officer
		(Principal executive officer)
		Repligen Corporation

Date: November 5, 2020	By:	/S/ JON SNODGRES
		Jon Snodgres
		Chief Financial Officer
		(Principal financial officer)
		Repligen Corporation

EX-31.1 2 d945763dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Tony J. Hunt, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Repligen Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2020

/s/ TONY J. HUNT

Tony J. Hunt

President and Chief Executive Officer

(Principal executive officer)

EX-31.2 3 d945763dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Jon Snodgres, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Repligen Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2020

/s/ JON SNODGRES

Jon Snodgres

Chief Financial Officer

(Principal financial officer)

EX-32.1 4 d945763dex321.htm EX-32.1 EX-32.1

Exhibit 32.1*

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repligen Corporation (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 5, 2020	By:	/S/ TONY J. HUNT
		Tony J. Hunt
		Chief Executive Officer and President
		(Principal executive officer)

Date: November 5, 2020	By:	/S/ JON SNODGRES
		Jon Snodgres
		Chief Financial Officer
		(Principal financial officer)

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.

EX-101.SCH 5 rgen-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Acquisitions link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Credit Losses link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Consolidated Balance Sheet Detail link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Convertible Senior Notes link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Acquisitions (Tables) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Credit Losses (Tables) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Consolidated Balance Sheet Detail (Tables) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Convertible Senior Notes (Tables) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Fair Value Measurement - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Acquisitions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Acquisitions (Fair Value of Net Assets Acquired) (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Acquisitions (Estimated Useful Life and Fair Value) (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Acquisitions (Unaudited Supplemental Pro Forma Information) (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Schedule - Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Revenue from Significant Customers (Detail) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Credit Losses - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Credit Losses - Summary Of Allowance For Credit Losses For Accounts Receivables (Detail) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Changes in Carrying Value of Goodwill (Detail) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Goodwill and Intangible Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Amortization Expense for Amortized Intangible Assets (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Schedule of Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Property, Plant and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Consolidated Balance Sheet - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Schedule of Accrued Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Convertible Senior Notes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Convertible Senior Notes - Convertible Debt (Detail) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Stock-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Summary of Option Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1059 - Disclosure - Summary of Option Activity (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 1060 - Disclosure - Summary of Restricted Stock Unit Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1061 - Disclosure - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 1062 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1063 - Disclosure - Change in Accumulated Other Comprehensive Loss (Detail) link:presentationLink link:definitionLink link:calculationLink 1064 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1065 - Disclosure - Summary of Tax Returns Periods Subject to Examination by Federal, State and International Tax Authorities (Detail) link:presentationLink link:definitionLink link:calculationLink 1066 - Disclosure - Earnings Per Share - (Additional Information) (Detail) link:presentationLink link:definitionLink link:calculationLink 1067 - Disclosure - Earnings Per Share - (Reconciliation of Basic and Diluted Shares Amounts) (Detail) link:presentationLink link:definitionLink link:calculationLink 1068 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1069 - Disclosure - Segment Reporting - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1070 - Disclosure - Segment Reporting - (Percentage of Revenue by Geographic Area) (Details) link:presentationLink link:definitionLink link:calculationLink 1071 - Disclosure - Segment Reporting - Percentage of Revenue from Significant Customers (Detail) link:presentationLink link:definitionLink link:calculationLink 1072 - Disclosure - Subsequent Events - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 rgen-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 rgen-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 rgen-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Current Fiscal Year End Date Document Period End Date Document Type Entity Current Reporting Status Entity Registrant Name Entity Interactive Data Current Entity Common Stock, Shares Outstanding Title of 12(b) Security Trading Symbol Security Exchange Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Entity Shell Company Entity Small Business Smaller reporting company Entity Emerging Growth Company Emerging growth company Local Phone Number Document Quarterly Report Document Transition Report Entity Filer Category Entity File Number Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Assets Total assets Assets, Current [Abstract] Current assets: Accounts Receivable, Net, Current Accounts receivable, net of allowances of $621 and $525 at September 30, 2020 and December 31, 2019, respectively Accounts receivable Assets, Current Total current assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Inventory, Net Inventories, net Total inventories, net Other Receivables, Gross, Current Royalties and other receivables Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Unbilled Receivables, Current Unbilled receivables Restricted Cash Restricted cash Goodwill Goodwill Business acquisition, goodwill acquired Balance as of December 31, 2019 Balance as of September 30, 2020 Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Net Carrying Value Other Assets, Noncurrent Other assets Property, Plant and Equipment, Net Property, plant and equipment, net Total property, plant and equipment, net Deferred Income Tax Assets, Net Deferred tax assets Operating Lease, Right-of-Use Asset Operating lease right of use assets Liabilities and Equity [Abstract] Liabilities and stockholders' equity Commitments and Contingencies Commitments and contingencies (Note 10) Convertible Notes Payable, Noncurrent Convertible senior notes, net Net carrying amount Deferred Tax and Other Liabilities, Noncurrent Deferred tax liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued liabilities Total accrued liabilities Liabilities, Current Total current liabilities Operating Lease, Liability, Current Operating lease liability Other Liabilities, Noncurrent Other liabilities, long-term Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Additional Paid in Capital, Common Stock Additional paid-in capital Common Stock, Value, Issued Common stock, $0.01 par value; 80,000,000 shares authorized; 52,606,700 shares at September 30, 2020 and 52,078,258 shares at December 31, 2019 issued and outstanding Preferred Stock, Value, Issued Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding Stockholders' Equity Attributable to Parent Total stockholders' equity Balance Balance Retained Earnings (Accumulated Deficit) Retained earnings Total liabilities Total liabilities Operating Lease, Liability, Noncurrent Operating lease liability, long-term Allowance for Doubtful Accounts Receivable, Current Accounts receivable, reserve for doubtful accounts Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Income Statement [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Costs and Expenses [Abstract] Costs and operating expenses: Cost of Goods and Services Sold Cost of product revenue Costs and Expenses Total costs and operating expenses Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Income Tax Expense (Benefit) Income tax provision Net Income (Loss) Attributable to Parent Net income Net income Operating Income (Loss) Income from operations Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss): Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustment Revenues [Abstract] Revenue: Revenue from Contract with Customer, Including Assessed Tax Revenue Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted average shares used in computing net income per share - diluted Weighted Average Number of Shares Outstanding, Basic Basic Weighted average shares used in computing net income per share - diluted Other Nonoperating Income (Expense) [Abstract] Other income (expenses): Interest Expense Interest expense Investment Income, Net Investment income Other Nonoperating Income (Expense) Other (expenses) income Nonoperating Income (Expense) Other expenses, net Gain (Loss) on Extinguishment of Debt Loss on extinguishment of debt Loss on extinguishment of debt Loss on extinguishment of debt Earnings Per Share [Abstract] Earnings per share: Earnings Per Share, Basic Basic Earnings Per Share, Diluted Diluted Product and Service [Axis] Product and Service [Domain] Product [Member] Products Product Royalty [Member] Royalty and Other Revenue Royalty and Other Revenue Statement of Stockholders' Equity [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Loss Additional Paid-in Capital [Member] Additional Paid- In Capital Common Stock [Member] Common Stock Retained Earnings [Member] Retained Earnings/ (Accumulated Deficit) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation expense Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Shares, New Issues Proceeds from issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Exercise of stock options and releases of restricted stock (in shares) Stock Issued During Period, Value, New Issues Proceeds from issuance of common stock, net of issuance costs Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Exercise of stock options and releases of restricted stock Stock Issued During Period, Value, Acquisitions Issuance of common stock pursuant to the acquisition of C Technologies, Inc. Stock Issued During Period, Shares, Acquisitions Issuance of common stock pursuant to the acquisition of C Technologies, Inc., (in shares) Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Translation adjustment Stock Issued During Period, Value, Conversion of Units Issuance of common stock for debt conversion Stock Issued During Period, Shares, Conversion of Units Issuance of common stock for debt conversion (in shares) Adjustments To Additional Paid In Capital Reduction For Equity Component Of Convertible Debt Reduction for equity component from debt conversion, net of tax Adjustments To Additional Paid In Capital Reduction For Equity Component Of Convertible Debt. Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Tax withholding on vesting of restricted stock units (in shares) Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Tax withholding on vesting of restricted stock units Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Equity component of 0.375% senior convertible notes, net of tax Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Proceeds from issuance of common stock, net of issuance cost Debt Instrument, Interest Rate, Stated Percentage Senior convertible notes Notes, interest rate Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Zero Point Three Seven Five Percentage Convertible Senior Notes Due Twenty Twenty Four [Member] 0.375% Convertible Senior Notes due 2024 Statement of Cash Flows [Abstract] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net increase in cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash, cash equivalents and restricted cash Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities Total cash provided by financing activities Proceeds from Convertible Debt Proceeds from issuance of convertible debt, net Proceeds from issuance of convertible senior notes, net of costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net Net proceeds from public offering Proceeds from Stock Options Exercised Proceeds from exercise of stock options Repayments of Convertible Debt Repayment of senior convertible notes Payment, Tax Withholding, Share-based Payment Arrangement Payment of tax withholding obligation on vesting of restricted stock Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities Total cash used in investing activities Payments to Acquire Businesses, Net of Cash Acquired Acquisitions, net of cash acquired Payments to Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Payments to Acquire Software Additions to capitalized software costs Net Cash Provided by (Used in) Operating Activities [Abstract] Cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Amortization of Debt Discount (Premium) Non-cash interest expense Accretion of the debt discount Deferred Income Tax Expense (Benefit) Deferred income taxes, net Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Share-based Compensation Stock-based compensation expense Other Noncash Income (Expense) Other Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities, excluding impact of acquisitions: Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Noncurrent Liabilities Long-term liabilities Increase (Decrease) in Other Receivables Royalties and other receivables Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Contract with Customer, Asset Unbilled receivables Increase Decrease in Operating Lease Right Of Use Asset Operating lease right of use assets The increase (decrease) during the reporting period in operating lease right of use asset. Increase Decrease in Operating Lease Liability Operating lease liability The increase (decrease) during the reporting period in operating lease liability. Increase (Decrease) in Other Operating Assets Other assets Net Cash Provided by (Used in) Operating Activities Total cash provided by operating activities Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of non-cash investing and financing activities: Stock Issued Fair value of common stock issued for acquisition of C Technologies, Inc. Debt Conversion, Converted Instrument, Amount Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes Total consideration on conversion Assets Acquired Under Operating Leases Assets acquired under operating leases Assets acquired under operating leases. Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Disclosure Text Block [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Text Block [Abstract] Business Combination Disclosure [Text Block] Acquisitions Revenue from Contract with Customer [Text Block] Revenue Recognition Credit Loss [Abstract] Credit Loss, Financial Instrument [Text Block] Credit Losses Goodwill And Other Intangible Assets Disclosure [Abstract] Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets Goodwill And Other Intangible Assets Disclosure abstract EX-101.PRE 9 rgen-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 d945763d10q_htm.xml IDEA: XBRL DOCUMENT 0000730272 2020-01-01 2020-09-30 0000730272 2020-09-30 0000730272 2019-12-31 0000730272 2020-07-01 2020-09-30 0000730272 2019-07-01 2019-09-30 0000730272 2019-01-01 2019-09-30 0000730272 2019-07-19 0000730272 2019-05-03 0000730272 2019-07-19 2019-07-19 0000730272 2019-05-03 2019-05-03 0000730272 2019-01-01 2019-12-31 0000730272 2019-09-30 0000730272 2020-11-02 0000730272 2020-04-01 2020-06-30 0000730272 2020-01-01 2020-03-31 0000730272 2020-06-30 0000730272 2018-12-31 0000730272 2019-06-30 0000730272 2020-03-31 0000730272 rgen:CTechnologiesMember 2020-09-30 0000730272 rgen:NonExecutiveMember rgen:RestrictedStockAndPerformanceStockUnitsMember 2020-09-30 0000730272 srt:ExecutiveOfficerMember rgen:RestrictedStockAndPerformanceStockUnitsMember 2020-09-30 0000730272 rgen:NonExecutiveMember us-gaap:EmployeeStockOptionMember 2020-09-30 0000730272 srt:ExecutiveOfficerMember us-gaap:EmployeeStockOptionMember 2020-09-30 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2020-09-30 0000730272 rgen:SpectrumIncMember srt:MinimumMember us-gaap:PrincipalOwnerMember 2020-09-30 0000730272 us-gaap:CustomerRelationshipsMember 2020-09-30 0000730272 us-gaap:TrademarksMember 2020-09-30 0000730272 us-gaap:OtherIntangibleAssetsMember 2020-09-30 0000730272 us-gaap:DevelopedTechnologyRightsMember 2020-09-30 0000730272 us-gaap:PatentsMember 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember 2020-09-30 0000730272 us-gaap:TrademarksMember 2020-09-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2020-09-30 0000730272 rgen:CTechnologiesMember us-gaap:CustomerRelationshipsMember 2020-09-30 0000730272 rgen:CTechnologiesMember us-gaap:DevelopedTechnologyRightsMember 2020-09-30 0000730272 rgen:CTechnologiesMember us-gaap:TrademarksAndTradeNamesMember 2020-09-30 0000730272 rgen:CTechnologiesMember us-gaap:NoncompeteAgreementsMember 2020-09-30 0000730272 rgen:TwoPointOneTwoFivePercentageNonConvertibleSeniorNotesDueTwentyTwentyOneMember 2020-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2020-09-30 0000730272 rgen:StockOptionAndIncentivePlanMember 2020-09-30 0000730272 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:CustomerRelationshipsMember 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:DevelopedTechnologyRightsMember 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:TradeNamesMember 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:NoncompeteAgreementsMember 2020-09-30 0000730272 rgen:CTechnologiesMember us-gaap:GoodwillMember 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:GoodwillMember 2020-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2020-09-30 0000730272 us-gaap:DevelopedTechnologyRightsMember 2019-12-31 0000730272 us-gaap:PatentsMember 2019-12-31 0000730272 us-gaap:CustomerRelationshipsMember 2019-12-31 0000730272 us-gaap:TrademarksMember 2019-12-31 0000730272 us-gaap:OtherIntangibleAssetsMember 2019-12-31 0000730272 us-gaap:TrademarksMember 2019-12-31 0000730272 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000730272 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000730272 srt:NorthAmericaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000730272 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000730272 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember 2020-07-01 2020-09-30 0000730272 us-gaap:ProductMember 2020-07-01 2020-09-30 0000730272 us-gaap:RoyaltyMember 2020-07-01 2020-09-30 0000730272 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000730272 rgen:CTechnologiesMember 2020-07-01 2020-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2020-07-01 2020-09-30 0000730272 rgen:NGLImpactAMember us-gaap:ResearchAndDevelopmentArrangementMember 2020-07-01 2020-09-30 0000730272 rgen:SpectrumIncMember 2020-07-01 2020-09-30 0000730272 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000730272 srt:NorthAmericaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000730272 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-07-01 2019-09-30 0000730272 rgen:MilliporeSigmaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-07-01 2019-09-30 0000730272 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000730272 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000730272 us-gaap:ProductMember 2019-07-01 2019-09-30 0000730272 us-gaap:RoyaltyMember 2019-07-01 2019-09-30 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-07-01 2019-09-30 0000730272 rgen:MilliporeSigmaMember 2019-07-01 2019-09-30 0000730272 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000730272 srt:NorthAmericaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000730272 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000730272 rgen:MilliporeSigmaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember 2020-01-01 2020-09-30 0000730272 rgen:CTechnologiesMember 2020-01-01 2020-09-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2020-01-01 2020-09-30 0000730272 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000730272 srt:MinimumMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-09-30 0000730272 srt:MaximumMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-01-01 2020-09-30 0000730272 rgen:NonEmployeeDirectorStockOptionMember 2020-01-01 2020-09-30 0000730272 rgen:UnvestedOptionsMember 2020-01-01 2020-09-30 0000730272 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000730272 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0000730272 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000730272 us-gaap:ProductMember 2020-01-01 2020-09-30 0000730272 us-gaap:RoyaltyMember 2020-01-01 2020-09-30 0000730272 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2020-01-01 2020-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2020-01-01 2020-09-30 0000730272 rgen:MilliporeSigmaMember 2020-01-01 2020-09-30 0000730272 country:US us-gaap:EarliestTaxYearMember 2020-01-01 2020-09-30 0000730272 country:US us-gaap:LatestTaxYearMember 2020-01-01 2020-09-30 0000730272 country:SE us-gaap:EarliestTaxYearMember 2020-01-01 2020-09-30 0000730272 country:SE us-gaap:LatestTaxYearMember 2020-01-01 2020-09-30 0000730272 country:DE us-gaap:LatestTaxYearMember 2020-01-01 2020-09-30 0000730272 country:NL us-gaap:EarliestTaxYearMember 2020-01-01 2020-09-30 0000730272 country:NL us-gaap:LatestTaxYearMember 2020-01-01 2020-09-30 0000730272 us-gaap:DevelopedTechnologyRightsMember 2020-01-01 2020-09-30 0000730272 us-gaap:PatentsMember 2020-01-01 2020-09-30 0000730272 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0000730272 us-gaap:TrademarksMember 2020-01-01 2020-09-30 0000730272 us-gaap:OtherIntangibleAssetsMember 2020-01-01 2020-09-30 0000730272 rgen:NGLImpactAMember us-gaap:ResearchAndDevelopmentArrangementMember 2020-01-01 2020-09-30 0000730272 us-gaap:SalesRevenueNetMember 2020-01-01 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:CustomerRelationshipsMember 2020-01-01 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:DevelopedTechnologyRightsMember 2020-01-01 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:TradeNamesMember 2020-01-01 2020-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:NoncompeteAgreementsMember 2020-01-01 2020-09-30 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2020-01-01 2020-09-30 0000730272 rgen:CytivaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000730272 us-gaap:TrustForBenefitOfEmployeesMember 2020-01-01 2020-09-30 0000730272 us-gaap:TrustForBenefitOfEmployeesMember rgen:CTechnologiesMember 2020-01-01 2020-09-30 0000730272 rgen:SpectrumIncMember 2020-01-01 2020-09-30 0000730272 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000730272 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000730272 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000730272 rgen:CTechnologiesMember 2019-01-01 2019-09-30 0000730272 srt:NorthAmericaMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000730272 srt:EuropeMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000730272 rgen:ApacOtherMember us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000730272 us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000730272 rgen:CytivaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000730272 rgen:MilliporeSigmaMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-09-30 0000730272 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000730272 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000730272 us-gaap:ProductMember 2019-01-01 2019-09-30 0000730272 us-gaap:RoyaltyMember 2019-01-01 2019-09-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2019-01-01 2019-09-30 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-01-01 2019-09-30 0000730272 rgen:CytivaMember 2019-01-01 2019-09-30 0000730272 rgen:MilliporeSigmaMember 2019-01-01 2019-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-31 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-31 0000730272 us-gaap:TrustForBenefitOfEmployeesMember 2020-06-30 0000730272 rgen:CTechnologiesMember 2019-05-31 2019-12-31 0000730272 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-12-31 0000730272 us-gaap:PatentsMember 2019-01-01 2019-12-31 0000730272 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0000730272 us-gaap:TrademarksMember 2019-01-01 2019-12-31 0000730272 us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-12-31 0000730272 rgen:CytivaMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0000730272 rgen:UnderwriterMember us-gaap:CommonStockMember 2019-07-19 2019-07-19 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-19 2019-07-19 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-07-19 2019-07-19 0000730272 rgen:ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-07-19 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-07-16 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember us-gaap:CommonStockMember 2019-07-22 2019-07-22 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-07-22 2019-07-22 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-07-22 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-09-01 2019-09-23 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember us-gaap:CommonStockMember 2019-09-01 2019-09-23 0000730272 rgen:TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember 2019-09-23 0000730272 rgen:UnderwriterMember us-gaap:CommonStockMember 2019-05-03 2019-05-03 0000730272 rgen:StockOptionAndIncentivePlanMember 2018-12-31 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2019-09-30 0000730272 rgen:ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember 2019-09-30 0000730272 rgen:EngineeredMoldingTechnologyLlcMember 2020-07-13 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:CustomerRelationshipsMember 2020-07-13 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:DevelopedTechnologyRightsMember 2020-07-13 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:TrademarksAndTradeNamesMember 2020-07-13 0000730272 rgen:EngineeredMoldingTechnologyLlcMember us-gaap:NoncompeteAgreementsMember 2020-07-13 0000730272 rgen:ArtesynBiosolutionsMember us-gaap:SubsequentEventMember 2020-10-27 2020-10-27 0000730272 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000730272 us-gaap:RetainedEarningsMember 2020-06-30 0000730272 us-gaap:CommonStockMember 2020-06-30 0000730272 us-gaap:CommonStockMember 2020-09-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000730272 us-gaap:RetainedEarningsMember 2020-09-30 0000730272 us-gaap:CommonStockMember 2019-06-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000730272 us-gaap:RetainedEarningsMember 2019-06-30 0000730272 us-gaap:CommonStockMember 2019-09-30 0000730272 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000730272 us-gaap:RetainedEarningsMember 2019-09-30 0000730272 rgen:RestrictedStockAndPerformanceStockUnitsMember 2019-12-31 0000730272 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000730272 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000730272 us-gaap:CommonStockMember 2019-12-31 0000730272 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000730272 us-gaap:RetainedEarningsMember 2019-12-31 0000730272 us-gaap:CommonStockMember 2018-12-31 0000730272 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000730272 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000730272 us-gaap:RetainedEarningsMember 2018-12-31 iso4217:USD shares pure utr:Year iso4217:USD shares rgen:Segment false Q3 0000730272

P3Y

P5Y

--12-31 MA 10-Q true 2020-09-30 2020 false 000-14656 REPLIGEN CORP DE 04-2729386 41 Seyon Street, Bldg. 1, Suite 100 Waltham 02453 781 250-0111 Common Stock RGEN NASDAQ Yes Yes Large Accelerated Filer false false false 52619271

553302000

528392000

9015000

621000

525000

55830000

43068000

95000

148000

456000

78531000

54832000

8970000

5917000

696728000

641828000

55355000

48455000

215385000

212552000

482043000

468413000

2192000

2920000

24201000

25707000

412000

238000

1476316000

1400113000

14483000

11425000

4460000

3557000

32041000

33331000

50984000

48313000

240942000

232767000

29435000

29944000

26378000

26995000

3707000

2326000

351446000

340345000

0.01

5000000

0.01

80000000

52606700

52078258

526000

521000

1087996000

1068431000

-9723000

-15027000

46071000

5843000

1124870000

1059768000

1476316000

1400113000

94029000

69419000

257521000

200701000

31000

26000

91000

70000

94060000

69445000

257612000

200771000

39626000

31425000

108471000

88978000

4422000

5427000

13460000

14278000

29051000

24629000

83277000

67326000

73099000

61481000

205208000

170582000

20961000

7964000

52404000

30189000

82000

1898000

1699000

3616000

-5650000

3052000

2857000

9032000

6326000

-248000

316000

-632000

-23000

-3218000

-6293000

-7965000

-8383000

17743000

1671000

44439000

21806000

3191000

12000

4211000

3999000

14552000

1659000

40228000

17807000

0.28

0.03

0.77

0.38

0.27

0.03

0.75

0.37

52545000

50852000

52341000

47087000

53469000

51809000

53300000

47930000

14552000

1659000

40228000

17807000

4390000

-6741000

5304000

-9901000

18942000

-5082000

45532000

7906000

52078258

521000

1068431000

-15027000

5843000

1059768000

40228000

528442

5000

7073000

7078000

12492000

5304000

52606700

526000

1087996000

-9723000

46071000

1124870000

52494884

525000

1082096000

-14113000

31519000

1100027000

14552000

111816

1000

1675000

1676000

4225000

4390000

52606700

526000

1087996000

-9723000

46071000

1124870000

43917378

439000

642590000

-11893000

-15568000

615568000

17807000

2316229

23000

198734000

198757000

-200079000 -200079000

311299

3000

1055000

1058000

779221

8000

53930000

53938000

-3077

290000

0.00375

38088000

18607000

4731531

48000

320665000

320713000

9459000

-9901000

52052581

521000

1064152000

-21794000

2239000

1045118000

48086422

481000

892960000

-15053000

580000

878968000

1659000

2316200

23000

198732000

198755000

-200079000 -200079000

66036

1000

493000

494000

-3077

290000

0.00375

38088000

6981000

1587000

16000

131073000

131089000

3175000

-6741000

52052581

521000

1064152000

-21794000

2239000

1045118000

40228000

17807000

19581000

14791000

8175000

4863000

12492000

9459000

72000

-9680000

-5650000

-228000

-114000

11515000

6734000

-157000

-26000

-456000

-2047000

22767000

4891000

2908000

1075000

-2574000 -787000

260000

66000

3317000

-780000

-2712000

7263000

-831000 -607000

1467000

10568000

47754000

49542000

28445000

182154000

3585000

4630000

11067000

11413000

-43097000

-198197000

7088000

1058000

10000

290000

278555000

320713000

114989000

7078000

485047000

4160000

-7785000

15895000

328607000

537407000

193822000

553302000

522429000

1456000

198757000

53938000

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> and Article 10 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> and do not include all of the information and footnote disclosures required by GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> (“Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K”)</div> for the fiscal year ended December 31, 2019.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum LifeSciences, LLC and its subsidiaries (“Spectrum”), C Technologies, Inc. (“C Technologies”), Engineered Molding Technology (“EMT”) and Repligen Singapore Pte. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company made no material changes in the application of<div style="letter-spacing: 0px; top: 0px;;display:inline;"> its</div> significant accounting policies that were disclosed in its Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K.</div> In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards Updates </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We consider the applicability and impact of all Accounting Standards Updates on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued Accounting Standards Updates that we feel may be applicable to the Company are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Standard Updates – Adopted During the Period </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.” </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> includes amendments that aim to improve the effectiveness of fair value measurement disclosures. The amendments in this guidance modify the disclosure requirements on fair value measurements based on the concepts in FASB Concepts Statement, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Conceptual Framework for Financial Reporting - Chapter 8: Notes to Financial Statements</div></div>,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">”</div></div> including the consideration of costs and benefits. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">In August 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Intangibles – Goodwill and Other – <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Internal-Use</div> Software (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">350-40):</div> Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-15</div> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software (and hosting arrangements that include an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">internal-use</div> software license). The guidance also requires the entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13,</div> “<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financial Instruments-Credit Losses (Topic 326).”</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments, including short-term trade receivables and contract assets, and expands disclosure requirements for credit quality of financial assets. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> on January 1, 2020. The Company assessed all potential impacts that the adoption of this guidance has on its consolidated financial statements. Based on the composition of the Company’s investment portfolio, accounts receivable, current market conditions and historical credit loss activity, the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13</div> by the Company did not have a material impact on its consolidated financial position, results of operations or cash flows as of and for the three and nine months ended September 30, 2020. The Company continues to monitor processes and controls for indications of an adjustment for future economic conditions at quarterly and annual reporting periods. See Note 5, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Credit Losses,” </div></div>below for more information on the Company’s adoption of ASC 326.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In November 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.” </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-18</div> clarifies the interaction between Topic 808, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Collaborative Arrangements,” </div></div>and Topic 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Revenue from Contracts with Customers,” </div></div>by making targeted improvements to GAAP for collaborative arrangements and providing guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. This includes improving comparability in the presentation of revenue for certain transactions between collaborative arrangement participants by allowing presentation of the units of account in collaborative arrangements that are within the scope of Topic 606 together with revenue accounted for under Topic 606. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In December 2019, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> “<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes.” </div></div>ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, including, but not limited to, the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, the exceptions related to the recognition of a deferred tax liability related to an equity method investment and the exception to methodology for calculating income taxes in an interim period when a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-date</div></div> loss exceeds the anticipated loss for the year. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Standard Updates – Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06,</div> “<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Debt - Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging - Contracts in Entity</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">’</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40).</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">”</div></div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the timing and impact of the adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2020-06</div> on the Company’s consolidated financial statements.</div>

395600000

415600000

287500000

0.00375

2024-07-15

semi-annually

240900000

416000000.0

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions </div></div></div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Engineered Molding Technology LLC </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 13, 2020, the Company completed the acquisition of 100% of the membership interests of Engineered Molding Technology LLC (“EMT”), a New York limited liability company<div style="letter-spacing: 0px; top: 0px;;display:inline;">,</div> pursuant to a Membership Interest Purchase Agreement, dated June 26, 2020, by and among the Company, EMT, and Michael Pandori and Todd Etesse, the legal and beneficial owners of EMT (such acquisition, the “EMT Acquisition”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">EMT, which is headquartered in Clifton Park, New York, is an innovator and manufacturer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> silicone assemblies and components used in the manufacturing of biologic drugs. EMT’s standard and custom molding as well as their over-molded connectors and silicone tubing products are key components in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> filtration and chromatography systems. EMT’s products will complement and expand Repligen’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> product offerings.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consideration Transferred </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The EMT <div style="letter-spacing: 0px; top: 0px;;display:inline;">Acquisition</div> was accounted for as a purchase of a business under ASC 805, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Business Combinations”. </div></div>Total consideration paid was $28.5 million<div style="display:inline;">,</div> which included $2.2 million<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">deposited into an escrow account against which the Company may make claim<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>for indemnification<div style="display:inline;">.</div> Under the acquisition method of accounting, the net assets of EMT were recorded as of the acquisition date, at their respective fair values, and consolidated with those of Repligen. The fair value of the net tangible assets acquired is estimated to be approximately $1.5 million, the fair value of the intangible assets acquired is estimated to be $14.4 million, and the residual goodwill is estimated to be approximately $12.6 million. The estimated consideration and preliminary purchase price information has been prepared using a preliminary valuation. The preparation of the valuation required the use of significant assumptions and<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">estimates<div style="letter-spacing: 0px; top: 0px;;display:inline;">. Critical estimates included, but were not </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that Repligen believes to be reasonable. However, actual results may differ from these estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition<div style="display:inline;">-</div>related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred $1.0 million and $1.1 million of acquisition related costs during the three and nine months ended September 30, 2020. The transaction costs are included in selling, general and <div style="letter-spacing: 0px; top: 0px;;display:inline;">administrative</div> expenses in the consolidated statements of comprehensive income (loss). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Net Assets Acquired </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. As additional information becomes available, the Company may further revise its preliminary purchase price allocation during the remainder of the measurement period (which will not exceed 12 months from July 13, 2020). Any such revisions or changes may be material. The components and allocation of the purchase price consists of the following amounts (amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">69</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,057</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">449</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">7</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">472</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right of use assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,050</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">11,080</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,910</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademark and tradename</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">320</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compete</div> agreements</div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">12,573</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(283</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(190</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(211</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, long-term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(839</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of net assets acquired</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28,514</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired Goodwill </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The goodwill of $12.6 million represents future economic benefits expected to arise from anticipated synergies from the integration of EMT. These synergies include certain cost savings, operating efficiencies and other strategic benefits projected to be achieved as a result of the EMT Acquisition. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the components of the identified intangible assets associated with the EMT Acquisition and their estimated useful lives: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">14 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">11,080</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">11 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,910</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademark and tradename</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">14 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">320</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-competition</div> agreements</div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14,360</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, Net Income and Pro Forma Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has included the operating results of EMT in its consolidated statements of comprehensive income (loss) since the July 13, 2020 acquisition date. The Company does not consider this acquisition to be material to its consolidated statements of comprehensive income (loss) and therefore has not included pro forma results. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">C Technologies, Inc. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May 31, 2019, Repligen acquired C Technologies, pursuant to the terms of a Stock Purchase Agreement (the “Agreement”), by and among Repligen, C Technologies and Craig Harrison, an individual and sole stockholder of C Technologies (such acquisition, the “C Technologies Acquisition”). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred $4.0 million in transaction costs for the nine months ended September 30, 2019. The transaction costs are included in selling, general and administrative expenses in the consolidated statements of comprehensive income (loss). In connection with the transaction, an additional $9.0 million was paid to employees during the second quarter of 2020, based on their continued employment with the Company one year after the date of the close of the C Technologies Acquisition.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">The</div> Company has recognized $3.7 million of compensation expense associated<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">with</div> this amount due to employees <div style="letter-spacing: 0px; top: 0px;;display:inline;">during the nine months ended September 30, 2020 </div>and has recognized $9.0 million of compensation expense associated with this amount due since the C Technologies Acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Net Assets Acquired </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allocation of purchase price is based on the fair value of assets acquired and liabilities assumed as of the acquisition date, based on the preliminary valuation. The Company obtained this information during due diligence and through other sources. In the months after closing, the Company obtained additional information about these assets and liabilities as it learned more about C Technologies. The Company refined the estimates of fair value to more accurately allocate the purchase price. Only items identified as of the acquisition date were considered for subsequent adjustment. We made appropriate adjustments to the purchase price allocation during the measurement period, which was one year from the acquisition date. The components and allocation of the purchase price consists of the following amounts (amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,795</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">26,933</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,044</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,783</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">93</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">40</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right of use asset</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,836</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">59,680</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">28,920</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademark and tradename</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,570</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-competition</div> agreements</div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">660</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">142,314</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(436</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(2,767</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(26,928</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,709</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(51</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, long-term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(3,785</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of net assets acquired</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">239,887</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquired Goodwill </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The goodwill of $142.3 million represents future economic benefits expected to arise from synergies from combining operations and commercial organizations to increase market presence and the extension of existing customer relationships. Substantially all of the goodwill recorded is expected to be deductible for income tax purposes. Pursuant to the Company’s business combination accounting policy included in Note 2, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of Significant Accounting Policies – Business Combinations, Goodwill and Intangible Assets,</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">”</div></div> of the Company’s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the fiscal year ended December 31, 2019, the Company</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">recorded goodwill adjustments for the effects on goodwill of changes to net assets acquired during the period that such change is identified, provided that any such change is within the measurement period (up to one year from the date of the acquisition). In March 2020, the Company recorded an adjustment to goodwill of $0.3 million related to additional state income tax liabilities to be paid to the seller, which were incurred from the Company’s finalized 338(h)(10) tax election.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, Net Income and Pro Forma Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recorded revenue from C Technologies of $9.0 million and $23.3 million for the three and nine months ended September 30, 2020, respectively, and $16.4 million from May 31, 2019, the date of acquisition, to December 31, 2019. The Company recorded a net income from C Technologies’ results of operations of $2.1 million and a net loss of $0.8 million for the three and nine months ended September 30, 2020, respectively, and a net loss of $7.4 million from May 31, 2019 to December 31, 2019. The Company has included the operating results of C Technologies in its consolidated statements of comprehensive income (loss) since the May 31, 2019 acquisition date. The following pro forma financial information presents the combined results of operations of Repligen and C Technologies as if the acquisition had occurred on January 1, 2019 after giving effect to certain pro forma adjustments. The pro forma adjustments reflected herein include only those adjustments that are directly attributable to the C Technologies Acquisition, factually supportable and have a recurring impact. These pro forma adjustments include amortization expense on the acquired identifiable intangible assets, adjustments to stock-based compensation expense for equity compensation issued to C Technologies employees and the income tax effect of the adjustments made. In addition, acquisition-related transaction costs and an accounting adjustment to record inventory at fair value were excluded from pro forma net income in 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the C Technologies Acquisition, C Technologies did not generate monthly or quarterly financial statements that were prepared in accordance with GAAP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following pro forma financial information does not reflect any adjustments for anticipated expense savings resulting from the acquisition and is not necessarily indicative of the operating results that would have actually occurred had the transaction been consummated on January 1, 2019 or of future results (amounts in thousands, except per share data): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma total revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">209,960</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net income</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">21,012</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma earnings per share:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.45</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.44</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

28500000

2200000 1500000

14400000

12600000

1000000.0

1100000

The components and allocation of the purchase price consists of the following amounts (amounts in thousands): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">69</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,057</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">449</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">7</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">472</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right of use assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,050</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">11,080</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,910</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademark and tradename</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">320</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compete</div> agreements</div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">12,573</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(283</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(190</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(211</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, long-term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(839</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of net assets acquired</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">28,514</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

69000

1057000

449000

7000

472000

1050000

11080000

2910000

320000

50000

12573000

283000

190000 211000 839000

28514000

12600000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the components of the identified intangible assets associated with the EMT Acquisition and their estimated useful lives: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 68%;"/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 9%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Useful life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">14 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">11,080</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">11 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,910</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademark and tradename</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">14 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">320</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-competition</div> agreements</div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14,360</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

P14Y

11080000

P11Y

2910000

P14Y

320000

P3Y

50000

14360000

4000000.0

9000000.0

3700000

9000000.0

The components and allocation of the purchase price consists of the following amounts (amounts in thousands): <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,795</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">26,933</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,044</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,783</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses and other current assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">93</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">40</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease right of use asset</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,836</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">59,680</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developed technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">28,920</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademark and tradename</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,570</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-competition</div> agreements</div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">660</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">142,314</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(436</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(2,767</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(26,928</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,709</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(51</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, long-term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(3,785</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value of net assets acquired</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">239,887</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

3795000

26933000

3044000

3783000

93000

40000

3836000

59680000

28920000

1570000

660000

142314000

895000

436000

2767000 26928000 1709000 51000 3785000

239887000

142300000

300000

9000000.0

23300000

16400000

2100000

800000

7400000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following pro forma financial information does not reflect any adjustments for anticipated expense savings resulting from the acquisition and is not necessarily indicative of the operating results that would have actually occurred had the transaction been consummated on January 1, 2019 or of future results (amounts in thousands, except per share data): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 13%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma total revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">209,960</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma net income</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">21,012</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pro forma earnings per share:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.45</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.44</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

209960000

21012000

0.45

0.44

<div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company generates revenue from the sale of bioprocessing products, equipment devices, and related consumables used with these equipment devices to customers in the life science and biopharmaceutical industries. Under ASC 606, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Revenue from Contracts with Customers,” </div></div>revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disaggregation of Revenue </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues for the three and nine months ended September 30, 2020 and 2019 were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 66%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">94,029</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">69,419</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">257,521</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">200,701</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Royalty and other income</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">31</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">26</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">70</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">94,060</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">69,445</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">257,612</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">200,771</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. Because all of its revenues are from bioprocessing customers, there are no differences in the nature, timing and uncertainty of the Company’s </div></div></div></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">revenues and cash flows from any of its product lines. However, given that the Company’s revenues are generated in different geographic regions, factors such as regulatory and geopolitical factors within those regions could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. In addition, a significant portion of the Company’s revenues are generated from two customers; therefore, economic factors specific to these two customers could impact the nature, timing and uncertainty of the Company’s revenues and cash flows. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Disaggregated revenue from contracts with customers by geographic region can be found in Note 15, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Segment Reporting,”</div></div> below.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cytiva (formerly GE Healthcare)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23,759</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MilliporeSigma</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">9,458</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">29,387</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">28,354</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chromatography Products </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company’s chromatography products include a number of products used in the downstream purification and quality control of biological drugs. The majority of chromatography revenue relates to the OPUS<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-packed</div> chromatography column line. OPUS columns are designed to be disposable following a production campaign. Each OPUS column is delivered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-packaged</div> with the customer’s choice of chromatography resin, which is either provided by the Company for the customer or customer supplied. In either scenario, the OPUS column and resin are not interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Chromatography product revenue is generally recognized at a point in time upon transfer of control to the customer.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Filtration Products </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company’s filtration products generate revenue through the sale of KrosFlo<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> hollow fiber TFF systems, TangenX<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> flat sheet cassettes, Spectrum<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> hollow fiber filters, membranes and modules, XCell ATF<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> systems and related consumables<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"> Supporting our systems, we also sell </div> ProConnex<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> flow path assemblies<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">and custom silicone-based, single-use flow path assemblies and components from EMT</div>.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s KrosFlo systems are used in the filtration, isolation, purification and concentration of biologics and diagnostic products. TFF is a rapid and efficient method for separation and purification of biomolecules that is widely used in laboratory, process development and process scale applications in biopharmaceutical manufacturing. Sales of large-scale systems generally include components and consumables as well as training and installation services at the request of the customer. Because the initial sale of components and consumables are necessary for the operation of the system, such items are combined with the systems as a single performance obligation. Training and installation services do not significantly modify or customize these systems and therefore represent a distinct performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s TangenX flat sheet cassettes (SIUS<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div>, SIUS Gamma<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div> and PRO) are not highly interdependent on one another and are therefore considered distinct products that represent separate performance obligations. Product revenue from the sale of TangenX flat sheet cassettes are generally recognized at a point in time upon transfer of control of the customer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company’s other filtration product offerings are not highly interdependent of one another and are therefore considered distinct products that represent separate performance obligations. Revenue on these products is generally recognized at a point in time upon transfer of control to the customer. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">606-10-55-18.</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company also markets the XCell ATF system, a technologically advanced filtration device used in upstream processes to continuously remove cellular metabolic waste products during the course of a fermentation run, freeing healthy cells to continue producing the biologic drug of interest. XCell ATF systems typically include a filtration system and consumables (i.e., tubing sets, metal stands) as well as training and installation services at the request of the customer. The filtration system and consumables are considered distinct products and therefore represent separate performance obligations. First time purchasers of the systems typically purchase a controller that is shipped with the tubing set(s) and metal stand(s). The controller is not considered distinct as it is a proprietary product that is highly interdependent with the filtration system; therefore, the controller is combined with the filtration system and accounted for as a single performance obligation. The training and installation services do not significantly modify or customize the XCell ATF system and therefore represent a distinct performance obligation. XCell<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally</div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">recognized at a point in time upon transfer of control to the customer. XCell ATF system service revenue related to training and installation services is generally recognized over time, as the customer simultaneously receives and consumes the benefits as the Company performs. The Company invoices the customer for the installation and training services in an amount that directly corresponds with the value to the customer of the Company’s performance to date; therefore, revenue recognized is based on the amount billable to the customer in accordance with the practical expedient under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">606-10-55-18.</div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">On July 13, 2020, the Company consummated the EMT Acquisition and added EMT’s silicone-based, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> components and manifolds to its filtration franchise. These products are key components in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> filtration and chromatography systems and will help expand its line of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> ProConnex flow paths, streamline its supply chain for ATF and provide more flexibility as the Company scales and expands its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-use</div> and systems portfolios.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Process Analytics Products </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Process Analytics franchise generates revenue primarily through the sale of the SoloVPE and FlowVPE Slope Spectroscopy systems, consumables and service. These products complement and support the Company’s existing Filtration, Chromatography and Proteins franchises as they allow end users to make <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-line</div> protein concentration measurements in filtration, chromatography and fill-finish applications, designed to allow for real-time process monitoring.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Protein Products </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company’s Protein franchise generates revenue through the sale of Protein A affinity ligands and growth factors. Protein A ligands are an essential component of Protein A chromatography resins (media) used in the purification of virtually all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mAb-based</div> drugs on the market or in development. The Company manufactures multiple forms of Protein A ligands under long-term supply agreements with major life sciences companies, who in turn sell their Protein A chromatography media to end users (biopharmaceutical manufacturers). The Company also manufactures growth factors for sale under long-term supply agreements with certain life sciences companies as well as<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">for<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>direct sales to its customers. Each protein product is considered distinct and therefore represents a separate performance obligation. Protein product revenue is generally recognized at a point in time upon transfer of control to the customer.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Products </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s other products include operating room products sold to hospitals. Other product revenue is generally recognized at a point in time upon transfer of control to the customer. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction Price Allocated to Future Performance Obligations </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Remaining performance obligations represents the transaction price of contracts for which work has not been performed or has been partially performed. The Company’s future performance obligations relate primarily to the installation and training of certain of its systems sold to customers. These performance obligations are completed within one year of receipt of a purchase order from its customers. Accordingly, the Company has elected to not disclose the value of these unsatisfied performance obligations as provided under ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">606-10-50-14.</div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Balances from Contracts with Customers </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about receivables and deferred revenues from contracts with customers as of September 30, 2020 (amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%; font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances from contracts with customers only:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">55,830</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue (included in accrued liabilities in the consolidated balance sheets)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">10,141</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognized during the nine-month period ended September 30, 2020 relating to:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The beginning deferred revenue balance</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,133</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in pricing related to products or services satisfied in previous periods</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The timing of revenue recognition, billings and cash collections results in the accounts receivables and deferred revenue balances on the Company’s consolidated balance sheets. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A contract asset is created when the Company satisfies a performance obligation by transferring a promised good to the customer. Contract assets may represent conditional or unconditional rights to consideration. The right is conditional, and recorded as a contract asset, if the Company must first satisfy another performance obligation in the contract before it is entitled to payment from the customer. Contract assets are transferred to billed receivables once the right becomes unconditional. If the Company has the unconditional right to receive consideration from the customer, the contract asset is accounted for as a billed receivable and presented separately from other contract assets. A right is unconditional if nothing other than the passage of time is required before payment of that consideration is due. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded. Contract liabilities are recognized as revenue after control of the products or services is transferred to the customer and all revenue recognition criteria have been met. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Costs to Obtain or Fulfill a Customer Contract </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Applying the practical expedient in paragraph <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">340-40-25-4,</div></div></div> the Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. These costs are included in selling, general, and administrative expenses. When shipping and handling costs are incurred after a customer obtains control of the products, the Company accounts for these as costs to fulfill the promise and not as a separate performance obligation.</div>

94029000

69419000

257521000

200701000

31000

26000

91000

70000

94060000

69445000

257612000

200771000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cytiva (formerly GE Healthcare)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23,759</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MilliporeSigma</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">9,458</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">29,387</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">28,354</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table>

23759000

9458000

29387000

28354000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information about receivables and deferred revenues from contracts with customers as of September 30, 2020 (amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%; font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balances from contracts with customers only:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">55,830</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue (included in accrued liabilities in the consolidated balance sheets)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;">10,141</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue recognized during the nine-month period ended September 30, 2020 relating to:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The beginning deferred revenue balance</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,133</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in pricing related to products or services satisfied in previous periods</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table>

55830000

10141000

3133000

55800000

600000

The following table provides a roll-forward of the allowance for credit losses in 2020 that is deducted from the amortized cost basis of accounts receivable to present the net amount expected to be collected (amounts in thousands): <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 91%; font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 1, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(525</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Current period change</div> for expected credit losses</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(133</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March 31, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(658</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current period change for write-offs</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">37</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current period change for expected credit losses</div></div> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"/> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: "Times New Roman"; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(538</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-family: "Times New Roman"; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current period change for expected credit losses</div></div> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(83</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"/> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(621</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"/> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgb(255, 255, 255);"> </td> </tr> </table>

525000

-133000

658000

37000

83000

538000

-83000

621000

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill and Intangible Assets </div></div></div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination and determined to have an indefinite useful life is not amortized, but instead is tested for impairment at least annually in accordance with ASC 350, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Intangibles – Goodwill and Other”</div></div>. The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2020 (amounts in thousands):</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2019</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">468,413</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Engineered Molding Technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">12,573</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill adjustment related to C Technologies, Inc.</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">293</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cumulative translation adjustment</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">764</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">482,043</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During each of the fourth quarters of 2019, 2018 and 2017, the Company completed its annual impairment assessments and concluded that goodwill was not impaired in any of those years. The Company has not identified any “triggering” events which indicate an impairment of goodwill in the three and nine months ended September 30, 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible Assets </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets with a definitive life are amortized over their useful lives using the straight-line method, and the amortization expense is recorded within cost of product revenue and selling, general and administrative expenses in the Company’s statements of comprehensive income (loss). Intangible assets and their related useful lives are reviewed at least annually to determine if any adverse conditions exist that would indicate the carrying value of these assets may not be recoverable. More frequent impairment assessments are conducted if certain conditions exist, including a change in the competitive landscape, any internal decisions to pursue new or different technology strategies, a loss of a significant customer, or a significant change in the marketplace, including changes in the prices paid for our products or changes in the size of the market for the Company’s products. An impairment results if the carrying value of the asset exceeds the estimated fair value of the asset. If the estimate of an intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset is amortized prospectively over the revised remaining useful life. The Company continues to believe that its intangible assets are recoverable at September 30, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net consisted of the following at September 30, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Useful Life</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finite-lived intangible assets:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Technology - developed</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">85,196</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(13,054</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">72,142</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">240</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,325</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(33,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">138,464</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">4,072</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(480</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,592</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">19</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other intangibles</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,750</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,263</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">487</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finite-lived intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">263,583</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(48,898</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">214,685</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible asset:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">264,283</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(48,898</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">215,385</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consisted of the following at December 31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Useful Life</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finite-lived intangible assets:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Technology - developed</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">82,169</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(9,669</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">72,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">19</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">240</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">160,825</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(25,642</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">135,183</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,752</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(333</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,419</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">20</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other intangibles</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,697</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(947</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">750</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finite-lived intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">248,683</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(36,831</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">211,852</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible asset:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">249,383</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(36,831</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">212,552</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for finite-lived intangible assets was $4.0 million and $3.9 million for the three months ended September 30, 2020 and 2019, respectively. Amortization expense was $11.8 million and $9.6 million for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, the Company expects to record the following amortization expense in future periods (amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Nine Months Ended September 30,</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Amortization<br/> Expense</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 (remaining three months)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,964</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,855</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,853</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,749</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,298</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">147,966</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">214,685</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2020 (amounts in thousands): <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 87%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2019</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">468,413</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisition of Engineered Molding Technology</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">12,573</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill adjustment related to C Technologies, Inc.</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">293</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cumulative translation adjustment</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">764</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">482,043</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

468413000

12573000

293000

-764000

482043000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net consisted of the following at September 30, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Useful Life</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finite-lived intangible assets:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Technology - developed</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">85,196</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(13,054</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">72,142</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">240</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,325</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(33,861</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">138,464</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">4,072</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(480</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,592</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">19</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other intangibles</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,750</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,263</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">487</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finite-lived intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">263,583</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(48,898</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">214,685</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible asset:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">264,283</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(48,898</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">215,385</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets consisted of the following at December 31, 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Useful Life</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finite-lived intangible assets:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Technology - developed</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">82,169</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(9,669</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">72,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">19</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patents</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">240</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(240</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer relationships</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">160,825</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(25,642</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">135,183</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,752</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(333</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,419</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">20</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other intangibles</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,697</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(947</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">750</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finite-lived intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">248,683</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(36,831</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">211,852</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">16</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indefinite-lived intangible asset:</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trademarks</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total intangible assets</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">249,383</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(36,831</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">212,552</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table>

85196000

13054000

72142000

P18Y

240000

P8Y

172325000

33861000

138464000

P15Y

4072000

480000

3592000

P19Y

1750000

1263000

487000

P3Y

263583000

48898000

214685000

P16Y

700000

264283000

48898000

215385000

82169000

9669000

72500000

P19Y

240000

P8Y

160825000

25642000

135183000

P15Y

3752000

333000

3419000

P20Y

1697000

947000

750000

P3Y

248683000

36831000

211852000

P16Y

700000

249383000

36831000

212552000

4000000.0

3900000

11800000

9600000

As of September 30, 2020, the Company expects to record the following amortization expense in future periods (amounts in thousands): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Nine Months Ended September 30,</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Amortization<br/> Expense</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020 (remaining three months)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,964</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,855</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,853</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,749</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">15,298</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025 and thereafter</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">147,966</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">214,685</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

3964000

15855000

15853000

15749000

15298000

147966000

214685000

42201000

29328000

6192000

8360000

30138000

17144000

78531000

54832000

1023000

989000

764000

29776000

23905000

39094000

36257000

8055000

6312000

14468000

8810000

6416000

6707000

348000

56000

100169000

83834000

44814000

35379000

55355000

48455000

2800000

1800000

7800000

5200000

14652000

19850000

2759000

3874000

1000000

123000

737000

1500000

1745000

1081000

10141000

5005000

1007000

1898000

32041000

33331000

287500000

0.00375

37500000

278500000

0.00375

Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020.

2024-07-15

8.6749

115.28

0.045

52100000

7400000 1600000

287500000

40764000

47921000

5794000

6812000

240942000

232767000

240942000

232767000

300000

2400000

300000

800000

7200000

1000000.0

0.051

240900000

416000000.0

0.02125

92000000.0

92300000

300000

1850155

161000000.0

253300000

163600000

4600000

23000000.0

466045

37800000

60800000

38300000

1100000

5700000

0.039

2021-06-01

200100000

96300000

115000000.0

100000

500000

100000

1300000

2400000

400000

0.066

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">9.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders’ Equity </div></div></div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public Offerings of Common Stock </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 19, 2019, the Company completed a public offering in which 1,587,000 shares of its common stock, including the underwriters’ exercise in full of an option to purchase an additional 207,000 shares, were sold to the public at a price of $87.00 per share (the “Stock Offering”). The net proceeds of the Stock Offering, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company, were approximately $131.1 million. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May 3, 2019, the Company completed a public offering in which 3,144,531 shares of its common stock, which includes the underwriters’ exercise in full of an option to purchase up to an additional 410,156 shares, were sold to the public at a price of $64.00 per share. The total proceeds received by the Company from this offering, net of underwriting discounts and commissions and other estimated offering expenses payable by the Company, totaled approximately $189.6 million. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Option and Incentive Plans </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Company’s 2018 annual meeting of shareholders held on May 16, 2018, the Company’s shareholders approved the 2018 Stock Option and Incentive Plan (the “2018 Plan”). Under the 2018 Plan the number of shares of the Company’s common stock that are reserved and available for issuance is 2,778,000 plus the number of shares of common stock available for issuance under the Company’s Amended and Restated 2012 Stock Option and Incentive Plan (the “2012 Plan”). The shares of common stock underlying any awards under the 2018 Plan and 2012 Plan (together, the “Plans”) that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of stock available for issuance under the 2018 Plan. At September 30, 2020, 2,325,314 shares were available for future grant under the 2018 Plan. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock-Based Compensation </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended September 30, 2020 and 2019, th<div style="display:inline;">e</div> Company recorded stock-based compensation expense of $4.2 million and $3.2 million, respectively, for share-based awards granted under the Plans. For the nine months ended September 30, 2020 and 2019, the Company recorded stock-based compensation expense of $12.5 million and $9.5 million, respectively. The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income (loss): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of product revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">563</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">375</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,421</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">992</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">326</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">351</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,092</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">992</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,336</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,449</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">9,979</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">7,475</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">4,225</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,175</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,492</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">9,459</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The 2018 Plan allows for the granting of incentive and nonqualified options to purchase shares of common stock, restricted stock and other equity awards. Employee grants under the Plans generally vest over a <span style="-sec-ix-hidden:hidden15372903">thre</span>e to <span style="-sec-ix-hidden:hidden15372906">five-year</span> period, with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">20%-33%</div> vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under the Plans generally vest over one year. In the first quarter of 2018, to create a longer-term retention incentive, the Company’s Compensation Committee granted long-term incentive compensation awards to its Chief Executive Officer consisting of both stock options and restricted stock units (“RSUs”) that are subject to time-based vesting over nine years. Options granted under the Plans have a maximum term of ten years from the date of grant and generally, the exercise price of the stock options equals the fair market value of the Company’s common stock on the date of grant. At September 30, 2020, options to purchase 723,914 shares and 675,567 stock units were outstanding under the Plans.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the Black-Scholes option pricing model to calculate the fair value of stock option awards on the grant date, and the Company uses the value of the common stock as of the grant date to value RSUs. The Company measures stock-based compensation cost at the grant date based on the estimated fair value of the award. The Company recognizes expense on awards with service-based vesting over the employee’s requisite service period on a straight-line basis. The Company issues performance stock units to certain employees that are tied to company and/or individual performance metrics and recognizes expense on performance-based awards over the vesting period based on the probability that the performance metrics will be achieved. The Company recognizes stock-based compensation expense for options that are ultimately expected to vest, and accordingly, such compensation expense has been adjusted for estimated forfeitures. </div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding option activity for the nine months ended September 30, 2020 under the Plans is summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%; font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 4%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">average</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">exercise</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic Value</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in Thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at December 31, 2019</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">957,559</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">30.81</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">69,698</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">104.61</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercised</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(303,343</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23.37</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/expired/cancelled</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options outstanding at September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">723,914</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">41.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">7.02</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">77,102</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercisable at September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">339,191</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">31.00</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6.05</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">39,528</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2020<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">693,689</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6.98</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">74,178</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"> </td> <td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the number of vested options as of September 30, 2020 plus the number of unvested options expected to vest as of September 30, 2020 based on the unvested outstanding options at September 30, 2020 adjusted for estimated forfeiture rates of 8% for awards granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> level employees and 3% for awards granted to executive level employees.</div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The aggregate intrinsic value in the table above represents the total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> intrinsic value (the difference between the closing price of the common stock on September 30, 2020, the last business day of the third quarter of 2020, of $147.54 per share and the exercise price of each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-the-money</div></div> option) that would have been received by the option holders had all option holders exercised their options on September 30, 2020. The aggregate intrinsic value of stock options exercised during the nine months ended September 30, 2020 and 2019 was $30.7 million and $5.2 million, respectively.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant date fair value of options granted during the nine months ended September 30, 2020 and 2019 was $48.13 and $30.07, respectively. The total fair value of stock options that vested during the nine months ended September 30, 2020 and 2019 was $2.6 million and $2.9 million, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2020 under the Plans is summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%; font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic Value</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in Thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December 31, 2019</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">734,984</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">187,942</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(225,204</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/expired/cancelled</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(22,155</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested at September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">675,567</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3.39</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">99,673</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2020<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">650,436</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3.20</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">95,965</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%;vertical-align: top;;text-align:left;">(1)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the number of vested stock units as of September 30, 2020 plus the number of unvested stock units expected to vest as of September 30, 2020 based on the unvested outstanding stock units at September 30, 2020 adjusted for estimated forfeiture rates of 8% for awards granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> level employees and 3% for awards granted to executive level employees.</div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The aggregate intrinsic value in the table above represents the total <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> intrinsic value (equal to the closing price of the common stock on September 30, 2020, the last business day of the third quarter of 2020, of $147.54 per share, as stock units do not have an exercise price) that would have been received by the stock unit holders had all holders exercised on September 30, 2020. The aggregate intrinsic value of stock units vested during the nine months ended September 30, 2020 and 2019 was $25.0 million and $15.5 million, respectively.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average grant date fair value of stock units vested during the nine months ended September 30, 2020 and 2019 was $66.00 and $33.46, respectively. The total fair value of stock units that vested during the nine months ended September 30, 2020 and 2019 was $9.8 million and $7.6 million, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2020, there was $47.0 million of total unrecognized compensation cost related to unvested share-based awards. This cost is expected to be recognized over a weighted average remaining requisite service period of 3.61 years. The Company expects 1,833,239 unvested options and stock units to vest over the next five years. </div></div>

1587000

207000

87.00

131100000

3144531

410156

64.00

189600000

2778000

2325314

4200000

3200000

12500000

9500000

The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income (loss): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of product revenue</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">563</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">375</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,421</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">992</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">326</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">351</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,092</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">992</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selling, general and administrative</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,336</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,449</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">9,979</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">7,475</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stock-based compensation</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">4,225</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">3,175</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,492</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">9,459</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

563000

375000

1421000

992000

326000

351000

1092000

992000

3336000

2449000

9979000

7475000

4225000

3175000

12492000

9459000

0.20

0.33

P9Y

P10Y

723914

675567

957559

30.81

69698

104.61

303343

23.37

723914

41.03

P7Y7D

77102000

339191

31.00

P6Y18D

39528000

693689

P6Y11M23D

74178000

0.08 0.03

147.54

30700000

5200000

48.13

30.07

2600000

2900000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of stock units is calculated using the closing price of the Company’s common stock on the date of grant. Information regarding stock unit activity, which includes activity for restricted stock units and performance stock units, for the nine months ended September 30, 2020 under the Plans is summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%; font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 5%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="width: 6%; vertical-align: bottom; font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> <td style="font-family: "Times New Roman";"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Term</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in Years)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic Value</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in Thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested at December 31, 2019</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">734,984</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awarded</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">187,942</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(225,204</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/expired/cancelled</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(22,155</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested at September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">675,567</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3.39</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">99,673</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested and expected to vest at September 30, 2020<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">650,436</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3.20</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">95,965</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> </table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"> </td> <td style="width: 5%;vertical-align: top;;text-align:left;">(1)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the number of vested stock units as of September 30, 2020 plus the number of unvested stock units expected to vest as of September 30, 2020 based on the unvested outstanding stock units at September 30, 2020 adjusted for estimated forfeiture rates of 8% for awards granted to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-executive</div> level employees and 3% for awards granted to executive level employees.</div> </td> </tr> </table>

734984

187942

225204

22155

675567

P3Y4M20D

99673000

650436 P3Y2M12D 95965000 0.08 0.03

147.54

25000000.0

15500000

66.00

33.46

9800000

7600000

47000000.0

P3Y7M9D

1833239

P5Y

<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: "Times New Roman"; font-size: 10pt; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies </div></div></div> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licensing and Research Agreements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company licenses certain technologies that are, or may be, incorporated into its technology under several agreements and also has entered into several clinical research agreements which require the Company to fund certain research projects. Generally, the license agreements require the Company to pay annual maintenance fees and royalties on product sales once a product has been established using the technologies. Research and development expenses associated with license agreements were immaterial amounts for the three and nine months ended September 30, 2020 and 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In June 2018, the Company secured an agreement with Navigo<div style="letter-spacing: 0px; top: 0px;;display:inline;"> Proteins</div> for the exclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> of multiple affinity ligands for which Repligen holds commercialization rights. The Company is manufacturing and has agreed to supply the first of these ligands, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NGL-Impact</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">®</div>, exclusively to Purolite Life Sciences (“Purolite”), who will pair the Company’s high-performance ligand with Purolite’s agarose jetting base bead technology used in their Jetted A50 Protein A resin product. The Company also signed a long-term supply agreement with Purolite for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NGL-Impact</div> and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, Repligen and Navigo Proteins successfully completed co-development of an affinity ligand targeting the SARS-CoV-2 spike protein, to be utilized in the purification of COVID-19 vaccines. The Company has proceeded with scaling up and manufacturing this ligand and the development and validation of the related affinity chromatography resin, which will be marketed by Repligen.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>The Navigo and Purolite agreements are supportive of the Company’s strategy to secure and reinforce the Company’s proteins business. The Company made royalty payments to Navigo of $0.2 million and $0.4 million during the three and nine months ended September 30, 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, respectively<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div>

200000

400000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following shows the changes in the components of accumulated other comprehensive loss for the nine months ended September 30, 2020 which consisted of only foreign currency translation adjustments for the periods shown (amounts in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 86%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Translation</div></div></td> <td style="vertical-align: bottom; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December 31, 2019</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(15,027</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,304</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of September 30, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(9,723</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

-15027000

5304000

-9723000

0.180

0.095

0.007

0.183

0.21

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s tax returns are subject to examination by federal, state and international tax authorities for the following periods: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%; font-family: 'Times New Roman';"/> <td style="width: 4%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jurisdiction</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal Years<br/> Subject to<br/> Examination</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States - federal and state</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-2019</div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sweden</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2013-2019</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Germany</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:center;">2019</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Netherlands</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2013-2019</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table>

2016

2019

2013

2019

2013

2019

<div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13.</div></div></td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings Per Share </div></div></div> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">The Company reports earnings per share in accordance with ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Earnings Per Share,”</div></div> which establishes standards for computing and presenting earnings per share. Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of common shares and dilutive common share equivalents then outstanding. Potential common share equivalents consist of restricted stock awards, performance stock units and the incremental common shares issuable upon the exercise of stock options. Under the treasury stock method, unexercised <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“in-the-money”</div></div> stock options and warrants are assumed to be exercised at the beginning of the period or at issuance, if later. The assumed proceeds are then used to purchase common shares at the average market price during the period. In periods when the Company has a net loss, stock awards are excluded from the calculation of earnings per share as their inclusion would have an antidilutive effect.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands, except per share data)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14,552</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,659</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">40,228</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17,807</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares used in computing net income per share -<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">diluted</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">52,545</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50,852</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">52,341</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">47,087</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive shares:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options and restricted stock awards</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">916</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">957</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">951</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of unvested performance stock units</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive potential common shares</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">957</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">959</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares used in computing net income per share - diluted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">53,469</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">51,809</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">53,300</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">47,930</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.28</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.77</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.38</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.27</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.75</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2020, there were outstanding options to purchase 723,914 shares of the Company’s common stock at a weighted average exercise price of $41.03 per share and 675,567 shares of common stock issuable upon the vesting of stock units, which include RSUs and performance stock units. For the three and nine months ended September 30, 2020, 60,202 and 117,160 shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At September 30, 2019, there were outstanding options to purchase 959,916 shares of the Company’s common stock at a weighted average exercise price of $30.44 per share and 740,213 shares issuable upon the vesting of stock units. For the three and nine months ended September 30, 2019, 47,705 and 85,503 shares of the Company’s common stock were excluded from the calculation of diluted earnings per share because the exercise prices of the stock options were greater than or equal to the average price of the common shares and were therefore anti-dilutive.</div></div> <div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As provided by the terms of the indenture underlying the </div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Notes, the Company had a choice to settl<div style="display:inline;">e</div> the conversion obligation for the </div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Notes in cash, shares or any combination of the two. During the third quarter of </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the Company settled the remaining </div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Notes for a total aggregate principal of $</div>115.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> million and </div>2,316,200<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> shares of its common stock. As of March </div>31<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, </div>2019<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, the par value of the </div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Notes is not included in the calculation of diluted earnings per share, but the dilutive effect of the conversion premium is considered in the calculation of diluted earnings per share using the treasury stock method. The dilutive impact of the </div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Notes was based on the difference between the Company’s current period average stock price and the conversion price of the </div>2016<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> Notes, provided there was a premium.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">In July 2019, the Company issued $287.5 million aggregate principal amount of the 2019 Notes. As provided by the terms of the indenture underlying the 2019 Notes, conversion of the 2019 Notes will be settled in cash, shares of the Company’s common stock or a combination thereof, at the Company’s election. As of <div style="letter-spacing: 0px; top: 0px;;display:inline;">September</div> 30, 2020, the 2019 Notes were not convertible. The Company currently intends to settle the par value of the 2019 Notes in cash and any excess conversion premium in shares. The Company applies the provisions of ASC 260, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">“Earnings Per Share”,</div></div> Subsection <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-45-44,</div></div> to determine the diluted weighted average shares outstanding as it relates to the conversion spread on the 2019 Notes. Accordingly, the par value of the 2019 Notes is not included in the calculation of diluted income per share, but the dilutive effect of the conversion premium is considered in the calculation of diluted net income per share using the treasury stock method. The dilutive impact of the 2019 Notes is based on the difference between the Company’s current period average stock price and the conversion price of the 2019 Notes, provided there is a premium. Pursuant to this accounting standard, there is no dilution from the accreted principal of the 2019 Notes for the three and nine months ended September 30, 2020.</div>

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding were as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Amounts in thousands, except per share data)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14,552</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,659</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">40,228</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17,807</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares used in computing net income per share -<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">diluted</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">52,545</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50,852</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">52,341</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">47,087</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effect of dilutive shares:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options and restricted stock awards</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">916</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">957</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">951</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive effect of unvested performance stock units</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">— </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dilutive potential common shares</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">957</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">959</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">843</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares used in computing net income per share - diluted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">53,469</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">51,809</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">53,300</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">47,930</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per share:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.28</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.77</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.38</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.27</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.75</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">0.37</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table>

14552000

1659000

40228000

17807000

52545000

50852000

52341000

47087000

916000

957000

951000

843000

8000

924000

957000

959000

843000

53469000

51809000

53300000

47930000

0.28

0.03

0.77

0.38

0.27

0.03

0.75

0.37

723914

41.03

675567

60202

117160

959916

30.44

740213

47705

85503

115000000.0

2316200

287500000

0.05

100000

500000

<div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table represents the Company’s total revenue by geographic area (based on the location of the customer): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended<br/> September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue by customers’ geographic locations:</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">North America</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">50</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">54</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">48</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">51</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">36</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">33</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">37</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgba(255, 255, 255, 0);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">APAC<div style="letter-spacing: 0px; top: 0px;;display:inline;">/Other</div></div></div> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">13</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgba(255, 255, 255, 0);">% </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt; background-color: rgba(255, 255, 255, 0);">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total revenue</div></div> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">100</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">100</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">100</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">100</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"/> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: "Times New Roman"; background-color: rgba(255, 255, 255, 0);"> </td> </tr> </table>

0.50

0.54

0.48

0.51

0.36

0.33

0.38

0.37

0.14

0.13

0.14

0.12

<div style="text-align: left;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows: </div></div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: "Times New Roman";"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cytiva (formerly GE Healthcare)</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MilliporeSigma</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">N/A</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">11</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table>

0.12

0.14

0.11

0.14

0.18

200000000

130000000

70000000

Represents the number of vested options as of September 30, 2020 plus the number of unvested options expected to vest as of September 30, 2020 based on the unvested outstanding options at September 30, 2020 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees. Represents the number of vested stock units as of September 30, 2020 plus the number of unvested stock units expected to vest as of September 30, 2020 based on the unvested outstanding stock units at September 30, 2020 adjusted for estimated forfeiture rates of 8% for awards granted to non-executive level employees and 3% for awards granted to executive level employees.

XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2020	Nov. 02, 2020
Cover [Abstract]
Amendment Flag	false
Document Type	10-Q
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Central Index Key	0000730272
Current Fiscal Year End Date	--12-31
Document Period End Date	Sep. 30, 2020
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity File Number	000-14656
Entity Registrant Name	REPLIGEN CORP
Entity Filer Category	Large Accelerated Filer
Trading Symbol	RGEN
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-2729386
Entity Address, Address Line One	41 Seyon Street, Bldg. 1, Suite 100
Entity Address, City or Town	Waltham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02453
City Area Code	781
Entity Shell Company	false
Smaller reporting company	false
Emerging growth company	false
Local Phone Number	250-0111
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		52,619,271

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 553,302	$ 528,392
Restricted cash		9,015
Accounts receivable, net of allowances of $621 and $525 at September 30, 2020 and December 31, 2019, respectively	55,830	43,068
Royalties and other receivables	95	148
Unbilled receivables		456
Inventories, net	78,531	54,832
Prepaid expenses and other current assets	8,970	5,917
Total current assets	696,728	641,828
Property, plant and equipment, net	55,355	48,455
Intangible assets, net	215,385	212,552
Goodwill	482,043	468,413
Deferred tax assets	2,192	2,920
Operating lease right of use assets	24,201	25,707
Other assets	412	238
Total assets	1,476,316	1,400,113
Current liabilities:
Accounts payable	14,483	11,425
Operating lease liability	4,460	3,557
Accrued liabilities	32,041	33,331
Total current liabilities	50,984	48,313
Convertible senior notes, net	240,942	232,767
Deferred tax liabilities	29,435	29,944
Operating lease liability, long-term	26,378	26,995
Other liabilities, long-term	3,707	2,326
Total liabilities	351,446	340,345
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.01 par value; 80,000,000 shares authorized; 52,606,700 shares at September 30, 2020 and 52,078,258 shares at December 31, 2019 issued and outstanding	526	521
Additional paid-in capital	1,087,996	1,068,431
Accumulated other comprehensive loss	(9,723)	(15,027)
Retained earnings	46,071	5,843
Total stockholders' equity	1,124,870	1,059,768
Total liabilities and stockholders' equity	$ 1,476,316	$ 1,400,113

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Accounts receivable, reserve for doubtful accounts	$ 621	$ 525
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	80,000,000	80,000,000
Common stock, shares issued	52,606,700	52,078,258
Common stock, shares outstanding	52,606,700	52,078,258

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue:
Revenue	$ 94,060	$ 69,445	$ 257,612	$ 200,771
Costs and operating expenses:
Cost of product revenue	39,626	31,425	108,471	88,978
Research and development	4,422	5,427	13,460	14,278
Selling, general and administrative	29,051	24,629	83,277	67,326
Total costs and operating expenses	73,099	61,481	205,208	170,582
Income from operations	20,961	7,964	52,404	30,189
Other income (expenses):
Investment income	82	1,898	1,699	3,616
Loss on extinguishment of debt		(5,650)	5,700	(5,650)
Interest expense	(3,052)	(2,857)	(9,032)	(6,326)
Other (expenses) income	(248)	316	(632)	(23)
Other expenses, net	(3,218)	(6,293)	(7,965)	(8,383)
Income before income taxes	17,743	1,671	44,439	21,806
Income tax provision	3,191	12	4,211	3,999
Net income	$ 14,552	$ 1,659	$ 40,228	$ 17,807
Earnings per share:
Basic	$ 0.28	$ 0.03	$ 0.77	$ 0.38
Diluted	$ 0.27	$ 0.03	$ 0.75	$ 0.37
Weighted average common shares outstanding:
Basic	52,545	50,852	52,341	47,087
Diluted	53,469	51,809	53,300	47,930
Net income	$ 14,552	$ 1,659	$ 40,228	$ 17,807
Other comprehensive income (loss):
Foreign currency translation adjustment	4,390	(6,741)	5,304	(9,901)
Comprehensive income (loss)	18,942	(5,082)	45,532	7,906
Products
Revenue:
Revenue	94,029	69,419	257,521	200,701
Royalty and Other Revenue
Revenue:
Revenue	$ 31	$ 26	$ 91	$ 70

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid- In Capital	Accumulated Other Comprehensive Loss	Retained Earnings/ (Accumulated Deficit)
Balance at Dec. 31, 2018	$ 615,568	$ 439	$ 642,590	$ (11,893)	$ (15,568)
Balance (in shares) at Dec. 31, 2018		43,917,378
Net income	17,807				17,807
Issuance of common stock for debt conversion	198,757	$ 23	198,734
Issuance of common stock for debt conversion (in shares)		2,316,229
Reduction for equity component from debt conversion, net of tax	(200,079)		(200,079)
Exercise of stock options and releases of restricted stock	1,058	$ 3	1,055
Exercise of stock options and releases of restricted stock (in shares)		311,299
Issuance of common stock pursuant to the acquisition of C Technologies, Inc.	53,938	$ 8	53,930
Issuance of common stock pursuant to the acquisition of C Technologies, Inc., (in shares)		779,221
Tax withholding on vesting of restricted stock units	(290)		(290)
Tax withholding on vesting of restricted stock units (in shares)		(3,077)
Equity component of 0.375% senior convertible notes, net of tax	38,088		38,088
Proceeds from issuance of common stock, net of issuance costs	320,713	$ 48	320,665
Proceeds from issuance of common stock, net of issuance costs (in shares)		4,731,531
Stock-based compensation expense	9,459		9,459
Translation adjustment at Dec. 31, 2018	(9,901)			(9,901)
Balance at Sep. 30, 2019	1,045,118	$ 521	1,064,152	(21,794)	2,239
Balance (in shares) at Sep. 30, 2019		52,052,581
Balance at Jun. 30, 2019	878,968	$ 481	892,960	(15,053)	580
Balance (in shares) at Jun. 30, 2019		48,086,422
Net income	1,659				1,659
Issuance of common stock for debt conversion	198,755	$ 23	198,732
Issuance of common stock for debt conversion (in shares)		2,316,200
Reduction for equity component from debt conversion, net of tax	(200,079)		(200,079)
Exercise of stock options and releases of restricted stock	494	$ 1	493
Exercise of stock options and releases of restricted stock (in shares)		66,036
Tax withholding on vesting of restricted stock units	(290)		(290)
Tax withholding on vesting of restricted stock units (in shares)		(3,077)
Equity component of 0.375% senior convertible notes, net of tax	38,088		38,088
Proceeds from issuance of common stock, net of issuance costs	131,089	$ 16	131,073
Proceeds from issuance of common stock, net of issuance costs (in shares)		1,587,000
Stock-based compensation expense	3,175		3,175
Translation adjustment at Jun. 30, 2019	(6,741)			(6,741)
Balance at Sep. 30, 2019	1,045,118	$ 521	1,064,152	(21,794)	2,239
Balance (in shares) at Sep. 30, 2019		52,052,581
Balance at Dec. 31, 2019	1,059,768	$ 521	1,068,431	(15,027)	5,843
Balance (in shares) at Dec. 31, 2019		52,078,258
Net income	40,228				40,228
Exercise of stock options and releases of restricted stock	7,078	$ 5	7,073
Exercise of stock options and releases of restricted stock (in shares)		528,442
Stock-based compensation expense	12,492		12,492
Translation adjustment at Dec. 31, 2019	5,304			5,304
Balance at Sep. 30, 2020	1,124,870	$ 526	1,087,996	(9,723)	46,071
Balance (in shares) at Sep. 30, 2020		52,606,700
Balance at Jun. 30, 2020	1,100,027	$ 525	1,082,096	(14,113)	31,519
Balance (in shares) at Jun. 30, 2020		52,494,884
Net income	14,552				14,552
Exercise of stock options and releases of restricted stock	1,676	$ 1	1,675
Exercise of stock options and releases of restricted stock (in shares)		111,816
Stock-based compensation expense	4,225		4,225
Translation adjustment at Jun. 30, 2020	4,390			4,390
Balance at Sep. 30, 2020	$ 1,124,870	$ 526	$ 1,087,996	$ (9,723)	$ 46,071
Balance (in shares) at Sep. 30, 2020		52,606,700

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2019 USD ($)
Proceeds from issuance of common stock, net of issuance cost	$ 6,981	$ 18,607
0.375% Convertible Senior Notes due 2024
Senior convertible notes	0.375%	0.375%

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities:
Net income	$ 40,228	$ 17,807
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	19,581	14,791
Non-cash interest expense	8,175	4,863
Stock-based compensation expense	12,492	9,459
Deferred income taxes, net	72	(9,680)
Loss on extinguishment of debt	(5,700)	5,650
Other	228	114
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(11,515)	(6,734)
Royalties and other receivables	157	26
Unbilled receivables	456	2,047
Inventories	(22,767)	(4,891)
Prepaid expenses and other assets	(2,908)	(1,075)
Operating lease right of use assets	2,574	787
Other assets	(260)	(66)
Accounts payable	3,317	(780)
Accrued expenses	(2,712)	7,263
Operating lease liability	(831)	(607)
Long-term liabilities	1,467	10,568
Total cash provided by operating activities	47,754	49,542
Cash flows from investing activities:
Acquisitions, net of cash acquired	(28,445)	(182,154)
Additions to capitalized software costs	(3,585)	(4,630)
Purchases of property, plant and equipment	(11,067)	(11,413)
Total cash used in investing activities	(43,097)	(198,197)
Cash flows from financing activities:
Proceeds from exercise of stock options	7,088	1,058
Payment of tax withholding obligation on vesting of restricted stock	(10)	(290)
Proceeds from issuance of convertible debt, net		278,555
Proceeds from issuance of common stock, net		320,713
Repayment of senior convertible notes		(114,989)
Total cash provided by financing activities	7,078	485,047
Effect of exchange rate changes on cash, cash equivalents and restricted cash	4,160	(7,785)
Net increase in cash, cash equivalents and restricted cash	15,895	328,607
Cash, cash equivalents and restricted cash, beginning of period	537,407	193,822
Cash, cash equivalents and restricted cash, end of period	553,302	522,429
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	$ 1,456
Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes		198,757
Fair value of common stock issued for acquisition of C Technologies, Inc.		$ 53,938

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Summary of Significant Accounting Policies

1.	Summary of Significant Accounting Policies

Basis of Presentation

10-Q

and Article 10 of Regulation

S-X

10-K

(“Form

10-K”)

for the fiscal year ended December 31, 2019.

The Company made no material changes in the application of

its

significant accounting policies that were disclosed in its Form

10-K.

Risks and Uncertainties

Recent Accounting Standards Updates

Recently Issued Accounting Standard Updates – Adopted During the Period

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”)

2018-13,

“Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.”

ASU

2018-13

“Conceptual Framework for Financial Reporting - Chapter 8: Notes to Financial Statements

”

including the consideration of costs and benefits. The Company adopted ASU

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

In August 2018, the FASB issued ASU

2018-15,

“Intangibles – Goodwill and Other –

Internal-Use

Software (Subtopic

350-40):

Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.”

ASU

2018-15

internal-use

software (and hosting arrangements that include an

internal-use

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

In June 2016, the FASB issued ASU

2016-13,

“

Financial Instruments-Credit Losses (Topic 326).”

ASU

2016-13

significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU

2016-13

“Credit Losses,”

below for more information on the Company’s adoption of ASC 326.

In November 2018, the FASB issued ASU

2018-18,

“Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.”

ASU

2018-18

clarifies the interaction between Topic 808,

“Collaborative Arrangements,”

and Topic 606,

“Revenue from Contracts with Customers,”

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

In December 2019, the FASB issued ASU

2019-12,

“

Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes.”

ASU

2019-12

year-to-date

loss exceeds the anticipated loss for the year. The Company adopted ASU

2018-13

on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020.

Recently Issued Accounting Standard Updates – Not Yet Adopted

In August 2020, the FASB issued ASU

2020-06,

“

Debt - Debt with Conversion and Other Options (Subtopic

470-20)

and Derivatives and Hedging - Contracts in Entity

’

s Own Equity (Subtopic

815-40).

”

ASU

2020-06

also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU

2020-06

on the Company’s consolidated financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Measurements

2.	Fair Value Measurements


		Level 1 –		Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access.
		Level 2 –		Valuations based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly.
		Level 3 –		Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

“Convertible Senior Notes”

to these consolidated financial statements.

The Company’s

non-financial

assets include goodwill and other intangible assets, which we classify as Level 3 items. These assets are measured at fair value on a

non-recurring

basis as part of our impairment testing. See Note 6,

“Goodwill and Intangible Assets,”

below for additional information related to goodwill and intangible assets, and our impairment testing.

During the three and nine months ended September 30, 2020, there were no remeasurements to fair value of financial assets and liabilities that are not measured at fair value on a recurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

Acquisitions

9 Months Ended

Sep. 30, 2020

Acquisitions

3.	Acquisitions

Engineered Molding Technology LLC

On July 13, 2020, the Company completed the acquisition of 100% of the membership interests of Engineered Molding Technology LLC (“EMT”), a New York limited liability company

EMT, which is headquartered in Clifton Park, New York, is an innovator and manufacturer of

single-use

filtration and chromatography systems. EMT’s products will complement and expand Repligen’s

single-use

product offerings.

Consideration Transferred

The EMT

Acquisition

was accounted for as a purchase of a business under ASC 805,

“Business Combinations”.

Total consideration paid was $28.5 million

which included $2.2 million

deposited into an escrow account against which the Company may make claim

for indemnification

estimates

. Critical estimates included, but were not

Acquisition

administrative

expenses in the consolidated statements of comprehensive income (loss).

Fair Value of Net Assets Acquired


Cash and cash equivalents	$	69
Accounts receivable		1,057
Inventory		449
Prepaid expenses and other current assets		7
Fixed assets, net		472
Operating lease right of use assets		1,050
Customer relationships		11,080
Developed technology		2,910
Trademark and tradename		320
Non-compete agreements		50
Goodwill		12,573
Accounts payable		(283	)
Accrued liabilities		(190	)
Operating lease liability		(211	)
Operating lease liability, long-term		(839	)

Fair value of net assets acquired	$	28,514

Acquired Goodwill

Intangible Assets

The following table sets forth the components of the identified intangible assets associated with the EMT Acquisition and their estimated useful lives:


	Useful life		Fair Value
			(Amounts in thousands)
Customer relationships		14 years	$	11,080
Developed technology		11 years		2,910
Trademark and tradename		14 years		320
Non-competition agreements		3 years		50

			$	14,360

Revenue, Net Income and Pro Forma Presentation

C Technologies, Inc.

The

Company has recognized $3.7 million of compensation expense associated

with

this amount due to employees

during the nine months ended September 30, 2020

and has recognized $9.0 million of compensation expense associated with this amount due since the C Technologies Acquisition.

Fair Value of Net Assets Acquired


Cash and cash equivalents	$	3,795
Restricted cash		26,933
Accounts receivable		3,044
Inventory		3,783
Prepaid expenses and other current assets		93
Fixed assets		40
Operating lease right of use asset		3,836
Customer relationships		59,680
Developed technology		28,920
Trademark and tradename		1,570
Non-competition agreements		660
Goodwill		142,314
Deferred taxes		895
Accounts payable		(436	)
Accrued liabilities		(2,767	)
Accrued bonus		(26,928	)
Deferred revenue		(1,709	)
Operating lease liability		(51	)
Operating lease liability, long-term		(3,785	)

Fair value of net assets acquired	$	239,887

Acquired Goodwill

“

Summary of Significant Accounting Policies – Business Combinations, Goodwill and Intangible Assets,

”

of the Company’s Annual Report on Form

10-K

for the fiscal year ended December 31, 2019, the Company

Revenue, Net Income and Pro Forma Presentation

Prior to the C Technologies Acquisition, C Technologies did not generate monthly or quarterly financial statements that were prepared in accordance with GAAP.


	Nine Months Ended September 30,
	2019
Pro forma total revenue	$	209,960
Pro forma net income	$	21,012
Pro forma earnings per share:
Basic	$	0.45

Diluted	$	0.44

XML 21 R11.htm IDEA: XBRL DOCUMENT

Revenue Recognition

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Revenue Recognition

4.	Revenue Recognition

“Revenue from Contracts with Customers,”

revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers.

Disaggregation of Revenue

Revenues for the three and nine months ended September 30, 2020 and 2019 were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Product revenue	$	94,029	$	69,419	$	257,521	$	200,701
Royalty and other income		31		26		91		70

Total revenue	$	94,060	$	69,445	$	257,612	$	200,771

Disaggregated revenue from contracts with customers by geographic region can be found in Note 15,

“Segment Reporting,”

below.

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Cytiva (formerly GE Healthcare)		N/A		N/A		N/A	$	23,759
MilliporeSigma		N/A	$	9,458	$	29,387	$	28,354

Chromatography Products

pre-packed

chromatography column line. OPUS columns are designed to be disposable following a production campaign. Each OPUS column is delivered

pre-packaged

Filtration Products

The Company’s filtration products generate revenue through the sale of KrosFlo

hollow fiber TFF systems, TangenX

flat sheet cassettes, Spectrum

hollow fiber filters, membranes and modules, XCell ATF

systems and related consumables

Supporting our systems, we also sell

ProConnex

single-use

flow path assemblies

and custom silicone-based, single-use flow path assemblies and components from EMT

The Company’s TangenX flat sheet cassettes (SIUS

, SIUS Gamma

606-10-55-18.

ATF system product revenue related to the filtration system (including the controller if applicable) and consumables is generally

606-10-55-18.

On July 13, 2020, the Company consummated the EMT Acquisition and added EMT’s silicone-based,

single-use

components and manifolds to its filtration franchise. These products are key components in

single-use

filtration and chromatography systems and will help expand its line of

single-use

ProConnex flow paths, streamline its supply chain for ATF and provide more flexibility as the Company scales and expands its

single-use

and systems portfolios.

Process Analytics Products

in-line

protein concentration measurements in filtration, chromatography and fill-finish applications, designed to allow for real-time process monitoring.

Protein Products

mAb-based

for

Other Products

The Company’s other products include operating room products sold to hospitals. Other product revenue is generally recognized at a point in time upon transfer of control to the customer.

Transaction Price Allocated to Future Performance Obligations

606-10-50-14.

Contract Balances from Contracts with Customers

The following table provides information about receivables and deferred revenues from contracts with customers as of September 30, 2020 (amounts in thousands):


	2020
Balances from contracts with customers only:
Accounts receivable	$	55,830
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	$	10,141
Revenue recognized during the nine-month period ended September 30, 2020 relating to:
The beginning deferred revenue balance	$	3,133
Changes in pricing related to products or services satisfied in previous periods	$	—

The timing of revenue recognition, billings and cash collections results in the accounts receivables and deferred revenue balances on the Company’s consolidated balance sheets.

Costs to Obtain or Fulfill a Customer Contract

The Company’s sales commission structure is based on achieving revenue targets. The commissions are driven by revenue derived from customer purchase orders which are short term in nature.

Applying the practical expedient in paragraph

340-40-25-4,

XML 22 R12.htm IDEA: XBRL DOCUMENT

Credit Losses

9 Months Ended

Sep. 30, 2020

Credit Loss [Abstract]

Credit Losses

5.	Credit Losses

Effective January 1, 2020, the Company adopted ASU

2016-13,

“Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,”

prospectively. ASU

2016-13


	2020
Balance at January 1, 2020	$	(525	)
Current period change for expected credit losses		(133	)

Balance at March 31, 2020		(658	)
Current period change for write-offs		37
Current period change for expected credit losses		83

Balance at June 30, 2020		(538	)
Current period change for expected credit losses		(83	)

Balance at September 30, 2020	$	(621	)

- Definition

The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2020

Goodwill And Other Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

6.	Goodwill and Intangible Assets

Goodwill

“Intangibles – Goodwill and Other”

. The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2020 (amounts in thousands):


Balance as of December 31, 2019	$	468,413
Acquisition of Engineered Molding Technology		12,573
Goodwill adjustment related to C Technologies, Inc.		293
Cumulative translation adjustment		764

Balance as of September 30, 2020	$	482,043

Intangible Assets

Indefinite-lived assets are reviewed for impairment at least annually. There has been no impairment of the Company’s intangible assets for the periods presented.

Intangible assets, net consisted of the following at September 30, 2020:


	September 30, 2020
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Useful Life (in years)
	(Amounts in thousands)
Finite-lived intangible assets:
Technology - developed	$	85,196	$	(13,054	)	$	72,142		18
Patents		240		(240	)		—		8
Customer relationships		172,325		(33,861	)		138,464		15
Trademarks		4,072		(480	)		3,592		19
Other intangibles		1,750		(1,263	)		487		3

Total finite-lived intangible assets		263,583		(48,898	)		214,685		16
Indefinite-lived intangible asset:
Trademarks		700		—			700		—

Total intangible assets	$	264,283	$	(48,898	)	$	215,385

Intangible assets consisted of the following at December 31, 2019:


	December 31, 2019
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Useful Life (in years)
	(Amounts in thousands)
Finite-lived intangible assets:
Technology - developed	$	82,169	$	(9,669	)	$	72,500		19
Patents		240		(240	)		—		8
Customer relationships		160,825		(25,642	)		135,183		15
Trademarks		3,752		(333	)		3,419		20
Other intangibles		1,697		(947	)		750		3

Total finite-lived intangible assets		248,683		(36,831	)		211,852		16
Indefinite-lived intangible asset:
Trademarks		700		—			700		—

Total intangible assets	$	249,383	$	(36,831	)	$	212,552


For the Nine Months Ended September 30,	Estimated Amortization Expense
2020 (remaining three months)	$	3,964
2021		15,855
2022		15,853
2023		15,749
2024		15,298
2025 and thereafter		147,966

Total	$	214,685

XML 24 R14.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet Detail

9 Months Ended

Sep. 30, 2020

Consolidated Balance Sheet Detail

7.	Consolidated Balance Sheet Detail

Inventories, net

Inventories, net consists of the following:


	As of
	September 30, 2020		December 31, 2019
	(Amounts in thousands)
Raw materials	$	42,201	$	29,328
Work-in-process		6,192		8,360
Finished products		30,138		17,144

Total inventories, net	$	78,531	$	54,832

Property, Plant and Equipment

Property, plant and equipment consist of the following:


	As of
	September 30, 2020			December 31, 2019
	(Amounts in thousands)
Land	$	1,023		$	1,023
Buildings		989			764
Leasehold improvements		29,776			23,905
Equipment		39,094			36,257
Furniture, fixtures and office equipment		8,055			6,312
Computer hardware and software		14,468			8,810
Construction in progress		6,416			6,707
Other		348			56

Total property, plant and equipment		100,169			83,834
Less - Accumulated depreciation		(44,814	)		(35,379	)

Total property, plant and equipment, net	$	55,355		$	48,455

Accrued Liabilities

Accrued liabilities consist of the following:


	As of
	September 30, 2020		December 31, 2019
	(Amounts in thousands)
Employee compensation	$	14,652	$	19,850
Taxes		2,759		3,874
Royalty and license fees		1,000		123
Warranties		737		1,500
Professional fees		1,745		1,081
Deferred revenue		10,141		5,005
Other		1,007		1,898

Total accrued liabilities	$	32,041	$	33,331

XML 25 R15.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes

9 Months Ended

Sep. 30, 2020

Convertible Senior Notes

8.	Convertible Senior Notes

0.375% Convertible Senior Notes due 2024

re-measured

as long as it continues to meet the conditions for equity classification.

The net carrying value of the liability component of the 2019 Notes is as follows:


	As of
	September 30, 2020			December 31, 2019
	(Amounts in thousands)
0.375% convertible senior notes due 2024:
Principal amount	$	287,500		$	287,500
Less: unamortized debt discount		(40,764	)		(47,921	)
Less: unamortized debt issuance costs		(5,794	)		(6,812	)

Total debt		240,942			232,767
Less: current portion		—			—

Net carrying amount	$	240,942		$	232,767

Conversion of the 2.125% Convertible Senior Notes due 2021

paid-in

capital on the Company’s consolidated balance sheet.

paid-in

XML 26 R16.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Stockholders' Equity

9.	Stockholders’ Equity

Public Offerings of Common Stock

Stock Option and Incentive Plans

Stock-Based Compensation

For the three months ended September 30, 2020 and 2019, th


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
			(Amounts in thousands)
Cost of product revenue	$	563	$	375	$	1,421	$	992
Research and development		326		351		1,092		992
Selling, general and administrative		3,336		2,449		9,979		7,475

Total stock-based compensation	$	4,225	$	3,175	$	12,492	$	9,459

20%-33%

vesting on the first anniversary of the date of grant and the remainder vesting in equal yearly installments thereafter. Nonqualified options issued to

non-employee

Information regarding option activity for the nine months ended September 30, 2020 under the Plans is summarized below:


	Shares			Weighted average exercise price		Weighted- Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Options outstanding at December 31, 2019		957,559		$	30.81
Granted		69,698		$	104.61
Exercised		(303,343	)	$	23.37
Forfeited/expired/cancelled		—		$	—

Options outstanding at September 30, 2020		723,914		$	41.03		7.02	$	77,102

Options exercisable at September 30, 2020		339,191		$	31.00		6.05	$	39,528

Vested and expected to vest at September 30, 2020 (1)		693,689					6.98	$	74,178

(1)

non-executive

level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total

pre-tax

in-the-money


	Shares			Weighted- Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Unvested at December 31, 2019		734,984
Awarded		187,942
Vested		(225,204	)
Forfeited/expired/cancelled		(22,155	)

Unvested at September 30, 2020		675,567			3.39	$	99,673

Vested and expected to vest at September 30, 2020 (1)		650,436			3.20	$	95,965

(1)

non-executive

level employees and 3% for awards granted to executive level employees.

The aggregate intrinsic value in the table above represents the total

pre-tax

XML 27 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments and Contingencies

10.	Commitments and Contingencies

Licensing and Research Agreements

In June 2018, the Company secured an agreement with Navigo

Proteins

for the exclusive

co-development

of multiple affinity ligands for which Repligen holds commercialization rights. The Company is manufacturing and has agreed to supply the first of these ligands,

NGL-Impact

and other potential additional affinity ligands that may advance from the Company’s Navigo collaboration.

, respectively

XML 28 R18.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss

9 Months Ended

Sep. 30, 2020

Accumulated Other Comprehensive Loss

11.	Accumulated Other Comprehensive Loss


	Foreign
	Currency
	Translation
	Adjustment
Balance as of December 31, 2019	$	(15,027	)
Other comprehensive income		5,304

Balance as of September 30, 2020	$	(9,723	)

XML 29 R19.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Sep. 30, 2020

Income Taxes

12.	Income Taxes

The Company’s effective tax rate for the three and nine months ended

September

30, 2020 was 18.0% and 9.5%, compared to 0.7% and 18.3% for the corresponding periods in the prior year. The effective tax rates for the three and nine months ended

September

30, 2020 and 2019 were lower than the U.S. statutory rate of 21% primarily due to windfall benefits on stock option exercises and the vesting of stock units.

The Company is subject to a territorial tax system under the Tax Cuts and Jobs Act (“TCJA”) enacted in December 2017, in which the Company is required to provide for tax on Global Intangible

Low-Taxed

On March 27, 2020, President Trump signed the $2.2 trillion bipartisan Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The CARES Act, the third congressional bill to address

COVID-19,

The Company’s tax returns are subject to examination by federal, state and international tax authorities for the following periods:


Jurisdiction	Fiscal Years Subject to Examination
United States - federal and state		2016-2019
Sweden		2013-2019
Germany		2019
Netherlands		2013-2019

XML 30 R20.htm IDEA: XBRL DOCUMENT

Earnings Per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share

13.	Earnings Per Share

The Company reports earnings per share in accordance with ASC 260,

“Earnings Per Share,”

“in-the-money”

Basic and diluted weighted average shares outstanding were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands, except per share data)
Net income	$	14,552	$	1,659	$	40,228	$	17,807

Weighted average shares used in computing net income per share - diluted		52,545		50,852		52,341		47,087
Effect of dilutive shares:
Stock options and restricted stock awards		916		957		951		843
Dilutive effect of unvested performance stock units		8		—		8		—

Dilutive potential common shares		924		957		959		843

Weighted average shares used in computing net income per share - diluted		53,469		51,809		53,300		47,930

Earnings per share:
Basic	$	0.28	$	0.03	$	0.77	$	0.38

Diluted	$	0.27	$	0.03	$	0.75	$	0.37

As provided by the terms of the indenture underlying the

2016

Notes, the Company had a choice to settl

the conversion obligation for the

2016

Notes in cash, shares or any combination of the two. During the third quarter of

2019

, the Company settled the remaining

2016

Notes for a total aggregate principal of $

115.0

million and

2,316,200

shares of its common stock. As of March

2019

, the par value of the

2016

Notes was based on the difference between the Company’s current period average stock price and the conversion price of the

2016

Notes, provided there was a premium.

September

“Earnings Per Share”,

Subsection

10-45-44,

XML 31 R21.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2020

Related Party Transactions

14.	Related Party Transactions

XML 32 R22.htm IDEA: XBRL DOCUMENT

Segment Reporting

9 Months Ended

Sep. 30, 2020

Segment Reporting [Abstract]

Segment Reporting

15.	Segment Reporting

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue by customers’ geographic locations:
North America		50	%		54	%		48	%		51	%
Europe		36	%		33	%		38	%		37	%
APAC /Other		14	%		13	%		14	%		12	%

Total revenue		100	%		100	%		100	%		100	%

Concentrations of Credit Risk and Significant Customers

Concentration of credit risk with respect to accounts receivable is limited to customers to whom the Company makes significant sales. While a reserve for the potential

write-off

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020			2019
Cytiva (formerly GE Healthcare)		N/A		N/A			N/A			12	%
MilliporeSigma		N/A		14	%		11	%		14	%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events

16.	Subsequent Events

Acquisition of

Non-Metallic

Solutions, Inc.

On October 15, 2020, the Company entered into a Stock Purchase Agreement with

Non-Metallic

single-use

product offerings.

10-K

Proposed Acquisition of ARTeSYN Biosolutions

XML 34 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Sep. 30, 2020
Basis of presentation	Basis of Presentation The consolidated financial statements included herein have been prepared by Repligen Corporation (the “Company”, “Repligen” or “we”) in accordance with generally accepted accounting principles in the United States (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10-Q and Article 10 of Regulation S-X and do not include all of the information and footnote disclosures required by GAAP. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2019. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Repligen Sweden AB, Repligen GmbH, Spectrum LifeSciences, LLC and its subsidiaries (“Spectrum”), C Technologies, Inc. (“C Technologies”), Engineered Molding Technology (“EMT”) and Repligen Singapore Pte. Ltd. All significant intercompany accounts and transactions have been eliminated in consolidation. The Company made no material changes in the application of its significant accounting policies that were disclosed in its Form 10-K. In the opinion of management, the accompanying unaudited consolidated financial statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations and cash flows. The results of operations for the interim periods presented are not necessarily indicative of results to be expected for the entire year.
Risks and Uncertainties	Risks and Uncertainties The ultimate impact that the current pandemic of the novel coronavirus (“COVID-19”), may have on the Company and its customers, employees, suppliers, vendors, business partners and distribution channels is currently unknown. The Company is closely monitoring the impact of this evolving situation on all aspects of its business. While COVID-19 did not materially affect the Company’s financial results and business operations in the Company’s three and nine months ended September 30, 2020, the Company is unable to predict the impact that COVID-19 may have on its financial position and operations moving forward due to numerous uncertainties. These estimates may change as new events occur and additional information is obtained, and actual results could differ materially from these estimates under different assumptions or conditions. The Company will continue to assess the evolving impact of COVID-19 and will make adjustments to its operations as necessary.
Recent Accounting Standards Updates	Recent Accounting Standards Updates We consider the applicability and impact of all Accounting Standards Updates on the Company’s consolidated financial statements. Updates not listed below were assessed and determined to be either not applicable or are expected to have minimal impact on the Company’s consolidated financial position or results of operations. Recently issued Accounting Standards Updates that we feel may be applicable to the Company are as follows: Recently Issued Accounting Standard Updates – Adopted During the Period In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. (“ASU”) 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement.” ASU 2018-13 includes amendments that aim to improve the effectiveness of fair value measurement disclosures. The amendments in this guidance modify the disclosure requirements on fair value measurements based on the concepts in FASB Concepts Statement, “Conceptual Framework for Financial Reporting - Chapter 8: Notes to Financial Statements , ” including the consideration of costs and benefits. The Company adopted ASU 2018-13 on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020. In August 2018, the FASB issued ASU 2018-15, “Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract.” ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The guidance also requires the entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. The Company adopted ASU 2018-13 on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020. In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments-Credit Losses (Topic 326).” ASU 2016-13 significantly changes how entities will account for credit losses for most financial assets and certain other instruments that are not measured at fair value through net income. ASU 2016-13 replaces the existing incurred loss model with an expected credit loss model that requires entities to estimate an expected lifetime credit loss on most financial assets and certain other instruments, including short-term trade receivables and contract assets, and expands disclosure requirements for credit quality of financial assets. The Company adopted ASU 2016-13 on January 1, 2020. The Company assessed all potential impacts that the adoption of this guidance has on its consolidated financial statements. Based on the composition of the Company’s investment portfolio, accounts receivable, current market conditions and historical credit loss activity, the adoption of ASU 2016-13 by the Company did not have a material impact on its consolidated financial position, results of operations or cash flows as of and for the three and nine months ended September 30, 2020. The Company continues to monitor processes and controls for indications of an adjustment for future economic conditions at quarterly and annual reporting periods. See Note 5, “Credit Losses,” below for more information on the Company’s adoption of ASC 326. In November 2018, the FASB issued ASU 2018-18, “Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.” ASU 2018-18 clarifies the interaction between Topic 808, “Collaborative Arrangements,” and Topic 606, “Revenue from Contracts with Customers,” by making targeted improvements to GAAP for collaborative arrangements and providing guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. This includes improving comparability in the presentation of revenue for certain transactions between collaborative arrangement participants by allowing presentation of the units of account in collaborative arrangements that are within the scope of Topic 606 together with revenue accounted for under Topic 606. The Company adopted ASU 2018-13 on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020. In December 2019, the FASB issued ASU 2019-12, “ Income Taxes (Topic 740) – Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, including, but not limited to, the exception to the incremental approach for intraperiod tax allocation when there is a loss from continuing operations and income or a gain from other items, the exceptions related to the recognition of a deferred tax liability related to an equity method investment and the exception to methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. The Company adopted ASU 2018-13 on January 1, 2020. The adoption did not have a material impact on the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020. Recently Issued Accounting Standard Updates – Not Yet Adopted In August 2020, the FASB issued ASU 2020-06, “ Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity ’ s Own Equity (Subtopic 815-40). ” ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and the number of embedded conversion features that could be recognized separately from the primary contract. ASU 2020-06 also enhances transparency and improves disclosures for convertible instruments and earnings per share guidance. ASU 2020-06 is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company is currently evaluating the timing and impact of the adoption of ASU 2020-06 on the Company’s consolidated financial statements.

XML 35 R25.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

9 Months Ended

Sep. 30, 2020

Engineered Molding Technology LLC [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The components and allocation of the purchase price consists of the following amounts (amounts in thousands):


Cash and cash equivalents	$	69
Accounts receivable		1,057
Inventory		449
Prepaid expenses and other current assets		7
Fixed assets, net		472
Operating lease right of use assets		1,050
Customer relationships		11,080
Developed technology		2,910
Trademark and tradename		320
Non-compete agreements		50
Goodwill		12,573
Accounts payable		(283	)
Accrued liabilities		(190	)
Operating lease liability		(211	)
Operating lease liability, long-term		(839	)

Fair value of net assets acquired	$	28,514

Schedule of Identified Intangible Assets and Estimated Useful Lives

The following table sets forth the components of the identified intangible assets associated with the EMT Acquisition and their estimated useful lives:


	Useful life		Fair Value
			(Amounts in thousands)
Customer relationships		14 years	$	11,080
Developed technology		11 years		2,910
Trademark and tradename		14 years		320
Non-competition agreements		3 years		50

			$	14,360

C Technologies [Member]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The components and allocation of the purchase price consists of the following amounts (amounts in thousands):


Cash and cash equivalents	$	3,795
Restricted cash		26,933
Accounts receivable		3,044
Inventory		3,783
Prepaid expenses and other current assets		93
Fixed assets		40
Operating lease right of use asset		3,836
Customer relationships		59,680
Developed technology		28,920
Trademark and tradename		1,570
Non-competition agreements		660
Goodwill		142,314
Deferred taxes		895
Accounts payable		(436	)
Accrued liabilities		(2,767	)
Accrued bonus		(26,928	)
Deferred revenue		(1,709	)
Operating lease liability		(51	)
Operating lease liability, long-term		(3,785	)

Fair value of net assets acquired	$	239,887

Unaudited Supplemental Pro Forma Information


	Nine Months Ended September 30,
	2019
Pro forma total revenue	$	209,960
Pro forma net income	$	21,012
Pro forma earnings per share:
Basic	$	0.45

Diluted	$	0.44

XML 36 R26.htm IDEA: XBRL DOCUMENT

Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Disaggregation of Revenue

Revenues for the three and nine months ended September 30, 2020 and 2019 were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Product revenue	$	94,029	$	69,419	$	257,521	$	200,701
Royalty and other income		31		26		91		70

Total revenue	$	94,060	$	69,445	$	257,612	$	200,771

Revenue from Significant Customers

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands)
Cytiva (formerly GE Healthcare)		N/A		N/A		N/A	$	23,759
MilliporeSigma		N/A	$	9,458	$	29,387	$	28,354

Summary of Receivables and Deferred Revenue from Contracts with Customers

The following table provides information about receivables and deferred revenues from contracts with customers as of September 30, 2020 (amounts in thousands):


	2020
Balances from contracts with customers only:
Accounts receivable	$	55,830
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	$	10,141
Revenue recognized during the nine-month period ended September 30, 2020 relating to:
The beginning deferred revenue balance	$	3,133
Changes in pricing related to products or services satisfied in previous periods	$	—

XML 37 R27.htm IDEA: XBRL DOCUMENT

Credit Losses (Tables)

9 Months Ended

Sep. 30, 2020

Credit Loss [Abstract]

Summary Of Allowance For Credit Losses For Accounts Receivables


	2020
Balance at January 1, 2020	$	(525	)
Current period change for expected credit losses		(133	)

Balance at March 31, 2020		(658	)
Current period change for write-offs		37
Current period change for expected credit losses		83

Balance at June 30, 2020		(538	)
Current period change for expected credit losses		(83	)

Balance at September 30, 2020	$	(621	)

XML 38 R28.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2020

Changes in Carrying Value of Goodwill

The following table represents the change in the carrying value of goodwill for the nine months ended September 30, 2020 (amounts in thousands):


Balance as of December 31, 2019	$	468,413
Acquisition of Engineered Molding Technology		12,573
Goodwill adjustment related to C Technologies, Inc.		293
Cumulative translation adjustment		764

Balance as of September 30, 2020	$	482,043

Intangible assets

Intangible assets, net consisted of the following at September 30, 2020:


	September 30, 2020
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Useful Life (in years)
	(Amounts in thousands)
Finite-lived intangible assets:
Technology - developed	$	85,196	$	(13,054	)	$	72,142		18
Patents		240		(240	)		—		8
Customer relationships		172,325		(33,861	)		138,464		15
Trademarks		4,072		(480	)		3,592		19
Other intangibles		1,750		(1,263	)		487		3

Total finite-lived intangible assets		263,583		(48,898	)		214,685		16
Indefinite-lived intangible asset:
Trademarks		700		—			700		—

Total intangible assets	$	264,283	$	(48,898	)	$	215,385

Intangible assets consisted of the following at December 31, 2019:


	December 31, 2019
	Gross Carrying Value		Accumulated Amortization			Net Carrying Value		Weighted Average Useful Life (in years)
	(Amounts in thousands)
Finite-lived intangible assets:
Technology - developed	$	82,169	$	(9,669	)	$	72,500		19
Patents		240		(240	)		—		8
Customer relationships		160,825		(25,642	)		135,183		15
Trademarks		3,752		(333	)		3,419		20
Other intangibles		1,697		(947	)		750		3

Total finite-lived intangible assets		248,683		(36,831	)		211,852		16
Indefinite-lived intangible asset:
Trademarks		700		—			700		—

Total intangible assets	$	249,383	$	(36,831	)	$	212,552

Schedule of Amortization Expense for Amortized Intangible Assets

As of September 30, 2020, the Company expects to record the following amortization expense in future periods (amounts in thousands):


For the Nine Months Ended September 30,	Estimated Amortization Expense
2020 (remaining three months)	$	3,964
2021		15,855
2022		15,853
2023		15,749
2024		15,298
2025 and thereafter		147,966

Total	$	214,685

XML 39 R29.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet Detail (Tables)

9 Months Ended

Sep. 30, 2020

Inventories

Inventories, net consists of the following:


	As of
	September 30, 2020		December 31, 2019
	(Amounts in thousands)
Raw materials	$	42,201	$	29,328
Work-in-process		6,192		8,360
Finished products		30,138		17,144

Total inventories, net	$	78,531	$	54,832

Property, Plant and Equipment

Property, plant and equipment consist of the following:


	As of
	September 30, 2020			December 31, 2019
	(Amounts in thousands)
Land	$	1,023		$	1,023
Buildings		989			764
Leasehold improvements		29,776			23,905
Equipment		39,094			36,257
Furniture, fixtures and office equipment		8,055			6,312
Computer hardware and software		14,468			8,810
Construction in progress		6,416			6,707
Other		348			56

Total property, plant and equipment		100,169			83,834
Less - Accumulated depreciation		(44,814	)		(35,379	)

Total property, plant and equipment, net	$	55,355		$	48,455

Accrued Liabilities

Accrued liabilities consist of the following:


	As of
	September 30, 2020		December 31, 2019
	(Amounts in thousands)
Employee compensation	$	14,652	$	19,850
Taxes		2,759		3,874
Royalty and license fees		1,000		123
Warranties		737		1,500
Professional fees		1,745		1,081
Deferred revenue		10,141		5,005
Other		1,007		1,898

Total accrued liabilities	$	32,041	$	33,331

XML 40 R30.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes (Tables)

9 Months Ended

Sep. 30, 2020

Carrying Value of Convertible Senior Notes

The net carrying value of the liability component of the 2019 Notes is as follows:


	As of
	September 30, 2020			December 31, 2019
	(Amounts in thousands)
0.375% convertible senior notes due 2024:
Principal amount	$	287,500		$	287,500
Less: unamortized debt discount		(40,764	)		(47,921	)
Less: unamortized debt issuance costs		(5,794	)		(6,812	)

Total debt		240,942			232,767
Less: current portion		—			—

Net carrying amount	$	240,942		$	232,767

XML 41 R31.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Stock-Based Compensation Expense

The following table presents stock-based compensation expense in the Company’s consolidated statements of comprehensive income (loss):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
			(Amounts in thousands)
Cost of product revenue	$	563	$	375	$	1,421	$	992
Research and development		326		351		1,092		992
Selling, general and administrative		3,336		2,449		9,979		7,475

Total stock-based compensation	$	4,225	$	3,175	$	12,492	$	9,459

Summary of Option Activity

Information regarding option activity for the nine months ended September 30, 2020 under the Plans is summarized below:


	Shares			Weighted average exercise price		Weighted- Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Options outstanding at December 31, 2019		957,559		$	30.81
Granted		69,698		$	104.61
Exercised		(303,343	)	$	23.37
Forfeited/expired/cancelled		—		$	—

Options outstanding at September 30, 2020		723,914		$	41.03		7.02	$	77,102

Options exercisable at September 30, 2020		339,191		$	31.00		6.05	$	39,528

Vested and expected to vest at September 30, 2020 (1)		693,689					6.98	$	74,178

(1)

non-executive

level employees and 3% for awards granted to executive level employees.

Summary of Restricted Stock Unit Activity


	Shares			Weighted- Average Remaining Contractual Term (in Years)		Aggregate Intrinsic Value (in Thousands)
Unvested at December 31, 2019		734,984
Awarded		187,942
Vested		(225,204	)
Forfeited/expired/cancelled		(22,155	)

Unvested at September 30, 2020		675,567			3.39	$	99,673

Vested and expected to vest at September 30, 2020 (1)		650,436			3.20	$	95,965

(1)

non-executive

level employees and 3% for awards granted to executive level employees.

XML 42 R32.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Changes in Accumulated Other Comprehensive Income


	Foreign
	Currency
	Translation
	Adjustment
Balance as of December 31, 2019	$	(15,027	)
Other comprehensive income		5,304

Balance as of September 30, 2020	$	(9,723	)

XML 43 R33.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2020

Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities

The Company’s tax returns are subject to examination by federal, state and international tax authorities for the following periods:


Jurisdiction	Fiscal Years Subject to Examination
United States - federal and state		2016-2019
Sweden		2013-2019
Germany		2019
Netherlands		2013-2019

XML 44 R34.htm IDEA: XBRL DOCUMENT

Earnings Per Share (Tables)

9 Months Ended

Sep. 30, 2020

Basic and Diluted Weighted Average Shares Outstanding

Basic and diluted weighted average shares outstanding were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(Amounts in thousands, except per share data)
Net income	$	14,552	$	1,659	$	40,228	$	17,807

Weighted average shares used in computing net income per share - diluted		52,545		50,852		52,341		47,087
Effect of dilutive shares:
Stock options and restricted stock awards		916		957		951		843
Dilutive effect of unvested performance stock units		8		—		8		—

Dilutive potential common shares		924		957		959		843

Weighted average shares used in computing net income per share - diluted		53,469		51,809		53,300		47,930

Earnings per share:
Basic	$	0.28	$	0.03	$	0.77	$	0.38

Diluted	$	0.27	$	0.03	$	0.75	$	0.37

XML 45 R35.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2020

Percentage of Revenue from Significant Customers

Revenue from significant customers that represent 10% or more of the Company’s total revenue is as follows:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2020		2019			2020			2019
Cytiva (formerly GE Healthcare)		N/A		N/A			N/A			12	%
MilliporeSigma		N/A		14	%		11	%		14	%

Total Revenue

Percentage by Geographic Area or Significant Customers

The following table represents the Company’s total revenue by geographic area (based on the location of the customer):


	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Revenue by customers’ geographic locations:
North America		50	%		54	%		48	%		51	%
Europe		36	%		33	%		38	%		37	%
APAC /Other		14	%		13	%		14	%		12	%

Total revenue		100	%		100	%		100	%		100	%

XML 46 R36.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Additional Information (Detail) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jul. 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 553,302,000	$ 528,392,000
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash and cash equivalents	$ 395,600,000	$ 415,600,000
0.375% Convertible Senior Notes due 2024
Summary Of Significant Accounting Policies [Line Items]
Principal amount				$ 287,500,000
Notes, due date	Jul. 15, 2024
Notes, frequency of periodic payment	semi-annually
Total convertible senior notes				240,900,000
Fair value of convertible senior notes				$ 416,000,000.0
Senior convertible notes	0.375%		0.375%

XML 47 R37.htm IDEA: XBRL DOCUMENT

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	7 Months Ended	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Jul. 13, 2020	Jun. 30, 2020
Business Acquisition [Line Items]
Business acquisition, goodwill acquired	$ 482,043	$ 468,413	$ 482,043
Employees
Business Acquisition [Line Items]
Transaction costs						$ 9,000
Compensation Expense, Excluding Cost of Good and Service Sold			3,700
Selling, general and administrative
Business Acquisition [Line Items]
Transaction costs				$ 4,000
C Technologies
Business Acquisition [Line Items]
Business acquisition, goodwill acquired	142,314		142,314
Business acquisition, revenue	9,000	16,400	23,300
Business acquisitions proforma net income	2,100	$ 7,400	800	$ 21,012
Deferred tax liability			300
C Technologies \| Employees
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold			9,000
C Technologies \| Goodwill [Member]
Business Acquisition [Line Items]
Intangible Asset Residual Value	142,300		142,300
Engineered Molding Technology LLC [Member]
Business Acquisition [Line Items]
Business combination, consideration transferred			28,500
Business acquisition, net tangible assets acquired	1,500		1,500
Business Combination, Acquisition Related Costs	1,000		1,100
Fair value of acquired finite lived intangible assets	14,400		14,400
Business acquisition, goodwill acquired	12,600		12,600		$ 12,573
Business acquisition, voting interest acquired					100.00%
Business acquisition, Indemnification escrow			2,200
Engineered Molding Technology LLC [Member] \| Goodwill [Member]
Business Acquisition [Line Items]
Intangible Asset Residual Value	$ 12,600		$ 12,600

XML 48 R38.htm IDEA: XBRL DOCUMENT

Acquisitions (Fair Value of Net Assets Acquired) (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jul. 13, 2020	Dec. 31, 2019
Business Acquisition [Line Items]
Goodwill	$ 482,043		$ 468,413
C Technologies
Business Acquisition [Line Items]
Cash and cash equivalents	3,795
Restricted cash	26,933
Accounts receivable	3,044
Inventory	3,783
Prepaid expenses and other current assets	93
Fixed assets	40
Operating lease right of use asset	3,836
Deferred taxes	895
Goodwill	142,314
Accounts payable	(436)
Accrued liabilities	(2,767)
Accrued bonus	(26,928)
Deferred revenue	(1,709)
Operating lease liability	(51)
Operating lease liability, long-term	(3,785)
Fair value of net assets acquired	239,887
C Technologies \| Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets	59,680
C Technologies \| Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets	28,920
C Technologies \| Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets	1,570
C Technologies \| Non-compete agreements
Business Acquisition [Line Items]
Business combination, intangible assets	660
Engineered Molding Technology LLC [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 69
Accounts receivable		1,057
Inventory		449
Prepaid expenses and other current assets		7
Fixed assets		472
Operating lease right of use asset		1,050
Business combination, intangible assets	14,400
Goodwill	$ 12,600	12,573
Accounts payable		(283)
Accrued liabilities		(190)
Operating lease liability		(211)
Operating lease liability, long-term		(839)
Fair value of net assets acquired		28,514
Engineered Molding Technology LLC [Member] \| Customer relationships
Business Acquisition [Line Items]
Business combination, intangible assets		11,080
Engineered Molding Technology LLC [Member] \| Developed technology
Business Acquisition [Line Items]
Business combination, intangible assets		2,910
Engineered Molding Technology LLC [Member] \| Trademark and tradename
Business Acquisition [Line Items]
Business combination, intangible assets		320
Engineered Molding Technology LLC [Member] \| Non-compete agreements
Business Acquisition [Line Items]
Business combination, intangible assets		$ 50

XML 49 R39.htm IDEA: XBRL DOCUMENT

Acquisitions (Estimated Useful Life and Fair Value) (Detail) - Engineered Molding Technology LLC [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Fair Value	$ 14,360
Customer Relationships [Member]
Weighted Average Useful Life (in years)	14 years
Fair Value	$ 11,080
Developed Technology Rights [Member]
Weighted Average Useful Life (in years)	11 years
Fair Value	$ 2,910
Trademark and tradename [Member]
Weighted Average Useful Life (in years)	14 years
Fair Value	$ 320
Noncompete Agreements [Member]
Weighted Average Useful Life (in years)	3 years
Fair Value	$ 50

XML 50 R40.htm IDEA: XBRL DOCUMENT

Acquisitions (Unaudited Supplemental Pro Forma Information) (Detail) - C Technologies [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	7 Months Ended	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Business Acquisition [Line Items]
Pro forma total revenue				$ 209,960
Pro forma net income	$ 2,100	$ 7,400	$ 800	$ 21,012
Basic				$ 0.45
Diluted				$ 0.44

XML 51 R41.htm IDEA: XBRL DOCUMENT

Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Revenue	$ 94,060	$ 69,445	$ 257,612	$ 200,771
Product
Disaggregation of Revenue [Line Items]
Revenue	94,029	69,419	257,521	200,701
Royalty and Other Revenue
Disaggregation of Revenue [Line Items]
Revenue	$ 31	$ 26	$ 91	$ 70

XML 52 R42.htm IDEA: XBRL DOCUMENT

Revenue from Significant Customers (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Concentration Risk [Line Items]
Revenue	$ 94,060	$ 69,445	$ 257,612	$ 200,771
Cytiva (formerly GE Healthcare)
Concentration Risk [Line Items]
Revenue				23,759
MilliporeSigma
Concentration Risk [Line Items]
Revenue		$ 9,458	$ 29,387	$ 28,354

XML 53 R43.htm IDEA: XBRL DOCUMENT

Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Balances from contracts with customers only:
Accounts receivable	$ 55,830	$ 43,068
Deferred revenue (included in accrued liabilities in the consolidated balance sheets)	10,141
Revenue recognized during the nine-month period ended September 30, 2020 relating to:
The beginning deferred revenue balance	3,133
Changes in pricing related to products or services satisfied in previous periods	$ 0

XML 54 R44.htm IDEA: XBRL DOCUMENT

Credit Losses - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Credit Loss [Abstract]
Accounts receivable	$ 55,830	$ 43,068
Accounts receivable, reserve for doubtful accounts	$ 621	$ 525

XML 55 R45.htm IDEA: XBRL DOCUMENT

Credit Losses - Summary Of Allowance For Credit Losses For Accounts Receivables (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Credit Loss [Abstract]
Beginning balance	$ (538)	$ (658)	$ (525)
Current period change for write-offs		37
Current period change for expected credit losses	(83)	83	(133)
Ending balance	$ (621)	$ (538)	$ (658)

XML 56 R46.htm IDEA: XBRL DOCUMENT

Changes in Carrying Value of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Goodwill [Line Items]
Balance as of December 31, 2019	$ 468,413
Cumulative translation adjustment	764
Balance as of September 30, 2020	482,043
C Technologies, Inc.
Goodwill [Line Items]
Goodwill arising from Acquisition	293
Balance as of September 30, 2020	142,314
Engineered Molding Technology
Goodwill [Line Items]
Goodwill arising from Acquisition	12,573
Balance as of September 30, 2020	$ 12,600

XML 57 R47.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Intangible Assets [Line Items]
Gross Carrying Value	$ 263,583	$ 248,683
Gross Carrying Value	264,283	249,383
Accumulated Amortization	(48,898)	(36,831)
Accumulated Amortization	(48,898)	(36,831)
Net Carrying Value	214,685	211,852
Net Carrying Value	$ 215,385	$ 212,552
Weighted Average Useful Life (in years)	16 years	16 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 700	$ 700
Net Carrying Value	700	700
Technology - developed
Intangible Assets [Line Items]
Gross Carrying Value	85,196	82,169
Accumulated Amortization	(13,054)	(9,669)
Net Carrying Value	$ 72,142	$ 72,500
Weighted Average Useful Life (in years)	18 years	19 years
Patents
Intangible Assets [Line Items]
Gross Carrying Value	$ 240	$ 240
Accumulated Amortization	$ (240)	$ (240)
Weighted Average Useful Life (in years)	8 years	8 years
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Value	$ 172,325	$ 160,825
Accumulated Amortization	(33,861)	(25,642)
Net Carrying Value	$ 138,464	$ 135,183
Weighted Average Useful Life (in years)	15 years	15 years
Trademark
Intangible Assets [Line Items]
Gross Carrying Value	$ 4,072	$ 3,752
Accumulated Amortization	(480)	(333)
Net Carrying Value	$ 3,592	$ 3,419
Weighted Average Useful Life (in years)	19 years	20 years
Other intangibles
Intangible Assets [Line Items]
Gross Carrying Value	$ 1,750	$ 1,697
Accumulated Amortization	(1,263)	(947)
Net Carrying Value	$ 487	$ 750
Weighted Average Useful Life (in years)	3 years	3 years

XML 58 R48.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Finite-Lived Intangible Liabilities [Line Items]
Amortization expense	$ 4.0	$ 3.9	$ 11.8	$ 9.6

XML 59 R49.htm IDEA: XBRL DOCUMENT

Amortization Expense for Amortized Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Finite-Lived Intangible Liabilities [Line Items]
2020 (remaining three months)	$ 3,964
2021	15,855
2022	15,853
2023	15,749
2024	15,298
2025 and thereafter	147,966
Total	$ 214,685	$ 211,852

XML 60 R50.htm IDEA: XBRL DOCUMENT

Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory [Line Items]
Raw materials	$ 42,201	$ 29,328
Work-in-process	6,192	8,360
Finished products	30,138	17,144
Total inventories, net	$ 78,531	$ 54,832

XML 61 R51.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Land	$ 1,023	$ 1,023
Buildings	989	764
Leasehold improvements	29,776	23,905
Equipment	39,094	36,257
Furniture, fixtures and office equipment	8,055	6,312
Computer hardware and software	14,468	8,810
Construction in progress	6,416	6,707
Other	348	56
Total property, plant and equipment	100,169	83,834
Less - Accumulated depreciation	(44,814)	(35,379)
Total property, plant and equipment, net	$ 55,355	$ 48,455

XML 62 R52.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheet - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Depreciation	$ 2.8	$ 1.8	$ 7.8	$ 5.2

XML 63 R53.htm IDEA: XBRL DOCUMENT

Schedule of Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule of Accrued Liabilities [Line Items]
Employee compensation	$ 14,652	$ 19,850
Taxes	2,759	3,874
Royalty and license fees	1,000	123
Warranties	737	1,500
Professional fees	1,745	1,081
Deferred revenue	10,141	5,005
Other	1,007	1,898
Total accrued liabilities	$ 32,041	$ 33,331

XML 64 R54.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Additional Information (Detail)			1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 22, 2019 USD ($) shares	Jul. 19, 2019 USD ($) $ / shares	Sep. 23, 2019 USD ($) shares	Sep. 30, 2020 USD ($) shares	Sep. 30, 2019 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2019 USD ($)	Jul. 31, 2019 USD ($)	Jul. 16, 2019 USD ($)
Debt Instrument [Line Items]
Proceeds from issuance of convertible senior notes, net of costs							$ 278,555,000
Accretion of the debt discount						$ 8,175,000	4,863,000
Total consideration on conversion							198,757,000
Loss on extinguishment of debt					$ (5,650,000)	5,700,000	(5,650,000)
Common Stock [Member]
Debt Instrument [Line Items]
Conversion of Convertible Securities Stock Issued \| shares \| shares				2,316,200
0.375% Convertible Senior Notes due 2024
Debt Instrument [Line Items]
Notes issued		$ 287,500,000						$ 287,500,000
Notes, interest rate		0.375%
Proceeds from issuance of convertible senior notes, net of costs		$ 278,500,000
Interest repayment terms		Interest is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on January 15, 2020.
Notes, due date		Jul. 15, 2024
Notes conversion ratio per $1,000 principal amount		8.6749
Notes initial conversion price \| $ / shares		$ 115.28
Notes redemption price		100.00%
Contractual coupon interest				$ 300,000		800,000
Accretion of the debt discount				2,400,000		7,200,000
Amortization of the debt issuance costs				$ 300,000		$ 1,000,000.0
Effective interest rate on the Notes				5.10%		5.10%
Notes, carrying value				$ 240,900,000		$ 240,900,000
Fair value of the note				416,000,000.0		$ 416,000,000.0
Additional Notes issued		$ 37,500,000
Discount rate						4.50%
Proceeds allocated to the conversion feature						$ 52,100,000
Transaction costs attributable to liability component						7,400,000
Transaction costs attributable to equity component				1,600,000		1,600,000
2.125% Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Notes issued				115,000,000.0		115,000,000.0			$ 92,000,000.0
Notes, interest rate									2.125%
Notes, due date		Jun. 01, 2021
Notes redemption price			100.00%
Notes issued, fair value				$ 96,300,000		$ 96,300,000
Contractual coupon interest					100,000		1,300,000
Accretion of the debt discount					500,000		2,400,000
Amortization of the debt issuance costs					$ 100,000		$ 400,000
Effective interest rate on the Notes				6.60%		6.60%
Repayment Of Senior Debt		$ 92,300,000	$ 23,000,000.0
Accrued interest		$ 300,000
Total consideration on conversion	$ 253,300,000
Face amount of remaining convertible debt			60,800,000
Equity component of converted debt	$ 163,600,000		38,300,000
Loss on extinguishment of debt			$ 1,100,000			$ 4,600,000
2.125% Convertible Senior Notes due 2021 \| Common Stock [Member]
Debt Instrument [Line Items]
Conversion of Convertible Securities Stock Issued \| shares \| shares	1,850,155		466,045
Conversion of Convertible Securities Stock Issued \| value	$ 161,000,000.0		$ 37,800,000
2.125% Non Convertible Senior Notes due 2021
Debt Instrument [Line Items]
Effective interest rate on the Notes				3.90%		3.90%
Equity component of converted debt				$ 200,100,000		$ 200,100,000

XML 65 R55.htm IDEA: XBRL DOCUMENT

Convertible Senior Notes - Convertible Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Principal amount	$ 287,500	$ 287,500
Less: unamortized debt discount	(40,764)	(47,921)
Less: unamortized debt issuance costs	(5,794)	(6,812)
Total debt	240,942	232,767
Net carrying amount	$ 240,942	$ 232,767

XML 66 R56.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended		9 Months Ended
	Jul. 19, 2019	May 03, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Stockholders Equity Note Disclosure [Line Items]
Common stock, shares issued	1,587,000	3,144,531	52,606,700		52,606,700		52,078,258
Common stock issue price per share	$ 87.00	$ 64.00
Exercised number of shares					303,343
Net proceeds from public offering	$ 131,100	$ 189,600				$ 320,713
Stock-based compensation expense			$ 4,225	$ 3,175	$ 12,492	$ 9,459
Incentive options, term					10 years
Stock options, outstanding			723,914	959,916	723,914	959,916	957,559
Closing price of common stock			$ 147.54		$ 147.54
Aggregate intrinsic value of stock options exercised					$ 30,700	$ 5,200
Weighted average grant date fair value of share-based awards granted					$ 48.13	$ 30.07
Total fair value of stock options vested					$ 2,600	$ 2,900
Total unrecognized compensation cost			$ 47,000		$ 47,000
Unrecognized compensation cost, weighted average remaining requisite service period					3 years 7 months 9 days
Number of unvested options and restricted stock units			1,833,239		1,833,239
2018 Plan
Stockholders Equity Note Disclosure [Line Items]
Common stock shares reserved for Issuance								2,778,000
Incentive options, vesting period			2,325,314		2,325,314
Employee Stock Option \| Minimum
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period					3 years
Employee Stock Option \| Minimum \| Vest Over Three Year
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting percentage					20.00%
Employee Stock Option \| Maximum
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period					5 years
Employee Stock Option \| Maximum \| Vest Over Three Year
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting percentage					33.00%
Non-Employee Directors
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period					9 years
Unvested Options
Stockholders Equity Note Disclosure [Line Items]
Incentive options, vesting period					5 years
Restricted Stock Units and Performance Stock Units
Stockholders Equity Note Disclosure [Line Items]
Restricted stock units, outstanding			675,567	740,213	675,567	740,213	734,984
Closing price of common stock			$ 147.54		$ 147.54
Aggregate intrinsic value of restricted stock units vested					$ 25,000	$ 15,500
Weighted average grant date fair value of restricted stock units granted					$ 66.00	$ 33.46
Total grant date fair value of restricted stock units vested					$ 9,800	$ 7,600
Underwriters \| Common Stock
Stockholders Equity Note Disclosure [Line Items]
Exercised number of shares	207,000	410,156

XML 67 R57.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 4,225	$ 3,175	$ 12,492	$ 9,459
Cost of product revenue
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	563	375	1,421	992
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	326	351	1,092	992
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,336	$ 2,449	$ 9,979	$ 7,475

XML 68 R58.htm IDEA: XBRL DOCUMENT

Summary of Option Activity (Detail)
$ / shares in Units, $ in Thousands

9 Months Ended

Sep. 30, 2020

USD ($)

$ / shares

Options Outstanding

Options outstanding at December 31, 2019 | shares

957,559

Granted | shares

69,698

Exercised | shares

(303,343)

Options outstanding at September 30, 2020 | shares

723,914

Options exercisable at September 30, 2020 | shares

339,191

Vested and expected to vest at September 30, 2020(1) | shares

693,689

^[1]

Weighted-Average Exercise Price Per Share

Options outstanding at December 31, 2019 | $ / shares

$ 30.81

Granted | $ / shares

104.61

Exercised | $ / shares

23.37

Options outstanding at September 30, 2020 | $ / shares

41.03

Options exercisable at September 30, 2020 | $ / shares

$ 31.00

Weighted-Average Remaining Contractual Term (in years)

Options outstanding at September 30, 2020

7 years 7 days

Options exercisable at September 30, 2020

6 years 18 days

Vested and expected to vest at September 30, 2020

6 years 11 months 23 days

^[1]

Aggregate Intrinsic Value

Options outstanding at September 30, 2020 | $

$ 77,102

Options exercisable at September 30, 2020 | $

39,528

Vested and expected to vest at September 30, 2020 | $

$ 74,178

^[1]

[1]

XML 69 R59.htm IDEA: XBRL DOCUMENT

Summary of Option Activity (Parenthetical) (Detail) - Employee Stock Option	Sep. 30, 2020
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

XML 70 R60.htm IDEA: XBRL DOCUMENT

Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock Units and Performance Stock Units
$ in Thousands

9 Months Ended

Sep. 30, 2020

USD ($)

Options Outstanding

Unvested at December 31, 2019

734,984

Awarded

187,942

Vested

(225,204)

Forfeited/expired/cancelled

(22,155)

Unvested at September 30, 2020

675,567

Vested and expected to vest at September 30, 2020

650,436

^[1]

Weighted-Average Remaining Contractual Term (in years)

Unvested at September 30, 2020

3 years 4 months 20 days

Vested and expected to vest at September 30, 2020

3 years 2 months 12 days

^[1]

Aggregate Intrinsic Value

Unvested at September 30, 2020 | $

$ 99,673

Vested and expected to vest at September 30, 2020 | $

$ 95,965

^[1]

[1]

XML 71 R61.htm IDEA: XBRL DOCUMENT

Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) - Restricted Stock Units and Performance Stock Units	Sep. 30, 2020
Awards Granted to Non-Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	8.00%
Awards Granted to Executive Level Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Estimated forfeiture rates	3.00%

XML 72 R62.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
NGL Impact A [Member] \| Research and Development Arrangement [Member]
Commitments and Contingencies [Line Items]
Payments to Navigo in connection with this program, which are recorded to research and development expenses	$ 0.2	$ 0.4

XML 73 R63.htm IDEA: XBRL DOCUMENT

Change in Accumulated Other Comprehensive Loss (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2020 USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 1,059,768
Balance	1,124,870
Foreign Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(15,027)
Other comprehensive loss	5,304
Balance	$ (9,723)

XML 74 R64.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail)	3 Months Ended		9 Months Ended
Income Taxes - Additional Information (Detail)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Taxes [Line Items]
Corporate tax rate	21.00%	21.00%	21.00%	21.00%
Income tax (benefit) provision	18.00%	0.70%	9.50%	18.30%

XML 75 R65.htm IDEA: XBRL DOCUMENT

Summary of Tax Returns Periods Subject to Examination by Federal, State and International Tax Authorities (Detail)	9 Months Ended
	Sep. 30, 2020
United States \| Earliest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2016
United States \| Latest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2019
Sweden \| Earliest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2013
Sweden \| Latest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2019
Germany \| Latest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2019
Netherlands \| Earliest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2013
Netherlands \| Latest Tax Year
Income Tax Examination [Line Items]
Fiscal year subject to examination	2019

XML 76 R66.htm IDEA: XBRL DOCUMENT

Earnings Per Share - (Additional Information) (Detail) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended
	Jul. 22, 2019	Sep. 23, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Jul. 31, 2019	Jul. 19, 2019	Jul. 16, 2019
Stock options, outstanding			723,914	959,916	723,914	959,916	957,559
Stock options, weighted average exercise price			$ 41.03	$ 30.44	$ 41.03	$ 30.44	$ 30.81
Common stock excluded from calculation of diluted earnings per share			60,202	47,705	117,160	85,503
Common Stock [Member]
Conversion of Convertible Securities Stock Issued			2,316,200
2.125% Convertible Senior Notes due 2021
Aggregate principal amount			$ 115,000,000.0		$ 115,000,000.0					$ 92,000,000.0
2.125% Convertible Senior Notes due 2021 \| Common Stock [Member]
Conversion of Convertible Securities Stock Issued	1,850,155	466,045
0.375% Convertible Senior Notes due 2024
Aggregate principal amount								$ 287,500,000	$ 287,500,000
Restricted Stock Units and Performance Stock Units
Restricted stock units, outstanding			675,567	740,213	675,567	740,213	734,984

XML 77 R67.htm IDEA: XBRL DOCUMENT

Earnings Per Share - (Reconciliation of Basic and Diluted Shares Amounts) (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Schedule Of Earnings Per Share Basic And Diluted [Line Items]
Net income	$ 14,552	$ 1,659	$ 40,228	$ 17,807
Weighted average shares used in computing net income per share - diluted	52,545	50,852	52,341	47,087
Effect of dilutive shares:
Stock options and restricted stock awards	916	957	951	843
Dilutive effect of unvested performance stock units	8		8
Dilutive potential common shares	924	957	959	843
Weighted average shares used in computing net income per share - diluted	53,469	51,809	53,300	47,930
Earnings per share:
Basic	$ 0.28	$ 0.03	$ 0.77	$ 0.38
Diluted	$ 0.27	$ 0.03	$ 0.75	$ 0.37

XML 78 R68.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2020 USD ($)	Sep. 30, 2020 USD ($)
Spectrum Inc.
Related Party Transaction [Line Items]
Rent expense	$ 0.1	$ 0.5
Principal Owner \| Minimum \| Spectrum Inc.
Related Party Transaction [Line Items]
Non controlling ownership interest minimum	5.00%	5.00%

XML 79 R69.htm IDEA: XBRL DOCUMENT

Segment Reporting - Additional Information (Detail) - Segment	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Number of operating segments	1
Customer Concentration Risk \| Accounts Receivable \| GE Healthcare
Accounts receivable, percentage by customer	0.00%	18.00%

XML 80 R70.htm IDEA: XBRL DOCUMENT

Segment Reporting - (Percentage of Revenue by Geographic Area) (Details) - Geographic Concentration Risk - Total Revenue	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Concentration Risk [Line Items]
Revenues, percentage by country	100.00%	100.00%	100.00%	100.00%
North America
Concentration Risk [Line Items]
Revenues, percentage by country	50.00%	54.00%	48.00%	51.00%
Europe
Concentration Risk [Line Items]
Revenues, percentage by country	36.00%	33.00%	38.00%	37.00%
APAC/Other
Concentration Risk [Line Items]
Revenues, percentage by country	14.00%	13.00%	14.00%	12.00%

XML 81 R71.htm IDEA: XBRL DOCUMENT

Segment Reporting - Percentage of Revenue from Significant Customers (Detail) - Customer Concentration Risk - Sales Revenue	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
GE Healthcare
Revenue, Major Customer [Line Items]
Revenue from significant customers			12.00%
MilliporeSigma
Revenue, Major Customer [Line Items]
Revenue from significant customers	14.00%	11.00%	14.00%

XML 82 R72.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Detail) - ARTeSYN Biosolutions [Member] - Subsequent Event [Member] $ in Millions	Oct. 27, 2020 USD ($)
Cash consideration	$ 130
Value of common stock issued	70
Business combination, consideration transferred	$ 200

EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 214 408 1 true 62 0 false 6 false false R1.htm 1001 - Document - Cover Page Sheet http://www.repligencorp.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.repligencorp.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 1003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Sheet http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) Statements 4 false false R5.htm 1005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 1006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Sheet http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) Statements 6 false false R7.htm 1007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 1008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - Fair Value Measurements Sheet http://www.repligencorp.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 1010 - Disclosure - Acquisitions Sheet http://www.repligencorp.com/role/Acquisitions Acquisitions Notes 10 false false R11.htm 1011 - Disclosure - Revenue Recognition Sheet http://www.repligencorp.com/role/RevenueRecognition Revenue Recognition Notes 11 false false R12.htm 1012 - Disclosure - Credit Losses Sheet http://www.repligencorp.com/role/CreditLosses Credit Losses Notes 12 false false R13.htm 1013 - Disclosure - Goodwill and Intangible Assets Sheet http://www.repligencorp.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 1014 - Disclosure - Consolidated Balance Sheet Detail Sheet http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail Consolidated Balance Sheet Detail Notes 14 false false R15.htm 1015 - Disclosure - Convertible Senior Notes Notes http://www.repligencorp.com/role/ConvertibleSeniorNotes Convertible Senior Notes Notes 15 false false R16.htm 1016 - Disclosure - Stockholders' Equity Sheet http://www.repligencorp.com/role/StockholdersEquity Stockholders' Equity Notes 16 false false R17.htm 1017 - Disclosure - Commitments and Contingencies Sheet http://www.repligencorp.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 1018 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 18 false false R19.htm 1019 - Disclosure - Income Taxes Sheet http://www.repligencorp.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 1020 - Disclosure - Earnings Per Share Sheet http://www.repligencorp.com/role/EarningsPerShare Earnings Per Share Notes 20 false false R21.htm 1021 - Disclosure - Related Party Transactions Sheet http://www.repligencorp.com/role/RelatedPartyTransactions Related Party Transactions Notes 21 false false R22.htm 1022 - Disclosure - Segment Reporting Sheet http://www.repligencorp.com/role/SegmentReporting Segment Reporting Notes 22 false false R23.htm 1023 - Disclosure - Subsequent Events Sheet http://www.repligencorp.com/role/SubsequentEvents Subsequent Events Notes 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 1025 - Disclosure - Acquisitions (Tables) Sheet http://www.repligencorp.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.repligencorp.com/role/Acquisitions 25 false false R26.htm 1026 - Disclosure - Revenue Recognition (Tables) Sheet http://www.repligencorp.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.repligencorp.com/role/RevenueRecognition 26 false false R27.htm 1027 - Disclosure - Credit Losses (Tables) Sheet http://www.repligencorp.com/role/CreditLossesTables Credit Losses (Tables) Tables http://www.repligencorp.com/role/CreditLosses 27 false false R28.htm 1028 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.repligencorp.com/role/GoodwillAndIntangibleAssets 28 false false R29.htm 1029 - Disclosure - Consolidated Balance Sheet Detail (Tables) Sheet http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables Consolidated Balance Sheet Detail (Tables) Tables http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail 29 false false R30.htm 1030 - Disclosure - Convertible Senior Notes (Tables) Notes http://www.repligencorp.com/role/ConvertibleSeniorNotesTables Convertible Senior Notes (Tables) Tables http://www.repligencorp.com/role/ConvertibleSeniorNotes 30 false false R31.htm 1031 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.repligencorp.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.repligencorp.com/role/StockholdersEquity 31 false false R32.htm 1032 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss 32 false false R33.htm 1033 - Disclosure - Income Taxes (Tables) Sheet http://www.repligencorp.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.repligencorp.com/role/IncomeTaxes 33 false false R34.htm 1034 - Disclosure - Earnings Per Share (Tables) Sheet http://www.repligencorp.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.repligencorp.com/role/EarningsPerShare 34 false false R35.htm 1035 - Disclosure - Segment Reporting (Tables) Sheet http://www.repligencorp.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.repligencorp.com/role/SegmentReporting 35 false false R36.htm 1036 - Disclosure - Fair Value Measurement - Additional Information (Detail) Sheet http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail Fair Value Measurement - Additional Information (Detail) Details 36 false false R37.htm 1037 - Disclosure - Acquisitions - Additional Information (Detail) Sheet http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail Acquisitions - Additional Information (Detail) Details 37 false false R38.htm 1038 - Disclosure - Acquisitions (Fair Value of Net Assets Acquired) (Detail) Sheet http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail Acquisitions (Fair Value of Net Assets Acquired) (Detail) Details http://www.repligencorp.com/role/AcquisitionsTables 38 false false R39.htm 1039 - Disclosure - Acquisitions (Estimated Useful Life and Fair Value) (Detail) Sheet http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail Acquisitions (Estimated Useful Life and Fair Value) (Detail) Details http://www.repligencorp.com/role/AcquisitionsTables 39 false false R40.htm 1040 - Disclosure - Acquisitions (Unaudited Supplemental Pro Forma Information) (Detail) Sheet http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail Acquisitions (Unaudited Supplemental Pro Forma Information) (Detail) Details http://www.repligencorp.com/role/AcquisitionsTables 40 false false R41.htm 1041 - Schedule - Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) Sheet http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail) Details 41 false false R42.htm 1042 - Disclosure - Revenue from Significant Customers (Detail) Sheet http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail Revenue from Significant Customers (Detail) Details 42 false false R43.htm 1043 - Disclosure - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) Sheet http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail) Details 43 false false R44.htm 1044 - Disclosure - Credit Losses - Additional Information (Detail) Sheet http://www.repligencorp.com/role/CreditLossesAdditionalInformationDetail Credit Losses - Additional Information (Detail) Details 44 false false R45.htm 1045 - Disclosure - Credit Losses - Summary Of Allowance For Credit Losses For Accounts Receivables (Detail) Sheet http://www.repligencorp.com/role/CreditLossesSummaryOfAllowanceForCreditLossesForAccountsReceivablesDetail Credit Losses - Summary Of Allowance For Credit Losses For Accounts Receivables (Detail) Details 45 false false R46.htm 1046 - Disclosure - Changes in Carrying Value of Goodwill (Detail) Sheet http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail Changes in Carrying Value of Goodwill (Detail) Details 46 false false R47.htm 1047 - Disclosure - Goodwill and Intangible Assets (Detail) Sheet http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail Goodwill and Intangible Assets (Detail) Details http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables 47 false false R48.htm 1048 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) Sheet http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail Goodwill and Intangible Assets - Additional Information (Detail) Details 48 false false R49.htm 1049 - Disclosure - Amortization Expense for Amortized Intangible Assets (Detail) Sheet http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail Amortization Expense for Amortized Intangible Assets (Detail) Details 49 false false R50.htm 1050 - Disclosure - Schedule of Inventories (Detail) Sheet http://www.repligencorp.com/role/ScheduleOfInventoriesDetail Schedule of Inventories (Detail) Details 50 false false R51.htm 1051 - Disclosure - Property, Plant and Equipment (Detail) Sheet http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail Property, Plant and Equipment (Detail) Details 51 false false R52.htm 1052 - Disclosure - Consolidated Balance Sheet - Additional Information (Detail) Sheet http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail Consolidated Balance Sheet - Additional Information (Detail) Details 52 false false R53.htm 1053 - Disclosure - Schedule of Accrued Liabilities (Detail) Sheet http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail Schedule of Accrued Liabilities (Detail) Details 53 false false R54.htm 1054 - Disclosure - Convertible Senior Notes - Additional Information (Detail) Notes http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail Convertible Senior Notes - Additional Information (Detail) Details 54 false false R55.htm 1055 - Disclosure - Convertible Senior Notes - Convertible Debt (Detail) Notes http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail Convertible Senior Notes - Convertible Debt (Detail) Details 55 false false R56.htm 1056 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail Stockholders' Equity - Additional Information (Detail) Details 56 false false R57.htm 1057 - Disclosure - Stock-Based Compensation Expense (Detail) Sheet http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail Stock-Based Compensation Expense (Detail) Details 57 false false R58.htm 1058 - Disclosure - Summary of Option Activity (Detail) Sheet http://www.repligencorp.com/role/SummaryOfOptionActivityDetail Summary of Option Activity (Detail) Details 58 false false R59.htm 1059 - Disclosure - Summary of Option Activity (Parenthetical) (Detail) Sheet http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail Summary of Option Activity (Parenthetical) (Detail) Details 59 false false R60.htm 1060 - Disclosure - Summary of Restricted Stock Unit Activity (Detail) Sheet http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail Summary of Restricted Stock Unit Activity (Detail) Details 60 false false R61.htm 1061 - Disclosure - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) Sheet http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail Summary of Restricted Stock Unit Activity (Parenthetical) (Detail) Details 61 false false R62.htm 1062 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 62 false false R63.htm 1063 - Disclosure - Change in Accumulated Other Comprehensive Loss (Detail) Sheet http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail Change in Accumulated Other Comprehensive Loss (Detail) Details 63 false false R64.htm 1064 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 64 false false R65.htm 1065 - Disclosure - Summary of Tax Returns Periods Subject to Examination by Federal, State and International Tax Authorities (Detail) Sheet http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail Summary of Tax Returns Periods Subject to Examination by Federal, State and International Tax Authorities (Detail) Details 65 false false R66.htm 1066 - Disclosure - Earnings Per Share - (Additional Information) (Detail) Sheet http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail Earnings Per Share - (Additional Information) (Detail) Details http://www.repligencorp.com/role/EarningsPerShareTables 66 false false R67.htm 1067 - Disclosure - Earnings Per Share - (Reconciliation of Basic and Diluted Shares Amounts) (Detail) Sheet http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail Earnings Per Share - (Reconciliation of Basic and Diluted Shares Amounts) (Detail) Details http://www.repligencorp.com/role/EarningsPerShareTables 67 false false R68.htm 1068 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 68 false false R69.htm 1069 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 69 false false R70.htm 1070 - Disclosure - Segment Reporting - (Percentage of Revenue by Geographic Area) (Details) Sheet http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails Segment Reporting - (Percentage of Revenue by Geographic Area) (Details) Details http://www.repligencorp.com/role/SegmentReportingTables 70 false false R71.htm 1071 - Disclosure - Segment Reporting - Percentage of Revenue from Significant Customers (Detail) Sheet http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail Segment Reporting - Percentage of Revenue from Significant Customers (Detail) Details 71 false false R72.htm 1072 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 72 false false All Reports Book All Reports d945763d10q.htm d945763dex311.htm d945763dex312.htm d945763dex321.htm rgen-20200930.xsd rgen-20200930_cal.xml rgen-20200930_def.xml rgen-20200930_lab.xml rgen-20200930_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true JSON 89 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d945763d10q.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 214, "dts": { "calculationLink": { "local": [ "rgen-20200930_cal.xml" ] }, "definitionLink": { "local": [ "rgen-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "d945763d10q.htm" ] }, "labelLink": { "local": [ "rgen-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "rgen-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "rgen-20200930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 585, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 2, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 7 }, "keyCustom": 29, "keyStandard": 379, "memberCustom": 18, "memberStandard": 42, "nsprefix": "rgen", "nsuri": "http://www.repligencorp.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.repligencorp.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Acquisitions", "role": "http://www.repligencorp.com/role/Acquisitions", "shortName": "Acquisitions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Revenue Recognition", "role": "http://www.repligencorp.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Credit Losses", "role": "http://www.repligencorp.com/role/CreditLosses", "shortName": "Credit Losses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CreditLossFinancialInstrumentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.repligencorp.com/role/GoodwillAndIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Consolidated Balance Sheet Detail", "role": "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail", "shortName": "Consolidated Balance Sheet Detail", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Convertible Senior Notes", "role": "http://www.repligencorp.com/role/ConvertibleSeniorNotes", "shortName": "Convertible Senior Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Stockholders' Equity", "role": "http://www.repligencorp.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Commitments and Contingencies", "role": "http://www.repligencorp.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Income Taxes", "role": "http://www.repligencorp.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - CONSOLIDATED BALANCE SHEETS", "role": "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Earnings Per Share", "role": "http://www.repligencorp.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Related Party Transactions", "role": "http://www.repligencorp.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Segment Reporting", "role": "http://www.repligencorp.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Subsequent Events", "role": "http://www.repligencorp.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020_EngineeredMoldingTechnologyLlcMemberusgaapBusinessAcquisitionAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Acquisitions (Tables)", "role": "http://www.repligencorp.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020_EngineeredMoldingTechnologyLlcMemberusgaapBusinessAcquisitionAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.repligencorp.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Credit Losses (Tables)", "role": "http://www.repligencorp.com/role/CreditLossesTables", "shortName": "Credit Losses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Consolidated Balance Sheet Detail (Tables)", "role": "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables", "shortName": "Consolidated Balance Sheet Detail (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Convertible Senior Notes (Tables)", "role": "http://www.repligencorp.com/role/ConvertibleSeniorNotesTables", "shortName": "Convertible Senior Notes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConvertibleDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.repligencorp.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfIncomeTaxExaminationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Income Taxes (Tables)", "role": "http://www.repligencorp.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SummaryOfIncomeTaxExaminationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.repligencorp.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Segment Reporting (Tables)", "role": "http://www.repligencorp.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Fair Value Measurement - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "shortName": "Fair Value Measurement - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_MoneyMarketFundsMemberusgaapCashAndCashEquivalentsAxis", "decimals": "-5", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Acquisitions - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "shortName": "Acquisitions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn06_30_2020_TrustForBenefitOfEmployeesMembersrtTitleOfIndividualAxis", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Acquisitions (Fair Value of Net Assets Acquired) (Detail)", "role": "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "shortName": "Acquisitions (Fair Value of Net Assets Acquired) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_CTechnologiesMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_EngineeredMoldingTechnologyLlcMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Acquisitions (Estimated Useful Life and Fair Value) (Detail)", "role": "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "shortName": "Acquisitions (Estimated Useful Life and Fair Value) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_EngineeredMoldingTechnologyLlcMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "role": "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2019To09_30_2019_CTechnologiesMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Acquisitions (Unaudited Supplemental Pro Forma Information) (Detail)", "role": "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail", "shortName": "Acquisitions (Unaudited Supplemental Pro Forma Information) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2019To09_30_2019_CTechnologiesMemberusgaapBusinessAcquisitionAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "1041 - Schedule - Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail", "shortName": "Summary of Disaggregation of Product Revenues from Contracts with Customers by Major Product Line (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Revenue from Significant Customers (Detail)", "role": "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "shortName": "Revenue from Significant Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "rgen:ScheduleOfRevenueByMajorCustomersTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2019To09_30_2019_CytivaMembersrtMajorCustomersAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail", "shortName": "Summary of Receivables and Deferred Revenue from Contracts with Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "lang": null, "name": "us-gaap:DeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Credit Losses - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/CreditLossesAdditionalInformationDetail", "shortName": "Credit Losses - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn06_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Credit Losses - Summary Of Allowance For Credit Losses For Accounts Receivables (Detail)", "role": "http://www.repligencorp.com/role/CreditLossesSummaryOfAllowanceForCreditLossesForAccountsReceivablesDetail", "shortName": "Credit Losses - Summary Of Allowance For Credit Losses For Accounts Receivables (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-3", "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Changes in Carrying Value of Goodwill (Detail)", "role": "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail", "shortName": "Changes in Carrying Value of Goodwill (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "rgen:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Goodwill and Intangible Assets (Detail)", "role": "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail", "shortName": "Goodwill and Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "rgen:ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "shortName": "Goodwill and Intangible Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Amortization Expense for Amortized Intangible Assets (Detail)", "role": "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail", "shortName": "Amortization Expense for Amortized Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "role": "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Schedule of Inventories (Detail)", "role": "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail", "shortName": "Schedule of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Property, Plant and Equipment (Detail)", "role": "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail", "shortName": "Property, Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Land", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Consolidated Balance Sheet - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail", "shortName": "Consolidated Balance Sheet - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Schedule of Accrued Liabilities (Detail)", "role": "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail", "shortName": "Schedule of Accrued Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2019To09_30_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromConvertibleDebt", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Convertible Senior Notes - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "shortName": "Convertible Senior Notes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn07_19_2019_ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMemberusgaapDebtInstrumentAxis", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Convertible Senior Notes - Convertible Debt (Detail)", "role": "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail", "shortName": "Convertible Senior Notes - Convertible Debt (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn07_19_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Stockholders' Equity - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "shortName": "Stockholders' Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn07_19_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Stock-Based Compensation Expense (Detail)", "role": "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_CostOfSalesMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Summary of Option Activity (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail", "shortName": "Summary of Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonExecutiveMembersrtTitleOfIndividualAxis", "decimals": "2", "first": true, "lang": null, "name": "rgen:PercentageOfSharesSubjectToForfeiture", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1059 - Disclosure - Summary of Option Activity (Parenthetical) (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "shortName": "Summary of Option Activity (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_NonExecutiveMembersrtTitleOfIndividualAxis", "decimals": "2", "first": true, "lang": null, "name": "rgen:PercentageOfSharesSubjectToForfeiture", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2019To09_30_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "role": "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2019To09_30_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1060 - Disclosure - Summary of Restricted Stock Unit Activity (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail", "shortName": "Summary of Restricted Stock Unit Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_NonExecutiveMembersrtTitleOfIndividualAxis_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "rgen:PercentageOfSharesSubjectToForfeiture", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1061 - Disclosure - Summary of Restricted Stock Unit Activity (Parenthetical) (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail", "shortName": "Summary of Restricted Stock Unit Activity (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020_NonExecutiveMembersrtTitleOfIndividualAxis_RestrictedStockAndPerformanceStockUnitsMemberusgaapAwardTypeAxis", "decimals": "2", "first": true, "lang": null, "name": "rgen:PercentageOfSharesSubjectToForfeiture", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_NGLImpactAMembersrtProductOrServiceAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1062 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_NGLImpactAMembersrtProductOrServiceAxis_ResearchAndDevelopmentArrangementMemberusgaapLongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermPurchaseCommitmentAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1063 - Disclosure - Change in Accumulated Other Comprehensive Loss (Detail)", "role": "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail", "shortName": "Change in Accumulated Other Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn12_31_2019_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1064 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "div", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxExaminationsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020_EarliestTaxYearMemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OpenTaxYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1065 - Disclosure - Summary of Tax Returns Periods Subject to Examination by Federal, State and International Tax Authorities (Detail)", "role": "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail", "shortName": "Summary of Tax Returns Periods Subject to Examination by Federal, State and International Tax Authorities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:SummaryOfIncomeTaxExaminationsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020_EarliestTaxYearMemberusgaapTaxPeriodAxis_USsrtStatementGeographicalAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OpenTaxYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1066 - Disclosure - Earnings Per Share - (Additional Information) (Detail)", "role": "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "shortName": "Earnings Per Share - (Additional Information) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1067 - Disclosure - Earnings Per Share - (Reconciliation of Basic and Diluted Shares Amounts) (Detail)", "role": "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail", "shortName": "Earnings Per Share - (Reconciliation of Basic and Diluted Shares Amounts) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesRestrictedStock", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_SpectrumIncMemberusgaapBusinessAcquisitionAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1068 - Disclosure - Related Party Transactions - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_SpectrumIncMemberusgaapBusinessAcquisitionAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1069 - Disclosure - Segment Reporting - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "shortName": "Segment Reporting - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1070 - Disclosure - Segment Reporting - (Percentage of Revenue by Geographic Area) (Details)", "role": "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "shortName": "Segment Reporting - (Percentage of Revenue by Geographic Area) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P07_01_2020To09_30_2020_GeographicConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2019To09_30_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CytivaMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1071 - Disclosure - Segment Reporting - Percentage of Revenue from Significant Customers (Detail)", "role": "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail", "shortName": "Segment Reporting - Percentage of Revenue from Significant Customers (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2019To09_30_2019_CustomerConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis_CytivaMembersrtMajorCustomersAxis_SalesRevenueNetMemberusgaapConcentrationRiskByBenchmarkAxis", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P10_27_2020To10_27_2020_ArtesynBiosolutionsMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1072 - Disclosure - Subsequent Events - Additional Information (Detail)", "role": "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail", "shortName": "Subsequent Events - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P10_27_2020To10_27_2020_ArtesynBiosolutionsMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Fair Value Measurements", "role": "http://www.repligencorp.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d945763d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 62, "tag": { "country_DE": { "auth_ref": [], "lang": { "en-US": { "role": { "definitionGuidance": "Germany", "label": "GERMANY" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "country_NL": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NETHERLANDS", "terseLabel": "Netherlands" } } }, "localname": "NL", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "country_SE": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "SWEDEN", "terseLabel": "Sweden" } } }, "localname": "SE", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r377" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r378" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss", "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables", "http://www.repligencorp.com/role/Acquisitions", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail", "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail", "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail", "http://www.repligencorp.com/role/CommitmentsAndContingencies", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables", "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotes", "http://www.repligencorp.com/role/ConvertibleSeniorNotesTables", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail", "http://www.repligencorp.com/role/EarningsPerShareTables", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables", "http://www.repligencorp.com/role/IncomeTaxes", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesTables", "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail", "http://www.repligencorp.com/role/RelatedPartyTransactions", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail", "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail", "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail", "http://www.repligencorp.com/role/StockholdersEquity", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Emerging growth company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Smaller reporting company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss", "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables", "http://www.repligencorp.com/role/Acquisitions", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail", "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail", "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail", "http://www.repligencorp.com/role/CommitmentsAndContingencies", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables", "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotes", "http://www.repligencorp.com/role/ConvertibleSeniorNotesTables", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail", "http://www.repligencorp.com/role/EarningsPerShareTables", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables", "http://www.repligencorp.com/role/IncomeTaxes", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesTables", "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail", "http://www.repligencorp.com/role/RelatedPartyTransactions", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail", "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail", "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail", "http://www.repligencorp.com/role/StockholdersEquity", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "rgen_AdjustmentsToAdditionalPaidInCapitalReductionForEquityComponentOfConvertibleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Adjustments To Additional Paid In Capital Reduction For Equity Component Of Convertible Debt.", "label": "Adjustments To Additional Paid In Capital Reduction For Equity Component Of Convertible Debt", "verboseLabel": "Reduction for equity component from debt conversion, net of tax" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalReductionForEquityComponentOfConvertibleDebt", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "rgen_AmendmentAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amendment [Axis]", "label": "Amendment [Axis]", "terseLabel": "Amendment [Axis]" } } }, "localname": "AmendmentAxis", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_AmendmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amendment [Domain]", "label": "Amendment [Domain]", "terseLabel": "Amendment [Domain]" } } }, "localname": "AmendmentDomain", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_ApacOtherMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "APAC Other [Member]", "verboseLabel": "APAC/Other" } } }, "localname": "ApacOtherMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "rgen_ArtesynBiosolutionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ARTeSYN Biosolutions", "label": "ARTeSYN Biosolutions [Member]", "terseLabel": "ARTeSYN Biosolutions [Member]" } } }, "localname": "ArtesynBiosolutionsMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_AssetsAcquiredUnderOperatingLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Assets acquired under operating leases.", "label": "Assets Acquired Under Operating Leases", "terseLabel": "Assets acquired under operating leases" } } }, "localname": "AssetsAcquiredUnderOperatingLeases", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationConsiderationIndemnificationEscrow": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Consideration Indemnification Escrow", "label": "Business Combination Consideration Indemnification Escrow", "terseLabel": "Business acquisition, Indemnification escrow" } } }, "localname": "BusinessCombinationConsiderationIndemnificationEscrow", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Accrued Bonus.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Bonus", "negatedLabel": "Accrued bonus" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedBonus", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Liabilities", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Liabilities", "negatedLabel": "Accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilityCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed deferred tax liability current.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liability Current", "negatedLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilityCurrent", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liability Current.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liability Current", "negatedLabel": "Operating lease liability" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityCurrent", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNonCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liability Non Current.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Liability Non Current", "negatedLabel": "Operating lease liability, long-term" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilityNonCurrent", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Right Of Use Asset.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Operating Lease Right Of Use Asset", "verboseLabel": "Operating lease right of use asset" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAsset", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of restricted cash, acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed Restricted Cash", "verboseLabel": "Restricted cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "rgen_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets", "verboseLabel": "Business acquisition, net tangible assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rgen_CTechnologiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "C Technologies [Member]", "terseLabel": "C Technologies, Inc.", "verboseLabel": "C Technologies" } } }, "localname": "CTechnologiesMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail" ], "xbrltype": "domainItemType" }, "rgen_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and Contingencies [Line Items]", "label": "Commitments and Contingencies [Line Items]", "terseLabel": "Commitments and Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commitments and Contingencies [Table]", "label": "Commitments and Contingencies [Table]", "terseLabel": "Commitments and Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_CommonStockIssuePricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock issue price per share.", "label": "Common Stock Issue Price Per Share", "terseLabel": "Common stock issue price per share" } } }, "localname": "CommonStockIssuePricePerShare", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "rgen_ConvertibleNotesTransactionCostsOfEquityComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Convertible notes transaction costs of equity component.", "label": "Convertible Notes Transaction Costs Of Equity Component", "verboseLabel": "Transaction costs attributable to equity component" } } }, "localname": "ConvertibleNotesTransactionCostsOfEquityComponent", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rgen_ConvertibleNotesTransactionCostsOfLiabilityComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Convertible notes transaction costs of liability component.", "label": "Convertible Notes Transaction Costs Of Liability Component", "verboseLabel": "Transaction costs attributable to liability component" } } }, "localname": "ConvertibleNotesTransactionCostsOfLiabilityComponent", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rgen_CytivaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cytiva.", "label": "Cytiva [Member]", "terseLabel": "GE Healthcare", "verboseLabel": "Cytiva (formerly GE Healthcare)" } } }, "localname": "CytivaMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "domainItemType" }, "rgen_DebtInstrumentFaceAmountRemaining": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt instrument face amount remaining", "label": "Debt Instrument Face Amount Remaining", "terseLabel": "Face amount of remaining convertible debt" } } }, "localname": "DebtInstrumentFaceAmountRemaining", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rgen_DiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount rate.", "label": "Discount Rate", "verboseLabel": "Discount rate" } } }, "localname": "DiscountRate", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "rgen_EngineeredMoldingTechnologyLlcMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Engineered Molding Technology LLC", "label": "Engineered Molding Technology LLC [Member]", "terseLabel": "Engineered Molding Technology" } } }, "localname": "EngineeredMoldingTechnologyLlcMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail" ], "xbrltype": "domainItemType" }, "rgen_FacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Facility [Axis]" } } }, "localname": "FacilityAxis", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_FacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Facility [Domain]" } } }, "localname": "FacilityDomain", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_FiniteLivedIntangibleLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finite-Lived Intangible Liabilities [Line Items]", "label": "Finite Lived Intangible Liabilities [Line Items]", "terseLabel": "Finite-Lived Intangible Liabilities [Line Items]", "verboseLabel": "Finite-Lived Intangible Liabilities [Line Items]" } } }, "localname": "FiniteLivedIntangibleLiabilitiesLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_GoodwillAndOtherIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "definitionGuidance": "Goodwill and Other Intangible Assets", "documentation": "Goodwill And Other Intangible Assets Disclosure abstract", "label": "Goodwill And Other Intangible Assets Disclosure [Abstract]", "verboseLabel": "Goodwill and Other Intangible Assets" } } }, "localname": "GoodwillAndOtherIntangibleAssetsDisclosureAbstract", "nsuri": "http://www.repligencorp.com/20200930", "xbrltype": "stringItemType" }, "rgen_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Income Taxes [Table]", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_IncreasedecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in operating lease liability.", "label": "Increase Decrease in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreasedecreaseInOperatingLeaseLiability", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rgen_IncreasedecreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in operating lease right of use asset.", "label": "Increase Decrease in Operating Lease Right Of Use Asset", "negatedLabel": "Operating lease right of use assets" } } }, "localname": "IncreasedecreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "rgen_IndefiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Indefinite Lived Intangible Assets Accumulated Amortization", "label": "Indefinite Lived Intangible Assets Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "IndefiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "rgen_IndefiniteLivedIntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Indefinite Lived Intangible Assets Net", "label": "Indefinite Lived Intangible Assets Net", "verboseLabel": "Net Carrying Value" } } }, "localname": "IndefiniteLivedIntangibleAssetsNet", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "rgen_IntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Assets [Line Items]", "label": "Intangible Assets [Line Items]", "terseLabel": "Intangible Assets [Line Items]" } } }, "localname": "IntangibleAssetsLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "rgen_MilliporeSigmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Millipore Sigma.", "label": "Millipore Sigma [Member]", "terseLabel": "MilliporeSigma" } } }, "localname": "MilliporeSigmaMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "domainItemType" }, "rgen_NGLImpactAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NGL Impact A[Member]", "label": "NGL Impact A [Member]" } } }, "localname": "NGLImpactAMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_NonEmployeeDirectorStockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non Employee Director Stock Option[Member]", "label": "Non Employee Director Stock Option[Member]", "terseLabel": "Non-Employee Directors" } } }, "localname": "NonEmployeeDirectorStockOptionMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_NonExecutiveMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non-Executive [Member]", "label": "Non-Executive [Member]", "terseLabel": "Awards Granted to Non-Executive Level Employees" } } }, "localname": "NonExecutiveMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "rgen_OptionToPurchaseAdditionalDebtFaceAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Option to purchase additional debt face amount.", "label": "Option to Purchase Additional Debt Face Amount", "verboseLabel": "Additional Notes issued" } } }, "localname": "OptionToPurchaseAdditionalDebtFaceAmount", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "rgen_PercentageOfSharesSubjectToForfeiture": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of shares subject to forfeiture.", "label": "Percentage of Shares Subject to Forfeiture", "terseLabel": "Estimated forfeiture rates" } } }, "localname": "PercentageOfSharesSubjectToForfeiture", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "percentItemType" }, "rgen_ReconciliationOfBasicAndDilutedSharesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reconciliation of Basic and Diluted Shares [Abstract]" } } }, "localname": "ReconciliationOfBasicAndDilutedSharesAbstract", "nsuri": "http://www.repligencorp.com/20200930", "xbrltype": "stringItemType" }, "rgen_RestrictedStockAndPerformanceStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restricted stock units and performance stock units.", "label": "Restricted Stock And Performance Stock Units [Member]", "terseLabel": "Restricted Stock Units and Performance Stock Units" } } }, "localname": "RestrictedStockAndPerformanceStockUnitsMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "rgen_RgenFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rgen Facility [Axis]", "label": "Rgen Facility [Axis]" } } }, "localname": "RgenFacilityAxis", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_RgenFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rgen Facility [Domain]", "label": "Rgen Facility [Domain]" } } }, "localname": "RgenFacilityDomain", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_RisksAndUncertaintiesInEntitiesBusinessPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Risks and Uncertainties in Entities Business [Policy Text Block]", "label": "Risks and Uncertainties in Entities Business [Policy Text Block]", "terseLabel": "Risks and Uncertainties" } } }, "localname": "RisksAndUncertaintiesInEntitiesBusinessPolicyTextBlock", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "rgen_ScheduleOfAccruedLiabilitiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Accrued Liabilities [Line Items]", "label": "Schedule of Accrued Liabilities [Line Items]", "terseLabel": "Schedule of Accrued Liabilities [Line Items]" } } }, "localname": "ScheduleOfAccruedLiabilitiesLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "rgen_ScheduleOfAccruedLiabilitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Accrued Liabilities [Table]", "label": "Schedule of Accrued Liabilities [Table]", "terseLabel": "Schedule of Accrued Liabilities [Table]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "rgen_ScheduleOfEarningsPerShareBasicAndDilutedLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Earnings Per Share Basic And Diluted [Line Items]", "label": "Schedule Of Earnings Per Share Basic And Diluted [Line Items]", "terseLabel": "Schedule Of Earnings Per Share Basic And Diluted [Line Items]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "stringItemType" }, "rgen_ScheduleOfEarningsPerShareBasicAndDilutedTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Earnings Per Share Basic And Diluted [Table]", "label": "Schedule Of Earnings Per Share Basic And Diluted [Table]", "terseLabel": "Schedule Of Earnings Per Share Basic And Diluted [Table]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "stringItemType" }, "rgen_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]", "label": "Schedule Of Finite Lived And Indefinite Lived Intangible Assets [Table Text Block]", "verboseLabel": "Intangible assets" } } }, "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "rgen_ScheduleOfIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Intangible Assets [Table]", "label": "Schedule of Intangible Assets [Table]", "terseLabel": "Schedule of Intangible Assets [Table]" } } }, "localname": "ScheduleOfIntangibleAssetsTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "rgen_ScheduleOfRelatedPartyTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Related Party [Table]", "label": "Schedule Of Related Party [Table]", "terseLabel": "Schedule Of Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_ScheduleOfRevenueByMajorCustomersTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Revenue By Major Customers [Table Text Block]", "label": "Schedule Of Revenue By Major Customers [Table Text Block]", "terseLabel": "Revenue from Significant Customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersTableTextBlock", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "rgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Number", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Number", "terseLabel": "Vested and expected to vest at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestNumber", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "rgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other Than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "label": "Share based Compensation Arrangement by Share based Payment Award, Equity Instruments Other Than Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "monetaryItemType" }, "rgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Vested and Expected to Vest Outstanding Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Vested and Expected to Vest Outstanding Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "durationItemType" }, "rgen_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "stringItemType" }, "rgen_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Equity Instruments Other Than Options, Nonvested, Number of Shares", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options and Equity Instruments Other Than Options, Nonvested, Number of Shares", "terseLabel": "Number of unvested options and restricted stock units" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedNumberOfShares", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "rgen_SpectrumIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Spectrum Inc.", "label": "Spectrum Inc [Member]", "terseLabel": "Spectrum Inc.", "verboseLabel": "Spectrum Inc." } } }, "localname": "SpectrumIncMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_StockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock Option and Incentive Plan [Member]", "label": "Stock Option And Incentive Plan [Member]", "terseLabel": "2018 Plan" } } }, "localname": "StockOptionAndIncentivePlanMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_StockholdersEquityNoteDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders Equity Note Disclosure [Line Items]", "label": "Stockholders Equity Note Disclosure [Line Items]", "terseLabel": "Stockholders Equity Note Disclosure [Line Items]" } } }, "localname": "StockholdersEquityNoteDisclosureLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_StockholdersEquityNoteDisclosureTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders Equity Note Disclosure [Table]", "label": "Stockholders Equity Note Disclosure [Table]", "terseLabel": "Stockholders Equity Note Disclosure [Table]" } } }, "localname": "StockholdersEquityNoteDisclosureTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "rgen_TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Point One Two Five Percentage Convertible Senior Notes Due Twenty Twenty One [Member]", "label": "Two Point One Two Five Percentage Convertible Senior Notes Due Twenty Twenty One [Member]", "terseLabel": "2.125% Convertible Senior Notes due 2021" } } }, "localname": "TwoPointOneTwoFivePercentageConvertibleSeniorNotesDueTwentyTwentyOneMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_TwoPointOneTwoFivePercentageNonConvertibleSeniorNotesDueTwentyTwentyOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Two Point One Two Five Percentage Non Convertible Senior Notes Due Twenty Twenty One [Member]", "terseLabel": "2.125% Non Convertible Senior Notes due 2021" } } }, "localname": "TwoPointOneTwoFivePercentageNonConvertibleSeniorNotesDueTwentyTwentyOneMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_UnderwriterMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Underwriter.", "label": "Underwriter [Member]", "terseLabel": "Underwriters" } } }, "localname": "UnderwriterMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_UnvestedOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Unvested Options [Member]", "label": "Unvested Options [Member]", "terseLabel": "Unvested Options" } } }, "localname": "UnvestedOptionsMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Zero Point Three Seven Five Percent Convertible Senior Notes Due Twenty Twenty Four [Member]", "terseLabel": "0.375% Convertible Senior Notes due 2024" } } }, "localname": "ZeroPointThreeSevenFivePercentConvertibleSeniorNotesDueTwentyTwentyFourMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "rgen_ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Zero Point Three Seven Five Percentage Convertible Senior Notes Due Twenty Twenty Four [Member]", "verboseLabel": "0.375% Convertible Senior Notes due 2024" } } }, "localname": "ZeroPointThreeSevenFivePercentageConvertibleSeniorNotesDueTwentyTwentyFourMember", "nsuri": "http://www.repligencorp.com/20200930", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Awards Granted to Executive Level Employees" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r132", "r209", "r213", "r369" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "domainItemType" }, "srt_NorthAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "North America [Member]", "terseLabel": "North America" } } }, "localname": "NorthAmericaMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r130", "r209", "r211", "r366", "r367" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r131", "r209", "r212", "r368", "r372", "r373" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r134", "r318" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Summary Of Allowance For Credit Losses For Accounts Receivables" } } }, "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CreditLossesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r20", "r135", "r136", "r210" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "terseLabel": "Accounts receivable, net of allowances of $621 and $525 at September 30, 2020 and December 31, 2019, respectively", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/CreditLossesAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r15", "r342", "r355" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Taxes" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r9", "r42" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r7", "r9", "r42" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Royalty and license fees" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r178" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less - Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56", "r59", "r60", "r61", "r300", "r306", "r308" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "periodStartLabel": "Translation adjustment" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r59", "r60", "r61" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r58", "r61", "r62", "r289" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r57", "r61", "r62", "r289" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "verboseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": { "auth_ref": [ "r164" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expected value at the end of their useful life of a major finite-lived intangible asset class acquired during the period either individually or as part of a group of assets (in either an asset acquisition or business combination). A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Acquired Finite-lived Intangible Asset, Residual Value", "verboseLabel": "Intangible Asset Residual Value" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "verboseLabel": "Weighted Average Useful Life (in years)" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r21" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid- In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Tax withholding on vesting of restricted stock units" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": { "auth_ref": [ "r187" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.", "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt", "terseLabel": "Equity component of 0.375% senior convertible notes, net of tax" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r219", "r221", "r249", "r250" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r196", "r202" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "presentationGuidance": "Proceeds from issuance of common stock, net of issuance cost" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r137", "r139", "r141", "r144" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "negatedPeriodEndLabel": "Ending balance", "negatedPeriodStartLabel": "Beginning balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CreditLossesSummaryOfAllowanceForCreditLossesForAccountsReceivablesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r26", "r137", "r139" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Accounts receivable, reserve for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.repligencorp.com/role/CreditLossesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r143" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "terseLabel": "Current period change for write-offs" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CreditLossesSummaryOfAllowanceForCreditLossesForAccountsReceivablesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r81", "r95", "r310" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Accretion of the debt discount", "verboseLabel": "Non-cash interest expense" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r74", "r95", "r312" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of the debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r95", "r162", "r171" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "verboseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock excluded from calculation of diluted earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r129", "r340", "r354" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r3", "r4", "r54" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r223", "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityTables", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r290", "r291" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r6", "r177" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, voting interest acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r268", "r269" ], "lang": { "en-US": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Basic" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r268", "r269" ], "lang": { "en-US": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Diluted" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r268", "r269" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Unaudited Supplemental Pro Forma Information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r268", "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Pro forma net income", "verboseLabel": "Business acquisitions proforma net income" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r268", "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "verboseLabel": "Pro forma total revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r280", "r281", "r282" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business combination, consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": { "auth_ref": [ "r280", "r281" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable", "verboseLabel": "Value of common stock issued" } } }, "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r94", "r284" ], "crdr": "debit", "lang": { "en-US": { "role": { "definitionGuidance": "Deferred tax liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/Acquisitions" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "auth_ref": [ "r267" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.", "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Business acquisition, revenue" } } }, "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r274" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r252", "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred taxes" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "positiveLabel": "Fair value of acquired finite lived intangible assets", "verboseLabel": "Business combination, intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r273", "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r273", "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r273", "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Fixed assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r274" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "terseLabel": "Fair value of net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "terseLabel": "Transaction costs" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r374" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 10.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Computer hardware and software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r36", "r97" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r92", "r97", "r101" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r92", "r305" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Asset and Liability [Abstract]", "verboseLabel": "Revenue recognized during the nine-month period ended September 30, 2020 relating to:" } } }, "localname": "ChangeInContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail", "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail", "http://www.repligencorp.com/role/EarningsPerShare", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEvents" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r49", "r182", "r345", "r362" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r181", "r183" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Common stock shares reserved for Issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r19" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r19", "r196" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r19" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.01 par value; 80,000,000 shares authorized; 52,606,700 shares at September 30, 2020 and 52,078,258 shares at December 31, 2019 issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationExpenseExcludingCostOfGoodAndServiceSold": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Other employee benefit expense includes, but is not limited to, service component of net periodic benefit cost for defined benefit plan. Excludes compensation cost in cost of good and service sold.", "label": "Compensation Expense, Excluding Cost of Good and Service Sold" } } }, "localname": "CompensationExpenseExcludingCostOfGoodAndServiceSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r65", "r67", "r68" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r85" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r124", "r125", "r302", "r303" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingTables" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r124", "r125", "r302", "r303", "r370" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingTables" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r124", "r125", "r302", "r303", "r370" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]", "verboseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r124", "r125", "r302", "r303" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "positiveLabel": "Revenues, percentage by country", "terseLabel": "Accounts receivable, percentage by customer", "verboseLabel": "Revenue from significant customers" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r121", "r124", "r125", "r126", "r302", "r304" ], "lang": { "en-US": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]", "verboseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r124", "r125", "r302", "r303" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r177" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 8.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Contract with Customer, Asset and Liability [Abstract]", "verboseLabel": "Balances from contracts with customers only:" } } }, "localname": "ContractWithCustomerAssetAndLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of contract balances and changes in contract balances.", "label": "Contract with Customer, Asset and Liability [Table Text Block]", "terseLabel": "Summary of Receivables and Deferred Revenue from Contracts with Customers" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r204", "r205", "r210" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "The beginning deferred revenue balance" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "auth_ref": [ "r207" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "verboseLabel": "Changes in pricing related to products or services satisfied in previous periods" } } }, "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.", "label": "Convertible Debt [Table Text Block]", "terseLabel": "Carrying Value of Convertible Senior Notes" } } }, "localname": "ConvertibleDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r47" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible Notes Payable, Noncurrent", "terseLabel": "Convertible senior notes, net", "verboseLabel": "Net carrying amount" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r16", "r343", "r356", "r371" ], "calculation": { "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "totalLabel": "Total debt" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r77" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r76" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "verboseLabel": "Costs and operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CreditLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Credit Loss [Abstract]" } } }, "localname": "CreditLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CreditLossFinancialInstrumentTextBlock": { "auth_ref": [ "r140", "r146", "r147", "r148", "r149", "r150", "r151" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.", "label": "Credit Loss, Financial Instrument [Text Block]", "verboseLabel": "Credit Losses" } } }, "localname": "CreditLossFinancialInstrumentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CreditLosses" ], "xbrltype": "textBlockItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r98", "r100" ], "lang": { "en-US": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r98", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Total consideration on conversion", "verboseLabel": "Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r98", "r100" ], "lang": { "en-US": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Name [Domain]" } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r341", "r343", "r353" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r16", "r189", "r343", "r353" ], "calculation": { "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail": { "order": 1.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "verboseLabel": "Principal amount" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Debt Instrument, Convertible, Beneficial Conversion Feature", "terseLabel": "Proceeds allocated to the conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": { "auth_ref": [ "r188" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.", "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component", "verboseLabel": "Equity component of converted debt" } } }, "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Notes initial conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r46", "r197", "r198", "r200" ], "lang": { "en-US": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Notes conversion ratio per $1,000 principal amount" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r311", "r313" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "presentationGuidance": "Aggregate principal amount", "terseLabel": "Notes issued", "verboseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r301" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Notes issued, fair value" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r47", "r350" ], "lang": { "en-US": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Notes, frequency of periodic payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "verboseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "auth_ref": [ "r44", "r192", "r311" ], "lang": { "en-US": { "role": { "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate on the Notes" } } }, "localname": "DebtInstrumentInterestRateEffectivePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Notes, interest rate", "verboseLabel": "Senior convertible notes" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument, Interest Rate Terms", "terseLabel": "Interest repayment terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r45", "r295" ], "lang": { "en-US": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Notes, due date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "auth_ref": [ "r351" ], "lang": { "en-US": { "role": { "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.", "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Notes redemption price" } } }, "localname": "DebtInstrumentRedemptionPricePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r47", "r103", "r197", "r199", "r200", "r201", "r310", "r311", "r313", "r352" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r310", "r313" ], "calculation": { "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail": { "order": 2.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedTerseLabel": "Less: unamortized debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r39", "r312" ], "calculation": { "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail": { "order": 3.0, "parentTag": "us-gaap_ConvertibleNotesPayable", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Less: unamortized debt issuance costs" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r257" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "verboseLabel": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r95", "r102", "r258", "r261" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred income taxes, net" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "verboseLabel": "Deferred revenue (included in accrued liabilities in the consolidated balance sheets)" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type [Axis]" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r8" ], "lang": { "en-US": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue [Domain]" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.", "label": "Deferred Tax and Other Liabilities, Noncurrent", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r95", "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r95", "r176" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "definitionGuidance": "Technology - developed", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "verboseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DilutiveSecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]", "verboseLabel": "Effect of dilutive shares:" } } }, "localname": "DilutiveSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "verboseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail", "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail", "http://www.repligencorp.com/role/SummaryOfReceivablesAndDeferredRevenueFromContractsWithCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Text Block [Abstract]" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarliestTaxYearMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Earliest identified tax year.", "label": "Earliest Tax Year [Member]", "terseLabel": "Earliest Tax Year" } } }, "localname": "EarliestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarlyRepaymentOfSeniorDebt": { "auth_ref": [ "r91" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the extinguishment of long-term borrowing, with the highest claim on the assets of the entity in case of bankruptcy or liquidation, before its maturity.", "label": "Early Repayment of Senior Debt", "terseLabel": "Repayment Of Senior Debt" } } }, "localname": "EarlyRepaymentOfSeniorDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r72", "r108", "r112", "r114", "r115", "r116", "r119", "r348", "r364" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share, Basic [Abstract]" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "definitionGuidance": "Earnings per share:", "label": "Earnings Per Share, Basic and Diluted [Abstract]" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r72", "r108", "r112", "r114", "r115", "r116", "r119", "r348", "r364" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r120" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r305" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r105", "r253", "r254" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "verboseLabel": "Income tax (benefit) provision" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r253", "r254", "r260" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Corporate tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost, weighted average remaining requisite service period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue, Major Customer [Line Items]", "terseLabel": "Revenue, Major Customer [Line Items]" } } }, "localname": "EntityWideRevenueMajorCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r196" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r292", "r298" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r215", "r216", "r218", "r293", "r323" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r292", "r293", "r294", "r295", "r299" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r215", "r216", "r218", "r293", "r324" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "verboseLabel": "Weighted Average Useful Life (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r170" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, after Year Five", "verboseLabel": "2025 and thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2020 (remaining three months)" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "verboseLabel": "Schedule of Amortization Expense for Amortized Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r172" ], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r172" ], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r172" ], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r172" ], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r163", "r167", "r170", "r174", "r325" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r170", "r325" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r163", "r169" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r170" ], "calculation": { "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Net Carrying Value", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r177" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 7.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture, fixtures and office equipment" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r95", "r193", "r194" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 12.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Loss on extinguishment of debt", "terseLabel": "Loss on extinguishment of debt", "verboseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeographicConcentrationRiskMember": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).", "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic Concentration Risk" } } }, "localname": "GeographicConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r155", "r156" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance as of September 30, 2020", "periodStartLabel": "Balance as of December 31, 2019", "positiveTerseLabel": "Business acquisition, goodwill acquired", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill arising from Acquisition" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r158" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "negatedLabel": "Cumulative translation adjustment" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "verboseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r108", "r338", "r346", "r365" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r180" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r256", "r259" ], "lang": { "en-US": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r102", "r128", "r262" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "definitionGuidance": "Income tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Unbilled receivables" } } }, "localname": "IncreaseDecreaseInContractWithCustomerAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, excluding impact of acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Royalties and other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": { "auth_ref": [ "r113", "r118" ], "calculation": { "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities", "terseLabel": "Dilutive effect of unvested performance stock units" } } }, "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r166", "r173" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r173" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "verboseLabel": "Gross Carrying Value" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r166", "r173" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Carrying Value" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r161", "r168" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "verboseLabel": "Net Carrying Value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r69", "r127", "r309", "r312", "r349" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 10.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.", "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual coupon interest" } } }, "localname": "InterestExpenseDebtExcludingAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryCurrentTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.", "label": "Inventory, Current [Table]", "terseLabel": "Inventory, Current [Table]" } } }, "localname": "InventoryCurrentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r28", "r154" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished products" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r1", "r53", "r153" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r30", "r154" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r29", "r154" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r79", "r81", "r82" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r5", "r37" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LatestTaxYearMember": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Latest identified tax year.", "label": "Latest Tax Year [Member]", "terseLabel": "Latest Tax Year" } } }, "localname": "LatestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r6", "r177" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Total liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r344", "r360" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r190", "r343", "r357" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Notes, carrying value", "verboseLabel": "Total convertible senior notes" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Fair value of convertible senior notes", "verboseLabel": "Fair value of the note" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Convertible Senior Notes" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount", "verboseLabel": "Payments to Navigo in connection with this program, which are recorded to research and development expenses" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by category of items purchased under a long-term purchase commitment.", "label": "Category of Item Purchased [Axis]" } } }, "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Category of Item Purchased [Domain]" } } }, "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r47", "r186" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r6", "r177" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners", "terseLabel": "Non controlling ownership interest minimum" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r215" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r92" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Total cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r92" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Total cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r92", "r93", "r96" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Total cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r63", "r66", "r71", "r96", "r118", "r347", "r363" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 15.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Standards Updates" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "verboseLabel": "Non-compete agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 8.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expenses, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonrecurringAdjustmentAxis": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Information about material and nonrecurring adjustment directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Axis]" } } }, "localname": "NonrecurringAdjustmentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NonrecurringAdjustmentDomain": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Material, nonrecurring adjustment(s) allocated (included) to (in) reported pro forma revenue and earnings (supplemental pro forma information).", "label": "Nonrecurring Adjustment [Domain]" } } }, "localname": "NonrecurringAdjustmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "verboseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.", "label": "Open Tax Year", "verboseLabel": "Fiscal year subject to examination" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r316" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r316" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 29.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating lease liability, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r315" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "verboseLabel": "Rent expense" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r9", "r10", "r42" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r56", "r307" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 14.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r64", "r67", "r286", "r287", "r288" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangibles" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities, long-term" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 11.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expenses) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expenses):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherReceivablesGrossCurrent": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Gross, Current", "terseLabel": "Royalties and other receivables" } } }, "localname": "OtherReceivablesGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r90" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 30.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payment of tax withholding obligation on vesting of restricted stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r86", "r283" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r86" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireSoftware": { "auth_ref": [ "r87" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.", "label": "Payments to Acquire Software", "negatedLabel": "Additions to capitalized software costs" } } }, "localname": "PaymentsToAcquireSoftware", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r223", "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r18" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r18" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r3", "r34", "r35" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrincipalOwnerMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Owner of record or known beneficial owner of more than 10 percent of the voting interests of the entity.", "label": "Principal Owner [Member]", "terseLabel": "Principal Owner" } } }, "localname": "PrincipalOwnerMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r89" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds from Convertible Debt", "terseLabel": "Proceeds from issuance of convertible senior notes, net of costs", "verboseLabel": "Proceeds from issuance of convertible debt, net" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r88" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from public offering", "verboseLabel": "Proceeds from issuance of common stock, net" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r247" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "presentationGuidance": "Product", "verboseLabel": "Products" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r42", "r184", "r185" ], "calculation": { "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "verboseLabel": "Warranties" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ScheduleOfAccruedLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r38", "r179" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r177" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Total property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r179", "r361" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Total property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r179" ], "calculation": { "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail": { "order": 9.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Other, Gross", "verboseLabel": "Other" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r179" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r177" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r73", "r142" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Current period change for expected credit losses" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CreditLossesSummaryOfAllowanceForCreditLossesForAccountsReceivablesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r217", "r317", "r319", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337" ], "lang": { "en-US": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfConvertibleDebt": { "auth_ref": [ "r91" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 29.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of senior convertible notes" } } }, "localname": "RepaymentsOfConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.", "label": "Research and Development Arrangement [Member]" } } }, "localname": "ResearchAndDevelopmentArrangementMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r251", "r374" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r101", "r339", "r358" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r22", "r202", "r359" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings/ (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r208", "r209" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/RevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "verboseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "definitionGuidance": "Royalty and Other Revenue", "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]", "verboseLabel": "Royalty and Other Revenue" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/SummaryOfDisaggregationOfProductRevenuesFromContractsWithCustomersByMajorProductLineDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r124" ], "lang": { "en-US": { "role": { "definitionGuidance": "Total Revenue", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales Revenue", "verboseLabel": "Total Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueByGeographicAreaDetails", "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail", "http://www.repligencorp.com/role/SegmentReportingTables" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Summary of Changes in Accumulated Other Comprehensive Income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "terseLabel": "Schedule of Identified Intangible Assets and Estimated Useful Lives" } } }, "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail", "http://www.repligencorp.com/role/AcquisitionsUnauditedSupplementalProFormaInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r221", "r244", "r248" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r221", "r244", "r248" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.", "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]" } } }, "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingPercentageOfRevenueFromSignificantCustomersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r163", "r169" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AmortizationExpenseForAmortizedIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangesInCarryingValueOfGoodwillDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r159", "r160" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "verboseLabel": "Changes in Carrying Value of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r31", "r32", "r33" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "verboseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r38", "r179" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/PropertyPlantAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "verboseLabel": "Percentage of Revenue from Significant Customers" } } }, "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r223", "r246" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]", "terseLabel": "Summary of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r228", "r238", "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Basic and Diluted Weighted Average Shares Outstanding" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r121", "r124", "r125", "r126", "r302", "r304" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Percentage by Geographic Area or Significant Customers" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r78", "r152" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 6.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [ "r84" ], "lang": { "en-US": { "role": { "definitionGuidance": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r94" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/StockBasedCompensationExpenseDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Incentive options, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited/expired/cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of restricted stock units granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at September 30, 2020", "periodStartLabel": "Unvested at December 31, 2019", "terseLabel": "Restricted stock units, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Unvested at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total grant date fair value of restricted stock units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Incentive options, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable at September 30, 2020 | shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r240" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Granted | shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of share-based awards granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r230", "r246" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding at September 30, 2020 | shares", "periodStartLabel": "Options outstanding at December 31, 2019 | shares", "terseLabel": "Stock options, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r229" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding at September 30, 2020", "periodStartLabel": "Options outstanding at December 31, 2019", "terseLabel": "Stock options, weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r241" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest at September 30, 2020" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest at September 30, 2020(1) | shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r220", "r226" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityTables", "http://www.repligencorp.com/role/SummaryOfOptionActivityParentheticalDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail", "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityParentheticalDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Compensation Award, Tranche One [Member]", "terseLabel": "Vest Over Three Year" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Closing price of common stock" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r224" ], "lang": { "en-US": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Incentive options, vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Unvested at September 30, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfRestrictedStockUnitActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate intrinsic value of restricted stock units vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Incentive options, term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable at September 30, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable at September 30, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding at September 30, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest at September 30, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r227" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of stock options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "terseLabel": "Tax withholding on vesting of restricted stock units (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r17", "r18", "r19", "r196" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail", "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail", "http://www.repligencorp.com/role/EarningsPerShare", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEvents" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r52", "r196" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss", "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables", "http://www.repligencorp.com/role/Acquisitions", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/CommitmentsAndContingencies", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables", "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotes", "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail", "http://www.repligencorp.com/role/ConvertibleSeniorNotesTables", "http://www.repligencorp.com/role/EarningsPerShare", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareTables", "http://www.repligencorp.com/role/FairValueMeasurements", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables", "http://www.repligencorp.com/role/IncomeTaxes", "http://www.repligencorp.com/role/IncomeTaxesTables", "http://www.repligencorp.com/role/RelatedPartyTransactions", "http://www.repligencorp.com/role/SegmentReportingAdditionalInformationDetail", "http://www.repligencorp.com/role/SegmentReportingTables", "http://www.repligencorp.com/role/StockholdersEquity", "http://www.repligencorp.com/role/StockholdersEquityTables", "http://www.repligencorp.com/role/SubsequentEvents", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLoss", "http://www.repligencorp.com/role/AccumulatedOtherComprehensiveLossTables", "http://www.repligencorp.com/role/Acquisitions", "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail", "http://www.repligencorp.com/role/AcquisitionsTables", "http://www.repligencorp.com/role/CommitmentsAndContingencies", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetAdditionalInformationDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetailTables", "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows", "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical", "http://www.repligencorp.com/role/ConvertibleSeniorNotes", "http://www.repligencorp.com/role/ConvertibleSeniorNotesConvertibleDebtDetail", "http://www.repligencorp.com/role/ConvertibleSeniorNotesTables", "http://www.repligencorp.com/role/EarningsPerShare", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareTables", "http://www.repligencorp.com/role/FairValueMeasurements", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsAdditionalInformationDetail", "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsTables", "http://www.repligencorp.com/role/IncomeTaxes", "http://www.repligencorp.com/role/IncomeTaxesTables", "http://www.repligencorp.com/role/RelatedPartyTransactions", "http://www.repligencorp.com/role/SegmentReportingTables", "http://www.repligencorp.com/role/StockholdersEquity", "http://www.repligencorp.com/role/StockholdersEquityTables", "http://www.repligencorp.com/role/SubsequentEvents", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPolicies", "http://www.repligencorp.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r98", "r99", "r100" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Stock Issued", "verboseLabel": "Fair value of common stock issued for acquisition of C Technologies, Inc." } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r18", "r19", "r202" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "verboseLabel": "Issuance of common stock pursuant to the acquisition of C Technologies, Inc., (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r51", "r196", "r197", "r202" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of Convertible Securities Stock Issued", "verboseLabel": "Conversion of Convertible Securities Stock Issued | shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/EarningsPerShareAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r18", "r19", "r196", "r197", "r202" ], "lang": { "en-US": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "verboseLabel": "Issuance of common stock for debt conversion (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r18", "r19", "r196", "r202" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r196", "r202" ], "lang": { "en-US": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Exercise of stock options and releases of restricted stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r18", "r19", "r196", "r202", "r233" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised | shares", "terseLabel": "Exercised number of shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r52", "r196", "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "verboseLabel": "Issuance of common stock pursuant to the acquisition of C Technologies, Inc." } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r52", "r196", "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of Convertible Securities Stock Issued | value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r52", "r196", "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Value, Conversion of Units", "verboseLabel": "Issuance of common stock for debt conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r18", "r19", "r196", "r202" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Proceeds from issuance of common stock, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r18", "r19", "r202", "r222", "r239" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Exercise of stock options and releases of restricted stock" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r19", "r23", "r24", "r138" ], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ChangeInAccumulatedOtherComprehensiveLossDetail", "http://www.repligencorp.com/role/ConsolidatedBalanceSheets", "http://www.repligencorp.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r203" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConvertibleSeniorNotesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/SubsequentEventsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SummaryOfIncomeTaxExaminationsTextBlock": { "auth_ref": [ "r256", "r259" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the increase or decrease in the liability from the prior period, and any penalties and interest that have been recorded.", "label": "Summary of Income Tax Examinations [Table Text Block]", "terseLabel": "Summary of Tax Returns Periods Subject to Examination by Federal, State and International Taxing Authorities" } } }, "localname": "SummaryOfIncomeTaxExaminationsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "Consolidated Balance Sheet Detail" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheetDetail" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "verboseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail", "http://www.repligencorp.com/role/SummaryOfTaxReturnsPeriodsSubjectToExaminationByFederalStateAndInternationalTaxAuthoritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trademark and tradename [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsEstimatedUsefulLifeAndFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksAndTradeNamesMember": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trademarks and Trade Names [Member]", "verboseLabel": "Trademark and tradename" } } }, "localname": "TrademarksAndTradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsFairValueOfNetAssetsAcquiredDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r276" ], "lang": { "en-US": { "role": { "definitionGuidance": "Trademark", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademark" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/GoodwillAndIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TrustForBenefitOfEmployeesMember": { "auth_ref": [ "r217", "r317", "r319" ], "lang": { "en-US": { "role": { "documentation": "Trust created by the entity that exists for the benefit of its employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management.", "label": "Trust for Benefit of Employees [Member]", "terseLabel": "Employees" } } }, "localname": "TrustForBenefitOfEmployeesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/AcquisitionsAdditionalInformationDetail", "http://www.repligencorp.com/role/CommitmentsAndContingenciesAdditionalInformationDetail", "http://www.repligencorp.com/role/FairValueMeasurementAdditionalInformationDetail", "http://www.repligencorp.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UnbilledReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.repligencorp.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer.", "label": "Unbilled Receivables, Current", "verboseLabel": "Unbilled receivables" } } }, "localname": "UnbilledReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r246" ], "lang": { "en-US": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/StockholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r116" ], "calculation": { "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "totalLabel": "Dilutive potential common shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r111", "r116" ], "calculation": { "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted average shares used in computing net income per share - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "presentationGuidance": "Weighted average common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r109", "r116" ], "calculation": { "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail": { "order": 4.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted average shares used in computing net income per share - diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesRestrictedStock": { "auth_ref": [ "r110" ], "calculation": { "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.", "label": "Weighted Average Number of Shares, Restricted Stock", "verboseLabel": "Stock options and restricted stock awards" } } }, "localname": "WeightedAverageNumberOfSharesRestrictedStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.repligencorp.com/role/EarningsPerShareReconciliationOfBasicAndDilutedSharesAmountsDetail" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e2646-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599" }, "r133": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919269-210447" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919272-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919236-210447" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r181": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r203": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r214": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e1043-128460" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(4)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r285": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r322": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r375": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r376": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r377": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r378": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r379": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "8", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" } }, "version": "2.1" } ZIP 90 0001193125-20-286931-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-286931-xbrl.zip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end